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Abstract 
 
Cancer is the collective group of diseases distinguished by uninhibited growth and 
spread of abnormal cells. It often results in death if the spread is not controlled. Most 
cancers are treated by surgery, radiation, chemotherapy, hormones, or immunotherapy. 
However, currently there are many issues with these forms of treatment, namely the lack 
of ability to consistently remove the entire tumor and the side effect of killing normal 
cells during the treatment process. Therefore there has been an increased interest in 
targeted drug delivery to tumors to specifically kill cancer cells. 
We have developed a highly adaptable amphiphilic alternating copolymer system 
that self-assembles into micelles for therapeutic delivery applications in cancer. The 
synthetic scheme includes the enzymatic polymerization of multifunctional linker 
molecules (dimethyl 5-hydroxyisopthalate) with poly(ethylene glycol). This chemo-
enzymatic synthesis is much faster and more convenient than an entirely chemical 
synthesis. Subsequent synthetic steps have been developed to attach ligands (for 
targeting), perfluorocarbons (19F MR imaging), fluorescent dyes (NIRF imaging), and 
radioiodine (nuclear imaging and radioimmunotherapy) to the backbone. Attachment of 
hydrocarbon or perfluorocarbon sidechains provides amphiphilicity to produce the 
multimodal self-assembling micelles. Additionally, encapsulation procedures for 
chemotherapeutic agents, doxorubicin and paclitaxel, have been established. These 
unique alternating copolymer micelle nanoparticles were designed as delivery vehicles 
targeted to human cancer cells expressing the underglycosylated mucin-1 antigen, which 
is found on almost all epithelial cell adenocarcinomas, by use of the peptide EPPT or the 
folate receptor (FR) by use of folate.  
Development of the synthetic schemes has been coupled with in vitro toxicity 
experiments using various cell viability assays to minimize the toxic effect of these 
copolymer structures. Overall the polymers used in this study were largely non-toxic 
when studied in vitro. The non-toxic polymers were brought forward into drug delivery 
and uptake experiments. Cell death due to doxorubicin increased with encapsulation in 
these alternating copolymers and increased slightly more with the addition of targeting 
ligand to the encapsulating polymer. Encapsulating paclitaxel in polymer also increased 
cell death as compared to free drug. These results demonstrate that these alternating 
copolymers have had some success as drug delivery vehicles. 
Other in vitro studies included the investigation of cellular uptake by 125I or 3H 
radioactive analysis and fluorescence confocal microscopy. Microscopy images of the 
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fluorescently labeled polymer alone demonstrated that the polymer was likely confined to 
vesicles within the cytoplasm and it was not found in the nucleus, but encapsulated 
doxorubicin was shown to be largely confined to the nucleus. Theoretical models of 
polyvalent binding were employed to guide the design of the targeting polymers, 
however, the polymers used in this study appeared largely non-specific for the targeted 
cells when studied in vitro. The cellular uptake of polymer targeted with EPPT was twice 
that of untargeted polymer, although the difference was not statistically significant. For 
polymers containing folate, regardless of the amount of folate attached, the length of the 
spacer used, or the type of radioactive label used, the uptake did not decrease in the 
presence of an excess of folate, indicating a high amount of non-specific uptake for all 
folate-containing polymers.  
When all of the folate-containing polymers were used to competitively inhibit 3H-
folate, almost all inhibited the uptake by 1 or 2 orders of magnitude, suggesting that the 
targeted polymers bind to the FR. An in-depth study of the cell-association of these 
polymers clarified that polymer was taken up non-specifically in high amounts. An 
excess of unlabeled folate, up- or down-regulation of the FR, and cleaving the FR did not 
measurably affect polymer uptake, but did alter folate uptake. It was also determined that 
a low level of polymer does bind to the FR. The amount of surface bound polymer was 
much lower than the total uptake of polymer in folate-free media for each polymer 
concentration investigated. In addition, the amount of surface bound folate and polymer 
decreased when the FR was cleaved, confirming the attachment of polymer to the FR. 
Light scattering measurements showed that polymers that contain folate form 
aggregates of multiple polymers chains. It is possible that this aggregation was allowing a 
portion of the folate ligands to be hidden in the aggregate and unavailable for binding to 
the FR, the most likely mechanistic cause of the failure of the folate-containing polymers 
to demonstrate targeting. The versatility of these polymer constructs allows for continued 
optimization of a targeting delivery system for drugs and imaging agents as lessons 
discovered from passed studies are incorporated into the design. 
Initial in vivo biodistribution studies were begun to explore the behavior of these 
polymers in mouse models of human cancers. The alternating copolymers used in this 
study do accumulate in tumors in vivo, comparable to the levels of accumulation 
observed in the literature. It is desirable to minimize the accumulation in other organs, 
while maximizing the accumulation in the tumor tissue. Therefore, this preliminary study 
warrants continued investigation of our polymer platform as a delivery vehicle in vitro 
and in vivo.   
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Chapter 1. Introduction 
 
1.1. Cancer 
Cancer is the collective group of diseases distinguished by uninhibited growth and 
spread of abnormal cells. It often results in death if the spread is not controlled. Cancer is 
second only to heart disease as the leading cause of death in the United States. It is 
estimated that 565,650 people in the United States died of cancer in 2008 and that the 
overall costs for cancer in the year 2007 were $219.2 billion [1]. Most cancers are treated 
by surgery, radiation, chemotherapy, hormones, or immunotherapy. However, currently 
there are many issues with these forms of treatment, namely the lack of ability to 
consistently remove the entire tumor and the side effect of killing normal cells during the 
treatment process. Therefore there has been an increased interest in targeted drug delivery 
to tumors to specifically kill cancer cells. 
1.2. Circulating delivery systems 
In response to this clear need for efficient and selective drug transport to primary 
tumors and their metastases, many circulating delivery systems have been created. There 
are three common types of circulating delivery systems, liposomes, dendrimers, and 
polymeric micelles [2], which are described in more detail below. Many of these systems 
are able to effectively circulate in the bloodstream by the addition of poly(ethylene 
glycol) (PEG) either by adsorption or chemical attachment. Addition of PEG to a delivery 
vehicle creates a dense ‘conformational cloud’ on the exterior conferring the property of 
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stealth to the particle [3]. It is proposed that both the hydrophilic nature and the chain 
flexibility of PEG are necessary to avoid opsonization by plasma proteins and subsequent 
macrophage attack [4]. Interestingly, PEG often serves a dual purpose in polymeric 
micelles, providing the hydrophilic ‘head-group’ necessary for micellization. 
1.2.1. Liposomes 
Liposomes are desirable as drug carriers due to their biocompatibility since they 
are typically constructed either using biological materials like phospholipids or made 
stealth via conjugation to PEG [5]. They form from closed bilayer structures when in 
aqueous solution [6]. Moreover, liposomes can carry both hydrophobic and hydrophilic 
materials and be varied in size and surface properties by careful preparation. The design 
of stealth liposomes (liposomes covered with PEG) targeted to colon cancer cells was 
investigated and it was demonstrated that these liposomes bind to colon cancer cells in a 
specific manner and are internalized through receptor-mediated endocytosis, indicating 
potential to deliver a therapeutic load directly to colon cancer cells in an efficient and 
specific manner [7]. Liposomes are, however, limited by issues of size since macrophage 
recognition and subsequent clearance occurs for particles above ~200 nm. Conjugation to 
PEG does slow macrophage detection, however this retarding effect decreases as 
liposome size increases [8]. Other issues include low stability, non-sterility, and poor 
encapsulation efficiency [9]. 
Polymersomes are an emerging subclass of liposomes.  These bilayer structures 
are self-assembled from synthetic polymers rather than natural polymers. The 
hydrophobic blocks of each molecule tend to associate with each other to minimize direct 
exposure to water, whereas the more hydrophilic blocks face the inner core of the particle 
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and the outer solution and thereby delimit the two interfaces of a typical bilayer 
membrane [10, 11]. Some polymer-based shells have exploited a thick hydrophobic 
membrane and a hydrophilic core to efficiently carry both hydrophobic and hydrophilic 
drugs, respectively paclitaxel and doxorubicin [12]. These polymersomes caused two-
fold higher cell death in tumors than free drug suggesting promise for multi-drug 
delivery. 
1.2.2. Dendrimers 
Dendrimers are highly branched macromolecules synthesized by either divergent 
or convergent methods [13] yielding highly monodisperse particles with a high number of 
surface units per area as well as an adaptable internal environment [14]. Although 
dendrimeric drug delivery systems have achieved successes in in vitro studies [15], the 
time-consuming and expensive methods required to synthesize dendrimers does not lead 
to a process scaleable to industrial production. In spite of these constraints, James 
Baker’s group at the University of Michigan has published quite promising in vivo results 
using a PAMAM dendrimeric system targeted to the folic acid receptor overexpressed in 
the KB human cancer cell line [16]. In this work, the chemotherapeutic methotrexate was 
delivered to mice bearing KB tumor xenografts. The dendrimers were covalently attached 
to both fluorescein-5-isothiocyanate  (FITC) and tritium for post-experiment histological 
assays. Their delivery system reduced methotrexate toxicity ten-fold and nearly doubled 
survival time in the methotrexate-treated group in comparison to controls. Additionally, 
current work in Paula Hammond’s lab at the Massachusetts Institute of Technology has 
focused on linear dendritic block copolymer micelles as targeted delivery systems [17]. 
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In this system, the linear block can be chosen to improve encapsulation, while the 
dendritic exterior provides many surface groups for addition of targeting capability.  
1.2.3. Polymeric micelles 
Polymeric micelles [18-21] are amphiphilic colloids that spontaneously form 
aggregates composed of several amphiphilic molecules at concentrations and 
temperatures conducive for doing so. The critical micelle concentration (CMC) is the 
concentration above which micelle formation begins at a particular temperature. Below 
the CMC, the amphiphilic sub-units remain solubilized in the solvent. The resulting 
particles are typically ~5-100 nm in diameter and are usually spherical in morphology. 
Polymeric micelles are composed of two major components. The interior, 
hydrophobic core is a hospitable environment for hydrophobic molecules, such as many 
contrast and therapeutic agents. The solubilization properties of this internal environment 
may be tailored to encapsulate these poorly soluble molecules, sheltering the molecule 
from biological degradation. The second major component is the hydrophilic corona that 
surrounds the hydrophobic core. As previously described, this corona is often PEG, a 
molecule that gives a ‘stealth’ property to a circulating particle [19]. 
According to Torchilin, the ideal polymeric micelle system would have a diameter 
between 5 and 100 nm, demonstrate stability both in vitro and in vivo (low CMC and 
stability until reaching the desired destination), disintegrate into biocompatible materials 
after delivery, and encapsulate the desired agent in sufficient quantities [18]. The upper 
limit of the size recommendation is necessary in order to avoid clearance by the 
macrophages of the reticuloendothelial system (RES). The lower limit ensures that the 
delivery vehicle avoids rapid clearance by renal exclusion and that it takes advantage of 
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the enhanced permeability and retention (EPR) effect where passive targeting is possible 
due to the ‘leaky’ vasculature often encountered in tumors [22-26], as described in more 
detail below. Acknowledging the tremendous advantages in size, stability, 
biocompatibility, and adaptability attributed to polymeric micelles, the next step is to 
endeavor to construct delivery systems with the most ideal biodistribution and 
pharmacokinetic characteristics. 
There has been a great deal of activity in the field of polymeric micelle drug 
delivery systems, particularly within the last 10-15 years. The most extensive 
achievement in polymeric micelle delivery has been by Kazunori Kataoka’s group at the 
University of Tokyo. Their work began with poly(ethylene glycol)-poly(aspartic acid) 
block copolymers [PEG-PAsp] [27] and has since expanded to include other block 
copolymers (including PEG-poly(D,L-lactide) [PEG-PLA]), as well as polyion complex 
(PIC) micelles [20]. Most, if not all, of Kataoka’s initial work does not include any 
targeting, instead relying on passive uptake via the EPR effect. The original PEG-PAsp 
system was chemically conjugated to the chemotherapeutic agent, doxorubicin, and this 
system is currently in clinical trials in Japan [28]. Other investigators have explored 
solubilization of aromatic molecules in poly(ethylene oxide)-poly(propylene oxide) block 
copolymer [PEO-PPO] micelles measuring various solute partition coefficients [29], 
while others have examined the cellular distribution of a PEO-poly(caprolactone) block 
copolymer showing accumulation in the cytoplasm and mitochondria, but not in the 
nucleus using a triple-staining technique [30]. 
Recent work using paclitaxel-loaded poly(DL-lactide-co-glycolide) [PLGA] block 
copolymer nanoparticles showed successful increase of tumor doubling time from 11 
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days in control animals to greater than 25 days for treated animals [31]. These PLGA 
nanoparticles, which included an isopropyl myristate release modifier, were targeted to 
the wheat germ agglutinin receptor. Other researchers have employed a poly(γ-glutamic 
acid)-b-poly(lactide) [PG-PLA] block copolymer conjugated with Rhodamine-123 
targeted to the ASGP receptor using galactosamine [32]. Their results have shown a 
linear uptake profile in time, suggesting ligand-mediated particle internalization as a 
potential mechanism. Most recently, Farokhzad and Langer have developed PLGA-b-
PEG block copolymer nanoparticles encapsulating docetaxel bioconjugated to an aptamer 
targeted to the prostate-specific membrane antigen [33]. Aptamers are oligonucleotides 
that fold into conformations that bind to targets with high affinity and specificity [34]. 
The treatment group receiving the targeted, drug-loaded nanoparticles had 100% survival 
with 5 of 7 animals having complete tumor regression, whereas only 20% or less of the 
control group mice survived during the 109 day experiment [33]. 
A number of shell cross-linked polymer micelle systems (SCKs) have been 
developed [35] in an attempt to improve micelle stability in the dilute conditions 
encountered upon injection in vivo. These SCKs are typically block copolymer micelles 
that include polyion metal complex cores that may be chemically induced to form cross-
links [36]. Moreover, these SCK systems have been used to try to alter the delivery 
pharmacokinetics. The Karen Wooley group at Washington University has developed 
SCK micelles that may be used for controlled release via thermolytic cleavage of the 
cross-linking bonds [37]. The Kazumori Kataoka group has developed an SCK-like 
system whose disulfide cross-linked stabilization is sensitive to glutathione concentration, 
the most abundant reducing agent present in the cytoplasm [38]. 
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1.3. Alternating copolymer micelle nanoparticles 
     Supramolecular assemblies can be made to form nanospherical structures for 
drug delivery or carrying contrast agent, such as liposomes [39-41] and polymer micelles 
[19, 42-45]. Polymeric micelles have previously been prepared from block copolymers 
containing hydrophobic and hydrophilic segments that aggregate in aqueous solution to 
form a nanoparticle with a hydrophobic cavity and the hydrophilic segments often 
forming part of the surface of the aggregate. To make the nanoparticles more 
biocompatible and nonimmunogenic, polyethylene glycol (PEG) is grafted to the 
aggregate or is one of the blocks. 
     The amphiphilic alternating copolymer system used in this work was first 
described in August, 2004 [46]. The alternating copolymer chains, which self-assemble 
into nanospheres, offer a number of advantages over both liposomes and block 
copolymer micelles as a result of their unique chemical structure. The fundamental units 
are a hydrophilic segment, typically PEG (MW 600-1,500 Da) and a trifunctional, 
hydrophobic linker molecule. These base units are polymerized to yield the base polymer 
(MW 5,000-20,000 Da). Hydrophobic side chains, such as hydrocarbons or 
perfluorocarbons, can be attached to the functional group of the linkers. For targeting 
purposes, ligands can be coupled to the free PEG hydroxyls at the ends of each base 
polymer chain or attached to the functional group of the linkers. When dissolved in water 
above the critical micelle concentration, about 8 to 12 polymer chains self assemble into 
a spherical micelle consisting of a compact core of hydrophobic side chains covered by 
linkers with an external corona of deformable PEG loops. Additional agents can be 
encapsulated in the core, for example, by dissolving the polymer and agent in a solvent, 
CHAPTER 1. INTRODUCTION 
 
 
  32  
evaporating the solvent, and dissolving the resulting viscous mixture in water. The 
structure is stabilized by the water-soluble PEG at the exterior surface and by 
hydrophobic interactions between the linkers, side chains, and agents. Depending upon 
chemical composition, the micelles have a molecular weight of about 100-200,000 Da.   
     Through the use of various PEG lengths, linkers, side chains, and ligands, 
great flexibility in chemical composition, size, structure, and function can be obtained. 
Conceptually, this kind of functionality might be achieved with conventional chemistry 
only by use of complex and time-consuming multiple-step reaction pathways that involve 
synthesis of a suitable monomer with a protected functional group prior to the 
polymerization step, followed by deprotection. Fortunately, the development of these 
alternating copolymer structures is carried out with a novel and straight-forward chemo-
enzymatic approach [46, 47] that makes synthesis of these nanoparticles feasible from a 
practical standpoint. Details of the synthesis and physical characterization of the 
polymers used in this study are given in Chapter 2. 
1.4. Targeting of tumor cells 
1.4.1. Passive targeting by the enhanced permeability and retention (EPR) effect 
The increased accumulation of soluble macromolecules, such as liposomes, 
polymer-conjugated drugs, and proteins, in solid tumors as compared to normal tissue has 
been well documented [48-55]. This phenomenon, described as the “enhanced 
permeability and retention (EPR) effect” [56-58], is attributed to pathophysiological 
characteristics of solid tumors that are not observed in normal tissue. These 
characteristics include defective tumor blood vessel architecture (often termed “leaky 
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vasculature”), defective lymphatic drainage system, and increased production of 
permeability mediators [22, 24]. It has been reported that particles >5 nm in diameter get 
trapped in the tumor tissue [18, 23], but tumors exhibit a characteristic pore cutoff size 
ranging from 200 nm to 1.2 μm [25]. Drug delivery particles in the 5-200 nm size range 
should benefit from the EPR effect. 
1.4.2. Active targeting with ligand/antigen pairs 
Targeting the polymer micelles to a tumor cell is necessary in drug delivery in 
order to kill the cancerous cells without damaging normal cells. There are many 
technologies which are being used to target molecules to tumor cells. Often, a 
monoclonal antibody, a peptide fragment, or a small molecule is used as the targeting 
agent. Typically these targeting agents form a ligand/antigen pair with the target found on 
the tumor cell surface. It is desirable for the target antigen to be over expressed on the 
tumor cells, be vital to tumor progression so that expression is not downregulated during 
the life of the tumor, and have limited shedding. The targeting ligand should have a high 
specific affinity for the target antigen, have low immunogenicity in vivo, and be 
efficiently internalized after binding to the antigen.  
One of the most difficult aspects of tumor cell targeting is that each type of cancer 
must often be targeted in its own way since different proteins are over expressed on 
various cancer cells. The table below shows some examples of ligand/antigen pairs and 
the type of cancer in which the antigen is over expressed. The most commonly studied 
targeting pairs are epidermal growth factor (EGF)/EGF receptor and the folate/folate 
receptor. 
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Table 1.1. Targeting pairs in cancer. 
Targeting Agent Target Type of Cancer Ref 
Lipid Low-Density Lipoprotein Receptor Most human cancers [59] 
Epidermal Growth Factor 
(EGF) EGF Receptor Most human cancers [41] 
Transferrin Transferrin Receptor Malignant gliomas [60, 61] 
EPPT/alpha-M2 uMUC1 Human epithelial cell adenocarcinomas [62] 
Vitamin B-12 (cobalamin) Transcobalamin and B-12 Receptor Most human cancers [63] 
Folate Folate Receptor Epithelial malignancies [64] 
Bombesin (BN)/Gastrin 
Releasing Peptide (GRP) BN/GRP Receptor Small cell lung cancer [65] 
Anti-Carcinoembryonic 
Antigen (CEA) antibody CEA Colorectal cancer [66] 
Telomerase Inhibitor Telomerase 90% of all malignant human cancers [67] 
 
1.4.2.1. EPPT as a targeting ligand to MUC1 
A successful in vivo drug carrier for cancer therapy needs (1) to be highly specific 
for tumor marker(s) and not normal tissues and (2) to display a high affinity for its 
molecular target. Conversely, the target for the drug carrier should be (1) present on a 
wide range of human cancers, (2) abundantly expressed on tumor cells but not on normal 
cells, and (3) indispensable for tumor survival and hence always present, showing 
nonvariable, high-level tumoral expression. As a suitable target, mucin-1 (MUC1), a 
transmembrane molecule, expressed by most glandular epithelial cells [68, 69] was 
selected. Several important features make mucin-1 an attractive target: 
 
1. MUC1 is overexpressed on the cell surface and in intracellular compartments of 
almost all human epithelial cell adenocarcinomas, including more than 90% of human 
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breast cancers [70-73], ovarian [74-76], pancreatic [77], colorectal [78], lung [79, 80], 
prostate [81], colon [77, 82] and gastric carcinomas [83, 84], and expression has been 
demonstrated in non-epithelial cancer cell lines (astrocytoma, melanoma, and 
neuroblastoma [82]), as well as in hematological malignancies such as multiple 
myeloma and some B-cell non-Hodgkin lymphomas [85-88], constituting more than 
50% of all cancers in humans [89]. 
2. In adenocarcinomatous tissue, the ordered architecture of the gland is lost, and 
basolateral and apical cell surfaces are not distinct. As a result, MUC1 is ubiquitously 
expressed all over the cell surface [90]. Because of its rod-like structure, the molecule 
extends more than 100-200 nm above the surface, which is 5-10 fold longer than most 
membrane molecules [91]. This feature makes MUC1 an accessible target for drug 
delivery nanospheres. 
3. MUC1 is heavily glycosylated (50-90% of its molecular mass is due to carbohydrates) 
in normal tissues but underglycosylated in neoplastic tissues. The biochemical basis of 
underglycosylated mucin-1 in tumors (uMUC1) has been well investigated. Normal 
MUC1 consists of a tandemly repeated 20-amino acid sequence found in the 
extracellular portion of the molecule and present in 30-90 copies. Within each repeat 
sequence, there are five potential glycosylation sites. However, in the malignant state, 
the oligosaccharide chains are prematurely terminated by the addition of sialic acids, 
which limit their branching potential[90]. Reduced glycosylation permits the immune 
system to access the epitopes of the peptide core of the tumor-associated uMUC1 [92] 
that are masked by oligosaccharides in the normal cells, making it possible to design 
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probes with discriminating capacity between normal cells and adenocarcinoma cells 
[93]. 
4. The extracellular domain of uMUC1 defined by the presence of a PDTRP sequence 
extends above the cell surface, thus interfering with the interaction between adhesion 
molecules on the tumor cell surface and their ligands on lymphocytes and aiding in the 
inaccessibility of tumor epitopes to immune recognition [94-100]. Therefore, there is 
little or no response to immunotherapy and, hence, no tumor antigen downregulation. 
The expression of uMUC1 on tumor cells of epithelial cell adenocarcinomas remains 
homogeneously upregulated during the life of the tumor [101]. Furthermore, uMUC1 
antigen is found both in primary tumors and tumor metastasis [73]. These features are 
important in designing the drug carriers for different stages of tumor progression. 
5. uMUC1 undergoes rapid turnover. It is internalized in clathrin-coated pits, which bud 
to form coated vesicles at a rate twice that of normal MUC1, trafficks though 
intracellular compartments including lysosomes, and recycles to the plasma membrane 
[102] in a process akin to receptor recycling in receptor-mediated endocytosis [103]. 
The total intracellular residence time is 66 minutes in human mammary carcinoma 
cells [104]. This rapid turnover continuously brings new uMUC1 to the cell surface, 
which would be beneficial to the targeting process. 
 
It is important to note, however, that there is one significant disadvantage to using 
mucin-1 as a target. It has been determined that the extracellular domain of mucin-1 
undergoes a proteolytic cleavage early in its processing. The extracellular subunit 
remains associated with the transmembrane region and cytoplasmic tail, via a 
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noncovalent bond, throughout intracellular processing and transport to the cell surface 
[105-107]. Despite the strong association of the noncovalent bond between the subunits, 
soluble forms of the extracellular region have been found in the media of cultured cells 
and in sera from cancer patients [107]. There have been numerous instances of MUC1 
shedding recently observed [108-111], but it remains to be seen whether or not this will 
affect the use of mucin-1 as the target in vivo.   
There are several cell lines that have been shown in the literature to be uMUC1-
positive or uMUC1-negative. Examples of uMUC1-positive cell lines include a human 
breast carcinoma cell line, BT-20, and a human colorectal adenocarcinoma, LS174T [62]. 
Examples of uMUC1-negative cell lines include a human glioblastoma cell line, U87, and 
a human lung fibroblast cell line, MRC-5 [62, 112]. 
Several investigations have examined uMUC1 as a target for immunotherapy. 
Multiple monoclonal antibodies have been produced to the PDTRP sequence of the 
tandem repeat since its protrusion property is the basis for its exclusive immunogenicity 
[101, 113-118]. However, when antibodies were used as targeting molecules, the 
immunogenicity and long plasma half-life of these proteins were detrimental [119]. 
Consequently, the use of small peptides instead may eliminate these shortcomings 
because peptide ligands are nonimmunogenic and have high affinity and selectivity for 
receptors. In this study it is proposed to use the synthetic peptide EPPT 
(YCAREPPTRTFAYWG), also known as alpha-M2 peptide, derived from the CDR3 Vh 
region of a monoclonal antibody (ASM2) raised against human epithelial cancer cells 
[113, 120]. Previously, this peptide has been labeled with (99mTc) and used to image 
breast carcinomas in vivo [120]. The peptide structure revealed a β-strand type of 
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sequence as the active binding site [121]. The EPPT synthetic peptide has significant 
affinity, KD=2.5 x 10-5 M, for the uMUC1-derived peptide PDTRP, although not as high 
as the affinity of the parent monoclonal antibody, KD=2 x 10-8 M [120]. The EPPT 
peptide was identified as the smallest possible molecule that could be derived from the 
original antibody while still retaining its specificity for the uMUC1 antigen. Six anti-
uMUC1 single-chain antibody fragments with binding affinities in the range of  1 to 12.5 
nM have been characterized [122]. While these peptides had affinities comparable to the 
parent monoclonal antibody, they are substantially larger than the 15-amino acid EPPT. 
Although the EPPT affinity is modest, both the targeted nanoparticle and uMUC1 antigen 
are multivalent, increasing the effective affinity of the particles for uMUC1. All the 
features of the uMUC1 protein listed above (overexpression throughout the cytoplasm 
and the cell surface, aberrant glycosylation exclusively on tumor cells, stability of the 
protein core, clathrin-mediated endocytosis), as well as those characteristics of EPPT 
mentioned here, make this receptor/ligand pair an ideal candidate for targeted drug 
delivery. 
1.4.2.2. Folate as a targeting ligand to the folate receptor 
The folate receptor, which can be targeted with folate, was chosen as a model 
target since it has been described extensively in the literature [123-126]. This model 
targeting system was used for two reasons: 1) to decrease costs associated with polymer 
synthesis during the probing phase of the project and 2) to verify the targeting ability of 
the polymer system in an extensively studied system.   
The folate receptor (FR) is a membrane bound protein that recycles between the 
cell surface and intracellular compartments, internalizing folate and folate conjugates 
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through receptor-mediated endocytosis [123, 127-129]. FR is a high affinity receptor for 
the small molecule folate, or folic acid, with a dissociation constant, KD, for this binding 
event of 1x10-10 M [124, 126, 130]. Its expression is often elevated on the surface of 
many human tumor cells, such as ovarian, lung, breast, brain, endometrial, renal, and 
colon cancers and it is up-regulated in more than 90% of non-mucinous ovarian 
carcinomas [131-135]. The high affinity for this targeting pair and the increased 
expression in malignant tissue makes FR an advantageous target. 
The human nasopharyngeal epidermoid carcinoma cell line, KB, is commonly 
used as the FR-positive cell line for in vitro studies in the literature [136-139]. The uptake 
of folate in KB cells was determined to be ~1x107 molecules per cell [140]. The human 
fibrosarcoma cell line, HT-1080, is often used as the FR-negative cell line and studies 
have shown essentially no uptake of folate in these cells [137, 138]. 
Many studies have used folate and FR for targeted drug delivery and imaging in 
cancer diagnosis and treatment [141, 142]. In vitro experiments have investigated the 
binding to and uptake in FR-positive cells of folate-targeted delivery vehicles such as 
dendrimers [143], liposomes [144, 145], micelles [146-149], nanocapsules [150], or other 
nanoparticles [135]. One study demonstrated a 5-10 fold increase in cell binding of 
liposomes containing PEG-folate conjugates over PEG-folate conjugates not incorporated 
into liposomes [145]. This increase is likely due to the multivalent nature of the 
liposome-bound folate. Other studies have demonstrated the ability of folate-conjugated 
micelles encapsulating the chemotherapeutic drug doxorubicin to be more effective in 
tumor cell killing as compared to micelles without folate due to the folate receptor-
mediated uptake of the targeted micelles in tumor cells [146, 147, 149]. Uptake of folate-
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PEG conjugated superparamagnetic iron oxide nanoparticles was found to be 12-fold 
higher than the untargeted nanoparticles, showing promise as a magnetic resonance 
imaging (MRI) contrast agent [135].  
Several investigations have examined the effect of folate-targeting on therapeutic 
response in vivo. Two groups have demonstrated that tumor volumes in mice treated with 
doxorubicin loaded, folate conjugated nanoparticles were significantly less than in mice 
treated with free doxorubicin or non-targeted nanoparticles [148, 151]. It has also been 
shown in biodistribution studies that dendrimers conjugated to folate and coupled to the 
chemotherapeutic drug methotrexate concentrated in the tumor tissue [16]. Further, these 
targeted dendrimers increased therapeutic efficacy by decreasing tumor volumes and also 
increasing the survival time of the mice as compared to the free drug and non-targeted 
dendrimers. The overexpression of FR in tumor cells, the high affinity of FR for folate, 
and the extensive number of published studies on targeting FR with folate make this 
targeting pair an excellent model for our system. 
1.5. Chemotherapy 
Chemotherapy is a systemic therapy in which the anti-cancer drug is circulated 
throughout the entire body. These chemotherapy drugs prevent cells from replicating in 
the typical, out-of-control manner in which cancer cells divide. In addition, since they are 
circulated through the entire body, these drugs can be effective in treating metastases. 
However, there are other cells in the body which undergo constant and rapid division, 
such as cells in the blood, mouth, intestinal tract, nose, nails, and hair. The growth and 
division of these cells is also slowed by the chemotherapy drugs, thus causing unwanted 
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side effects. Chemotherapy drugs are divided into several categories based on how they 
affect specific chemical substances within cancer cells, which cellular activities or 
processes the drug interferes with, and which specific phases of the cell cycle the drug 
affects. Table 1.2 outlines these categories and includes examples of chemotherapy drugs 
from each group [152]. 
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Table 1.2. Chemotherapy drugs and their mode of action. 
 Mode of Action Cell Cycle Phase Examples 
Alkylating 
agents 
work directly on 
DNA to prevent the 
cancer cell from 
reproducing 
not phase-
specific 
busulfan, cisplatin, carboplatin, 
chlorambucil, cyclophosphamide, 
ifosfamide, dacarbazine (DTIC), 
mechlorethamine (nitrogen 
mustard), and melphalan 
Nitrosoureas 
interfere with 
enzymes that help 
repair DNA 
not phase-
specific 
Carmustine (BCNU) and 
lomustine (CCNU) 
Antimetabolites interfere with DNA and RNA growth S phase 
5-fluorouracil, capecitabine, 
methotrexate, gemcitabine, 
cytarabine (ara-C), and 
fludarabine 
Antitumor 
antibiotics 
interfere with DNA 
by stopping 
enzymes and 
mitosis or altering 
the membranes that 
surround cells 
not phase-
specific 
dactinomycin, daunorubicin, 
doxorubicin (Adriamycin), 
idarubicin, and mitoxantrone 
Mitotic inhibitors 
inhibit, or stop, 
mitosis or inhibit 
enzymes for 
making proteins 
needed for 
reproduction of the 
cell 
M phase 
paclitaxel, docetaxel, etoposide 
(VP-16), vinblastine, vincristine, 
and vinorelbine 
Corticosteroid 
hormones 
used to kill cancer 
cells or slow their 
growth 
not phase-
specific Prednisone and dexamethasone 
Sex hormones 
slow the growth of 
breast, prostate, and 
endometrial cancers
not phase-
specific 
anti-estrogens (tamoxifen, 
fulvestrant), aromatase inhibitors 
(anastrozole, letrozole), 
progestins (megestrol acetate), 
anti-androgens (bicalutamide, 
flutamide), and LHRH agonists 
(leuprolide, goserelin) 
Immunotherapy 
stimulate the 
immune system to 
more effectively 
recognize and 
attack cancer cells 
- - 
Other - - L-asparaginase and tretinoin 
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1.5.1. Doxorubicin  
Doxorubicin (C27H29NO11) was chosen as one of the chemotherapy drugs to be 
used in this project. Doxorubicin hydrochloride, or adriamycin, is approved by the FDA 
for cancer treatment. As shown in the table above, it belongs to the group of 
chemotherapy drugs known as antitumor antibiotics or anthracycline antibiotics. It is used 
to treat non–Hodgkin’s lymphoma, multiple myeloma, acute leukemias, and cancers of 
the breast, adrenal cortex, endometrium, lung, and ovary [153]. In the form of the 
hydrochloride salt, doxorubicin is given by intravenous injection over about 15 minutes. 
An alternative form of this drug is the doxorubicin hydrochloride liposome injection, also 
known as Doxil, in which the active pharmaceutical ingredient, doxorubicin, is 
encapsulated in a liposome coated with polyethylene glycol (PEG) to protect it from 
being damaged by the immune system [154, 155]. This form is given by injection in a 
vein over 1 hour [156]. However, in treatment using either of these forms of doxorubicin, 
normal cells are affected and side effects are experienced.   
One way to decrease the effect on normal cells is to target the chemotherapy drug 
to the cancer cells. A study was recently carried out in which PEG-coated liposomal 
doxorubicin was targeted to breast cancer cells using a monoclonal antibody, B27.29, 
against the uMUC1 antigen [157]. Two models of breast cancer, pseudometastatic and 
metastatic, were examined in mice. In the pseudometastatic model, tumor cells were 
injected into the mouse and metastases were studied in the absence of a primary tumor. In 
this case, survival time was used as the main criterion for determining treatment efficacy. 
When the mice were treated with targeted liposomal doxorubicin, the mean survival time 
was increased from 36.8 days for free doxorubicin and 46.2 days for liposomal 
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doxorubicin to 62.4 days. In the metastatic model, a primary tumor was implanted in the 
fatpad of immunodeficient mice. The therapeutic efficacy was determined by observing 
the growth of the primary tumor by measuring the tumor diameter using calipers. It was 
shown that targeted liposomal doxorubicin and non-targeted liposomal doxorubicin were 
equally effective in preventing growth of the primary tumor, while free doxorubicin was 
ineffective, however, the study was limited by the inability to completely remove the 
primary tumor and therefore the effect on the metastases could not be observed in this 
model. The liposomes used in this study were 90-120 nm in diameter, by dynamic light 
scattering. It is likely that these drug carriers were too large, causing transport issues to 
and throughout the tumors. However, these results are promising for the future of 
targeted anti-cancer drug delivery. 
1.5.2. Paclitaxel 
Paclitaxel (C47H51NO14) was also chosen as one of the chemotherapy drugs to be 
used in this project.  Paclitaxel, or taxol, is a mitotic inhibitor, as shown in Table 1.2. It 
was discovered in 1967 when it was isolated from the bark of the Pacific yew tree. 
Paclitaxel is also available commercially under the name Abraxane, in which the 
paclitaxel is bound to albumin as the delivery agent. Paclitaxel interferes with the normal 
function of microtubules, arresting their function by hyper-stabilizing their structure 
[158]. This destroys the cell's ability to use its cytoskeleton in a flexible manner. 
Specifically, paclitaxel binds to the β subunit of tubulin, the "building block" of 
microtubules. The resulting microtubule/paclitaxel complex does not have the ability to 
disassemble. This adversely affects cell function because the shortening and lengthening 
of microtubules (termed dynamic instability) is necessary for their function as a 
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mechanism to transport other cellular components, such as the chromosomes during 
mitosis. Paclitaxel is approved by the Food and Drug Administration (FDA) to treat 
ovarian and breast cancer, and AIDS-related Kaposi sarcoma. It is also approved to be 
used together with cisplatin, a chemotherapeutic drug, to treat advanced ovarian cancer 
and non-small cell lung cancer (NSCLC) [159].  Paclitaxel has very low water solubility 
(1.5 μg/mL). As a result, this agent already requires administration with a surfactant 
carrier. Currently, the clinically approved carrier to solubilize the drug is Cremophor® 
EL, a polyethylene glycol modified castor oil. Though useful in drug administration, the 
delivery agent itself has negative side effects therefore, an alternate delivery system using 
PEG-PLA micelles, Genexol-PM, has been developed [160]. 
Several groups have used paclitaxel as the therapeutic agent in studies of drug 
delivery systems in order to enhance the solubility of paclitaxel, increasing the drug 
payload that can be delivered to tumor cells.  Paclitaxel-entrapped polymeric micelles, 
based on amphiphilic block copolymers of poly(2-ethyl-2-oxazoline) (PEtOz) and poly(ε-
caprolactone) (PCL), exhibited comparable activity to that observed with the clinically 
used formulation of Cremophore EL-based paclitaxel in inhibiting the growth of KB cells 
[161]. Paclitaxel-loaded nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene 
glycol)-poly(D,L-lactide) (PLA/MPEG-PLA) blends were formulated by the 
nanoprecipitation method for controlled release of paclitaxel [162]. The formulation of 
these nanoparticles could be tailored to achieve a desired release rate of the drug. Others 
have extended this research, using paclitaxel in targeted drug delivery systems, in order 
to increase the selective killing of tumor cells while decreasing the effect on normal cells. 
In one study, self-assembled nanoparticles were composed of block copolymers 
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synthesized by poly(γ-glutamic acid) and poly(lactide) loaded with paclitaxel and 
conjugated to galactosamine for the potential targeting of liver cancer cells [163, 164]. In 
the in vitro studies, it was found that the nanoparticles had similar release and 
cytotoxicity profiles to paclitaxel. The biodistribution and anti-tumor efficacy of the 
prepared nanoparticles were studied in hepatoma-tumor-bearing nude mice and it was 
found that the group injected with the galactosamine conjugated, paclitaxel loaded 
nanoparticles appeared to have the most significant efficacy in the reduction of the size of 
the tumor. Several groups have used folate, mentioned in the targeting of tumor cells 
section above, as a targeting agent for paclitaxel delivery. PEO-PPO-PEO/PEG shell 
cross-linked nanocapsules encapsulating an oil phase in their nanoreservoir structure and 
further conjugated with folate were developed as a target-specific carrier for paclitaxel to 
achieve folate receptor targeted delivery [150]. Confocal microscopy and flow cytometric 
analysis revealed that folate-mediated targeting significantly enhanced the cellular uptake 
and apoptotic effect against cancer cells overexpressing the folate receptor. In addition, 
cholesterol-grafted poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide-co-
undecenoic acid) was synthesized and folate was subsequently attached to the hydrophilic 
segment of the polymer [165]. Using a membrane dialysis method, the polymer was then 
self-assembled into micelles whose hydrophobic cores could be utilized to encapsulate 
paclitaxel. In vitro cytotoxicity assays performed against KB cells then provided 
concluding evidence of selective cell death due to a receptor-assisted endocytosis 
process. 
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1.6. Objectives 
In order to improve cancer treatment by selectively killing tumor cells while 
leaving normal cells unaffected, new drug delivery systems specifically targeting tumors 
are necessary. The central hypothesis of this thesis is that targeting PEG-based alternating 
copolymer nanoparticles to tumor cells will increase the cellular uptake of these 
nanoparticles, thereby enhancing the therapeutic efficacy of these nanoparticles when 
used as drug delivery vehicles. I have studied the in vitro cytotoxicity of these particles, 
with or without targeting ligands and containing or not containing chemotherapeutic 
drugs, at relevant dose levels. In addition I have investigated the cellular uptake of the 
nanoparticles to determine the selectivity of these particles for the targeted cells. A 
comprehensive description of the synthesis of the copolymer nanoparticles and details of 
the experimental studies are found in the subsequent chapters. 
1.7. Overview 
Chapter 2: Synthesis of Alternating Copolymer Structures 
This chapter describes the methods that were used by Professor Arthur 
Watterson’s group at the University of Massachusetts, Lowell, to synthesize all of the 
polymers employed in this work and the rationale for designing each of these polymers. 
First, the methods by which the backbone polymers were produced are explained. Next, I 
describe the addition of the ligands to the polymers. Then the techniques to attach a 
variety of side chains and radioactive labels are discussed. The procedures used to 
encapsulate material in the polymer micelles are reported. Finally, a review of the 
physical characterization is given. 
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Chapter 3: In Vitro Cytotoxicity of Alternating Copolymers as Drug Delivery Vehicles 
This chapter discusses the cytotoxic effects of the alternating copolymer 
structures in vitro. Cell death is assessed by mitochondrial function using the tetrazolium 
salt MTS assay. Studies examining the cytotoxicity of the polymers without 
chemotherapeutic drugs are reported. In vitro culture experiments were also carried out to 
assess therapeutic efficacy of the alternating copolymers encapsulating chemotherapeutic 
drugs. 
 
Chapter 4: Evaluation of the Cellular Uptake of Alternating Copolymers In Vitro 
This chapter reports on the assessment of the binding and internalization of the 
alternating copolymers with tumor cells.  The selectivity of the polymers for the targeted 
cells was evaluated using target-positive and target-negative cell lines as well as 
polymers containing the targeting ligand and those not containing the targeting ligand. 
Cellular association was determined by radioactive labeling of the polymer with 125I, 14C, 
or 3H, or by competitive inhibition of radioactively labeled ligand. Theoretical modeling, 
including polyvalency estimates and ligand tether length calculations, was used to direct 
the design of the targeting polymers, as well as compliment the experimental results.   
 
Chapter 5: Initial Results on the Pharmacokinetics of Alternating Copolymers In Vivo 
This chapter describes the in vivo experimental work that was done in 
collaboration with Kevin Brower from the Colton Lab in the Department of Chemical 
Engineering at the Massachusetts Institute of Technology. Preliminary pharmacokinetic 
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studies were performed to examine the biodistribution and blood-half lives of the 
alternating copolymers in xenograft models of human tumors in nude mice using 
radioactively labeled polymers.  Results were obtained by collecting blood samples and 
harvesting organs at specified time points and measuring the radioactivity of these 
samples.   
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Chapter 2. Synthesis of Alternating Copolymer Structures 
 
The syntheses of all polymers used in this project were carried out by Dr. Rahul 
Tyagi, Dr. Mukesh Pandey, and Bhavna Gupta in Prof. Arthur Watterson’s group at the 
University of Massachusetts, Lowell (UML). The radioiodination of these polymers was 
performed by Kevin Brower in Professor Clark Colton’s group at the Massachusetts 
Institute of Technology (MIT). The physical characterization was performed by Dr. Jin 
Zhou Dawson in Prof. Clark Colton’s group at MIT. The following descriptions are based 
on papers published (or to be published) by the Watterson group and the Colton Group, 
the doctoral thesis of Rahul Tyagi, and the doctoral thesis of Jin Zhou Dawson [1-7]. A 
detailed description of each synthesis protocol can be found in Appendix I and a list of all 
polymer structures used in this project is given in Appendix II. 
2.1. Enzymatic polymerization 
Recent investigation has demonstrated the utility of employing enzymes to 
perform traditional chemical polymerizations in a more efficient and selective manner [8, 
9]. In particular, immobilized Candida antarctica Lipase B (Novozyme-435) for organic 
synthesis overcomes a number of problems traditionally encountered in polyester 
chemistry. The high enantio- and regiospecificity of the enzyme in the condensation 
reaction of diacids/diesters with diols to form polyesters is desirable since protection and 
deprotection steps may be avoided while attaining a high molecular weight linear 
polymerization product with very little branching. An additional benefit is that the 
chemistry can proceed without a solvent due to the solubility, albeit to a limited extent, of 
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diacids in diols. The polymerization, therefore, is an example of a ‘green chemistry’ [3]. 
The immobilized lipase has been used in various polyesterifications, two of which are 
presented as examples in Figure 2.1 and Figure 2.2. 
 
 
 
Figure 2.1. Examples of bulk polyesterification of a diester with diol using 
Novozyme-435 under mild reaction conditions, where R = -CH=CH2 [10], -H [11]. 
 
 
 
 
Figure 2.2. Chemo-enzymatic condensation using Novozyme-435 of a diester and 
diol to form a polyester. 
 
A critical factor in achieving a high molecular weight product is the removal of 
the condensation byproduct, ROH, such as water (Figure 2.1) or methanol (Figure 2.2), or 
the vinyl alcohol byproduct, acetaldehyde (CH3CHO) (Figure 2.1) [10, 11]. Continual 
removal of the byproduct shifts the equilibrium towards the polymer product. 
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The mechanism for the polymerization by Novozyme-435 has been investigated 
by Binns et. al. by performing GPC analysis of the oligomers present during the reaction 
using synthesized low molecular weight intermediates for comparison [11]. In the 
proposed mechanism, shown in Figure 2.2, the enzyme forms an active complex by 
acylating the diacid (or diester), A, which then reacts with the diol, B, to form the 
intermediate, AB. The enzyme then acylates the second acid site forming an activated 
Enz-AB complex for addition to a B(AB)n oligomer. Essentially, in the acylation step, the 
enzyme attaches itself to the oligomer via a ‘pseudo-ester bond’ forming a highly reactive 
intermediate where the enzyme itself is the leaving group in the subsequent reaction. This 
step-wise mechanism was also reported during investigation of polyesterification using 
Aspergillus niger lipase [12]. 
A reaction scheme has been developed by Watterson and colleagues at UML [1-4, 
13] that utilizes Novozyme-435 to synthesize the backbone polymer as the first step in 
the production of amphiphilic alternating copolymers with potential application in the 
field of imaging and drug delivery. It is presented in Figure 2.2. For this reaction, 
dimethyl 5-hydroxyisophthalate participates as the diester while poly(ethylene glycol-
900) (PEG-900) is the diol. The product is the polyester poly[poly(oxyethylene-900)-
oxy-5-hydroxyisophthaloyl]. The condensation byproduct, methanol, is removed from the 
reacting mixture by vacuum. The condensation product is the ‘backbone polymer.’ 
Application of a suitably low vacuum to remove the methanol is necessary to shift the 
equilibrium towards the polymer product since the reaction energetics alone are not 
favorable enough to achieve sufficiently high molecular weights.   
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A portion of the dimethyl 5-hydroxyisophthalate can be replaced with dimethyl 5-
aminoisophthalate if amino groups are desired for downstream functionalization, as 
shown in Figure 2.3. This demonstrates the basis of the flexibility of these amphiphilic 
polymers. After the backbone polymer is produced by the enzymatic polymerization, the 
subsequent synthetic steps are determined by the desired functionality for the ultimate 
alternating amphiphilic copolymer product. 
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Figure 2.3. Backbone polymer synthesis using two linker molecules with distinct 
functionality. 
 
2.2. Attachment of hydrocarbon side chains 
Hydrocarbon side chains can be attached to the hydroxyl or amino groups on the linkers 
by simple substitution reactions along the backbone to give the resulting product its 
amphiphilic nature. It is this amphiphilic property that allows for the formation of 
micelles, demonstrated by the cartoon in Figure 2.4. The hydrocarbon side chains can be 
attached by several different linkages, including an ether bond (example shown in Figure 
2.5), an ester bond (example shown in Figure 2.6), an amide bond, or an ether ester bond. 
CHAPTER 2. SYNTHESIS OF ALTERNATING COPOLYMER STRUCTURES 
 
 
  69  
In the attachment via the ester linkage, the highly reactive acid chloride terminus of the 
nonanoyl chloride reacts with the many free hydroxyl groups on the backbone. The acid 
chloride is so reactive that it is likely that it also reacts with the free hydroxyl group on 
the end of the polymer backbone. During the development of this project, the cytotoxicity 
of the polymers formed by hydrocarbon attachment via each of these bonds was 
investigated. These results are discussed in Chapter 3. Different bonds were used 
throughout the project depending on the desired properties of the polymer.   
 
Chemical Reaction
Trifunctional Linker
+
PEG
Enzymatic Reaction
Alternating 
Copolymer 
Backbone
+
= CH3, OH, COOH, NH2
Self Assemble
Micelle
 
Figure 2.4. Formation of self-assembling alternating copolymer micelles. 
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Figure 2.5. Hydrocarbon side chain attachment via the ether bond. 
 
 
 
 
Figure 2.6. Hydrocarbon side chain attachment via the ester bond. 
 
2.3. Attachment of perfluorocarbon side chains 
A synthetic method was also developed for the attachment of perfluorinated side 
chains. These side chains serve a dual purpose in that they not only act as a contrast agent 
in 19F-MRI but are also extremely hydrophobic thereby imparting amphiphilicity to the 
resulting polymer. Thus, these perfluorocarbon (PFC) side chains can replace the need for 
hydrocarbon side chains in the self-assembly mechanism for micelle formation. PFC side 
chains have been attached by an ether ester bond to the hydroxyl linkers (shown in Figure 
2.7) or by an amide bond to the amino linkers. To accomplish the attachment through an 
ether ester bond, a perfluorinated alcohol is converted into a perfluorinated bromoester by 
addition of bromoacetic acid in the presence of the lipase Novozyme-435 under vacuum. 
This activated perfluorocarbon is then added to the linker hydroxyl group on the 
backbone polymer in acetonitrile with potassium carbonate to produce polymer having 
perfluorinated side chains [4]. To accomplish the attachment through an amide bond, the 
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acid chloride of the PFC was reacted with the backbone polymer containing free amino 
groups on the linkers, giving the desired polymer with perfluorinated side chains. 
 
 
 
Figure 2.7. Attachment of perfluorinated sidechains to the backbone polymer for 
potential use in 19F MRI imaging applications. 
 
2.4. Attachment of fluorescent labels 
Fluorescent labels were attached to the studied polymers for two purposes. First, 
the labeled polymers could be observed in vitro experiments by confocal microscopy to 
provide insight into the interaction of these polymers with cells. In addition, the 
attachment of some fluorescent labels, for example Cy 5.5, offers the potential for these 
labeled polymers to be used for near infrared fluorescence (NIRF) imaging. The amino 
group on the linker can be used as an attachment point for fluorescent dyes including 
FITC and Cy 5.5. The attachment of the former is demonstrated in Figure 2.8 where the 
amine group on the backbone polymer readily reacts with the isothiocyanate group (NCS) 
on FITC to produce the labeled polymer, which can be functionalized as desired [5]. 
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Figure 2.8. Attachment of the fluorescent dye, FITC, to the amine functionality of 
the backbone polymer. 
 
2.5. Attachment of targeting ligands 
2.5.1. EPPT 
Our collaborators at UML successfully attached the targeting peptide, EPPT, via 
two synthetic routes. The first synthetic route, shown in Figure 2.9, attached the EPPT via 
the spacer triethylene glycol (TEG). The first step involved the attachment of the small 
hydrophilic spacer molecule to the polymer at the hydroxyl groups of the linkers. The 
quantity of triethylene glycol added to the reaction mixture determined the percent of side 
chains in the final product that were devoted to the peptide. Next, the hydroxyl group of 
the hydrophilic spacer was activated by the addition of disuccinimidyl carbonate. The 
entire EPPT molecule (Ahx-AREPPTRTFAYWG) consists of a short polypeptide 
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terminated by an aminohexanoyl (Ahx) group. The Ahx group provided both a reaction 
site in the amine group as well as an additional spacer between the peptide and reaction 
site [14]. To complete the attachment, EPPT was reacted with the activated group on the 
spacer to produce the targeted polymer. The combined hydrophilic nature of both the 
spacer and the targeting peptide itself are believed to cause the peptide side chains to 
present themselves on the micelle exterior upon self-assembly.  
As will be discussed in Chapter 4, it was determined through experiments and 
modeling that the triethylene glycol spacer used to attach the EPPT to the polymer in the 
first synthetic scheme may not be long enough to allow free binding with no steric 
hindrances. Because of this, a second synthetic route was established by our collaborators 
using bifunctional PEG-3400 as the peptide attachment spacer. The first step of this 
synthetic route involved the protection of the hydroxyl group on the PEG-3400, followed 
by activation of the carboxyl group on the PEG-3400. This activated hydrophilic spacer 
molecule was reacted with the hydroxyl group of the linkers on the polymer backbone. 
Again, the quantity of spacer added to the reaction mixture determines the percent of side 
chains in the final product that will be devoted to the peptide. Next, the end of the 
hydrophilic spacer was deprotected and activated and EPPT was reacted with this 
activated group on to produce the targeted polymer with a longer spacer. Again, the 
combined hydrophilic nature of both the spacer and the targeting peptide should cause the 
peptide side chains to present themselves on the micelle exterior upon self-assembly.  
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Figure 2.9. Attachment of targeting peptide, EPPT, via triethylene glycol. 
 
2.5.2. Folate 
In addition to EPPT, folate, which targets the folate receptor, was chosen as a 
model target. This targeting system was used for two reasons: 1) to decrease costs 
associated with polymer synthesis during the probing phase of the project and 2) to verify 
the targeting ability of the polymer system in an extensively studied system, as targeting 
with folate has been described at length in the literature (see Chapter 1). Our 
collaborators at UML successfully attached folate via two synthetic routes. In the first 
synthetic route, folate was attached directly to the backbone polymer via the hydroxyl 
groups on the linkers. The folate was first activated and then directly reacted with the 
backbone polymer. The hydrophilic nature of the targeting ligand will allow for the folate 
to present itself on the micelle exterior upon self-assembly. 
As mentioned above, it was determined through experiments and modeling that a 
long spacer may be needed in order to allow free binding of the targeting ligand with the 
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target, avoiding steric hindrances. As with EPPT, a second synthetic route was 
established by our collaborators using bifunctional PEG-3400 as the spacer to attach 
folate. The first step of this synthetic route involved the protection of the hydroxyl group 
on the PEG-3400, followed by activation of the carboxyl group on the PEG-3400. This 
activated hydrophilic spacer molecule was reacted with the hydroxyl group of the linkers 
on the polymer backbone. The end of the hydrophilic spacer was deprotected and 
activated and folate was reacted with this activated group on the spacer to produce the 
targeted polymer with a long spacer. Again, the combined hydrophilic nature of both the 
spacer and the targeting peptide should cause the peptide side chains to present 
themselves on the micelle exterior upon self-assembly. 
2.6. Radiolabeling of polymers 
As with the attachment of PFC side chains and fluorescent labels, radiolabeling of 
polymers has two intentions. Labeling of the polymer with 125I, 14C, or 3H allow for 
measurement of cellular uptake of these polymers in vitro. Results obtained from these 
measurements are discussed in Chapter 4. The same labeling techniques can be used to 
attach 124I to the polymer, allowing for positron emission tomography (PET) imaging. 
Radioiodine can be added via exchange with the aromatic hydrogens that are 
present on the linker molecule as well as with the tyrosine, phenylalanine, and tryptophan 
molecules on the EPPT peptide. There are a number of methods available to perform the 
exchange reaction, including the iodogen and iodobead methods [15]. In the iodobead 
method the targeted polymer is added to a vial containing a single iodobead along with 
Na125I. The iodobead is conjugated to a molecule that catalyzes the iodine substitution 
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labeling. All radioiodinations were performed by Kevin Brower in the Colton group at 
MIT. Polymers labeled with 125I can be quantified using a gamma counter. 
Labeling of polymers with 14C is easily accomplished through methylation. A 
methyl group containing 14C can react by nucleophilic substitution at a hydroxyl group, 
such as the hydroxyl group on the linker, thereby labeling the polymer with 14C. 
Alternatively, 3H is added to the polymer by using commercially available 3H-folate in 
the targeting ligand attachment step. For this project, polymers containing folate were the 
only ones labeled with 3H. Polymers labeled with 14C or 3H can be quantified using a 
scintillation counter. 
2.7. Encapsulation of chemotherapeutic drugs in polymer micelles 
It has been demonstrated that a variety of small molecules including drugs 
(aspirin, naproxen) may be encapsulated by the self-assembly process described above [3, 
16]. Larger molecules such as proteins (insulin) and polysaccharides (inulin) have also 
been encapsulated since the nanospheres can adjust to the size of the encapsulant 
molecule in the self-assembly process. For use in this study, a hydrophilic 
chemotherapeutic drug, doxorubicin, was encapsulated in the form of its hydrochloride 
salt. All encapsulations were performed by our collaborators in Professor Arthur 
Watterson’s lab at UML, as described in Appendix I. To encapsulate doxorubicin, the 
polymer and drug were each dissolved in water, the solutions were mixed, and then 
dialyzed against water to remove unencapsulated drug. During the study, it was 
determined that this procedure may not be reliable or reproducible, as discussed in 
Chapter 3. In order to use a more reliable procedure, a hydrophobic chemotherapeutic 
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drug, paclitaxel, was used. To encapsulate paclitaxel, the polymer and drug were 
dissolved in a solvent, such as chloroform or methanol, the solvent was evaporated, and 
the viscous mixture was dissolved in water to allow for formation of the encapsulating 
micelles. The structure of the micelles is stabilized by the water-soluble PEG at the 
exterior surface and by hydrophobic interactions between the linkers, side chains and 
encapsulated drug.  
2.8. Physical Characterization 
The physical characterization of the polymers was the focus of the doctoral thesis 
of Jin Zhou Dawson in the Colton group at MIT [7]. The size and morphology of the 
nanoparticles was characterized by dynamic light scattering, transmission electron 
microscopy (TEM), cryo-TEM, and small angle neutron scattering (SANS). It was 
determined that micelles formed from the polymers described above are spheroidal with a 
radius of about 4-5 nm with hydrocarbon side chains, 8-9 nm with PFC side chains, and 
11 nm with PFC side chains and encapsulated PFC. The hydrodynamic radius of micelles 
did not change with polymer concentration, PEG length, sample preparation method, or 
time after sample preparation. The polymers were found to form two populations of 
particles – small micelles and large secondary aggregates. The large secondary 
aggregates were most likely compound micelles. The sample preparation method, 
polymer molecular weight, and time after sample preparation could change the proportion 
of micelles versus aggregates.  
The critical micelle concentration (CMC) was determined by surface tension 
measurements. The CMC was measured as 12 μM for polymers with hydrocarbon side 
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chains and 2 μM for polymers with PFC side chains. The PFC side chains may be useful 
when it is desired to keep the micelle intact at low concentration.  
Preliminary studies of the polymers with PFC side chains by 19F-MRI were 
performed to investigate the use of the polymers as imaging agents. Micellization of these 
polymers caused the spectral lines, as measured by 19F-NMR, to broadened indicating a 
reduction in the signal-to-noise ratio (SNR).  Consequently, it is difficult to utilize 19F-
NMR to measure biological samples loaded with polymers with PFC side chains in vitro 
because the SNR is too low. 
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Chapter 3. In Vitro Cytotoxicity of Polymers as Drug Delivery Vehicles 
 
3.1. Introduction 
Polymeric micelle-based carriers have been developed by many groups and are 
currently under investigation for drug and imaging agent delivery [1-20]. Polymeric 
micelles, with various drugs incorporated into the inner core by chemical conjugation or 
physical entrapment, are expected to increase the accumulation of those drugs in tumor 
tissues by using passive and active targeting. Targeted micelles are selective for tumor 
cells, allowing for reduced incidence of the adverse side effects of chemotherapeutic 
drugs. Several polymeric micelle systems, for which clinical trials are now underway, 
have been reviewed [21]. 
One of the essential requirements for drug and imaging agent carriers is that they 
have no inherent cytotoxicity [22-25]. In the present study, we investigated the toxic 
effects of a variety of alternating copolymers using cell culture systems. In addition, we 
examined the use of these carriers as drug delivery vehicles when loaded with 
chemotherapeutic drugs. Cytotoxicity was assessed by measuring the mitochondrial 
function of the cells being tested. The MTS assay tests the reduction of the tetrazolium 
salt MTS by mitochondrial reactions to form a dye molecule with an absorbance 
spectrum different from the parent dye [26-28]. The measurement of absorbance over 
time is correlated to the viability of the cells. We selected five types of cultured cells (BT-
20 (uMUC1+), U87 (uMUC1-), KB (FR+), HT-1080 (FR-), and INS-1), applicable to the 
uptake studies discussed in Chapter 4, for use in these cytotoxicity studies.  
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This chapter clarifies the effect of the structure of the alternating copolymer, 
including linker type, PEG length, side chain type, side chain bond type, side chain 
length, ligand type, ligand spacer type, and imaging agent type, on the degree of toxicity 
in cultured cells and establishes the drug delivery capabilities of these alternating 
copolymers. A detailed description of the synthesis protocol for each polymer can be 
found in Appendix I. A list of all polymer structures used in this study is given in 
Appendix II. The numbers referred to throughout the text correspond to polymer 
structures in the table in Appendix II. 
3.2. Methods 
3.2.1. Materials and reagents 
All polymers were provided by our collaborators in Professor Arthur Watterson’s 
lab at the University of Massachusetts, Lowell. All reagents were obtained from 
commercial sources. Poly-ethylene glycol (PEG-900), 5-methyl hydroxyl isophthalate, 5-
methyl amino isophthalate, and β-mercaptoethanol were obtained from Sigma Aldrich. 
Dulbecco’s phosphate buffered saline (DPBS) and distilled deionized sterile water, 
trypsin EDTA (1X, 0.25% trypsin/0.53 mM EDTA in HBSS), penicillin-streptomycin 
solution, RPMI, D-glucose, L-glutamine, sodium pyruvate, and fetal bovine serum (FBS) 
were purchased from Mediatech, Inc. Minimum essential media, Eagle, with 2 mM L-
glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-
essential amino acids, and 1.0 mM sodium pyruvate (EMEM) was purchased from 
ATCC. CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay kits (for MTS) 
were purchased from Promega. Fluorescein-5-isothiocyanate (FITC) was purchased from 
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American Peptide. Rhodamine B was purchased from EMD Chemicals. Doxorubicin 
(DOX) and paclitaxel (PAC) were purchased from EMD Biosciences. 
3.2.2. Cell lines and culture 
BT-20 cells (human breast carcinoma; uMUC1+), U87 cells (human brain 
glioblastoma; uMUC1-), MRC-5 cells (human lung fibroblast; uMUC1-), KB cells 
(human epidermoid carcinoma; FR+), and HT-1080 cells (human fibrosarcoma; FR-) 
were purchased from American Type Culture Collection and INS-1 cells (rat insulinoma) 
were a gift from Chris Newgard at Duke University. BT-20, U87, MRC-5, KB, and HT-
1080 cells were all cultured in EMEM supplemented with 10% FBS and 1% penicillin–
streptomycin solution. INS-1 cells were cultured in RPMI supplemented with 11.1 mM 
D-glucose, 1% penicillin–streptomycin solution, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 μM β-mercaptoethanol, and 10% FBS. All cells were grown under sterile 
conditions at 37°C in a humidified atmosphere containing 5% CO2. 
3.2.3. Cytotoxicity assay 
The MTS-based in vitro cytotoxicity assay was performed to determine the effects 
of polymers against relevant cell lines. Reduction of a water soluble tetrazolium 
compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetraolium, inner salt (MTS), by cells was measured using the CellTiter 96® Aqueous 
Non-Radioactive Cell Proliferation Assay kit. The cells growing as a mono-layer were 
harvested with trypsin EDTA (1X, 0.25% trypsin/0.53 mM EDTA in HBSS). Each cell 
line was seeded on a 96-well plate at a cell density of 2 x 105 cells/mL 16 hours before 
the start of the test. Solutions were made by dissolving polymer (0.1-13.2 g/L; 1 g/L 
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unless otherwise noted), polymer component (1 g/L), or drug (0.0003-0.02 g/L) in cell 
media and sterile filtering through a 0.2 μm filter. Cells were incubated with the test 
solution under sterile conditions at 37°C in a humidified atmosphere containing 5% CO2. 
At each time point (0, 2, 6, 24, and 48 hr), the cell media (for control cells) or polymer 
solution (for test cells) was removed from each well of the 96-well plate. The combined 
electron coupling reagent phenazine methosulfate and MTS solution (MTS/PMS) and 25 
mM glucose in DPBS are premixed in a ration of 1:5. For each well, 120 μL of the 
premixed solution are added. The same amount of this solution is also added to three 
empty wells to be used as background readings. The absorbance is measured at 490 nm at 
10 min intervals for 60 min in a plate reader (FLUOstar/POLARstar Galaxy, BMG 
LABTECH, Durham, NC). The slope (rate of increase of absorbance with time), 
determined by linear least squares regression, is proportional to the number of viable 
cells. The fraction of viable cells was calculated relative to control cells, thus accounting 
for normal cell population growth. 
3.2.4. Imaging of aggregation 
Polymer solutions in cell media (100 μL) were pipetted into a 96-well plate. At 
each time point, the polymer solution was observed under an optical light microscope and 
photographs of each were taken. Polymer solutions were observed for various times (0-48 
hours) at several concentrations (1-10 g/L) to determine the time- and concentration-
dependent aggregation of polymer. 
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3.2.5. Encapsulation of drug 
Separate solutions were made of 200 mg polymer (any polymer containing 
hydrophobic side chains which can form a micelle) in 5 mL distilled deionized sterile 
water and 5 mg DOX in 5 mL distilled deionized sterile water. The two solutions were 
mixed together and further diluted to make a resultant solution of 20 mL. The mixture 
was dialyzed against distilled deionized sterile water (100 mL) using a MWCO 1000 
membrane. The dialysate water was changed frequently. Dialysis was continued while 
the DOX content of the dialysate was analyzed in a fluorescence plate reader 
(FLUOstar/POLARstar Galaxy, BMG LABTECH, Durham, NC) with excitation at 480 
nm and emission at 590 nm. 
3.2.6. Statistical analysis 
All data were represented as mean ± standard deviation. 
3.3. Results 
3.3.1. Backbone Polymers 
The cytotoxicity of each of the three major components that make up the polymer 
backbone, poly-ethylene glycol (PEG-900), 5-methyl hydroxyl isophthalate, and 5-
methyl amino isophthalate, was established using the MTS assay. A solution of each 
polymer component in cell media was prepared at a concentration of 1 g/L. Each of these 
reagents showed no cytotoxicity in uMUC1- (U87) cells over 48 hours. However, in 
uMUC1+ (BT-20) cells some mild toxicity was observed for the amino isophthalate and a 
significant amount of toxicity was measured for the hydroxyl isophthlate (Figure 3.1). 
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Figure 3.1. Cytotoxicity of the individual polymer components poly-ethylene glycol 
(PEG-900), 5-methyl hydroxyl isophthalate, and 5-methyl amino isophthalate at 1 
g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
 
The backbone of the polymer was produced using three variations of linker 
molecules: 100% 5-methyl hydroxyl isophthalate (#23), 100% 5-methyl amino 
isophthalate (#32), and 95% 5-methyl hydroxyl isophthalate plus 5% 5-methyl amino 
isophthalate (#24). The cytotoxicity of each backbone polymer was determined at a 
concentration of 1 g/L using the MTS assay. All three backbone polymers were non-toxic 
to both the uMUC1- (U87) and uMUC1+ (BT-20) cells (Figure 3.2). 
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Figure 3.2.  Cytotoxicity of backbone polymers with various linkers: 100% 5-methyl 
hydroxyl isophthalate (#23), 100% 5-methyl amino isophthalate (#32), and 95% 5-
methyl hydroxyl isophthalate plus 5% 5-methyl amino isophthalate (#24) at 1 g/L in 
uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
 
3.3.2. Base Polymers 
Some polymers with only hydrocarbon side chains, which were expected to have 
no cytotoxicity, exhibited some toxicity in vitro. It was hypothesized that residual 
triethylamine (TEA), a reagent used in the hydrocarbon side chain attachment reaction, 
caused the toxicity. When TEA was replaced by potassium bromide (KBr) as the base in 
the attachment step, in vitro experiments did not indicate cytotoxicity. This confirms that 
polymers synthesized in the presence of TEA (#22) were cytotoxic, while those 
synthesized in the absence of TEA (#27) were not (Figure 3.3). 
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Figure 3.3. Cytotoxicity due to residual TEA: polymers synthesized in the presence 
of TEA (#22) were cytotoxic, while those synthesized in the absence of TEA (#27) at 
1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
 
Polymers synthesized in the presence of TEA (#22) also aggregated when in 
solution at a concentration of 1 g/L at 37°C over the course of 48 hours. Examples of this 
aggregation are shown in the time-course optical microscope images in Figure 3.4. 
Perhaps this aggregation resulted in the observed cytotoxicity of these polymers. When 
the synthesis was altered to avoid the use of TEA, the aggregation was no longer 
observed. 
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Figure 3.4. Example of aggregation of polymers synthesized in the presence of TEA 
(#22) when in solution at 1 g/L at 37°C over the course of 48 hours. 
 
Base polymers were also synthesized using backbone polymer containing 
different PEG lengths. Figure 3.5 shows the cytotoxicity results for three base polymers 
with hydrocarbon side chains attached via an amide bond. Each polymer differed in the 
length of the PEG that was used to synthesize the backbone polymer: PEG-600 (#52), 
PEG-900 (#53), or PEG-1500 (#54). The polymer containing PEG-600 in the backbone 
demonstrated toxic effects in the FR- cells (HT-1080), but not in the FR+ cells (KB). 
Otherwise, no differences in cytotoxicity were observed due to PEG length. 
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Figure 3.5. Effect of PEG length on cytotoxicity: polymer with PEG-600 (#52), PEG-
900 (#53), or PEG-1500 (#54) in the backbone at = 1 g/L in FR- (HT-1080) and FR+ 
(KB) cells (n=3). 
 
The effects of five different hydrocarbon side chain bond types were explored. 
The attachment of the side chain to the backbone at the linker molecule was 
accomplished using ether (#26), ester (#27), ester and amide (#25), amide (#53), and 
ether-ester (#57) bond types. The toxicity of each was assayed, showing that polymer 
with side chains attached by ether bonds were cytotoxic in uMUC1- and uMUC1+ cells 
after 48 hours of incubation, but polymer with side chains attached by ester bonds or by 
ester and amide bonds were not cytotoxic in vitro (Figure 3.6). In addition, polymers with 
side chains attached by amide bonds were slightly cytotoxic in FR+ cells at 48 hours, but 
not in FR- cells, and polymers with side chains attached by ether-ester bonds were not 
cytotoxic (Figure 3.7). All bond types were not tested in all cell types due to cell line 
availability issues and material limitations. 
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Figure 3.6. Effect of side chain bond type on cytotoxicity: polymer with attachment 
of the side chain to the backbone at the linker molecule using ether (#26), ester 
(#27), or ester and amide (#25) bond at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-
20) cells (n=3). 
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Figure 3.7. Effect of side chain bond type on cytotoxicity: polymer with attachment 
of the side chain to the backbone at the linker molecule using amide (#53) and ether-
ester (#57) bond at 1 g/L in FR- (HT-1080) and FR+ (KB) cells (n=3). 
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In the study of the effect of bond types, the ether bond was used to attach a 9 
carbon side chain, the ester bond was used to attach a 10 carbon side chain, and the ether-
ester bond was used to attach an 8 carbon side chain. Therfore, it was unclear whether the 
side chain length or the bond type was responsible for the toxicity. It was hypothesized 
that the number of carbons in the hydrocarbon side chain could affect the toxicity, either 
by affecting the length of the side chain or by determining the odd or even numbered 
nature of the side chain. The results of the cytotoxicity of polymers with hydrocarbon 
side chains, containing 9 carbons (#34) or 10 carbons (#26), attached by ether bonds are 
shown in Figure 3.8. Both polymers were cytotoxic, however, the polymer with 9-carbon 
side chains caused more cell death. In Figure 3.9, toxicity results are shown for polymers 
with hydrocarbon side chains attached by ester bonds, again with either 9 carbons (#27) 
or 10 carbons (#31). No cytotoxicity was observed for either polymer with ester bonds. 
Figure 3.10 exhibits the toxicity results for polymers with hydrocarbon side chains, with 
6 (#58), 8 (#57), or 12 (#62) carbons, attached by ether-ester bonds. The polymer with 6-
carbon side chains was cytotoxic in FR- cells, but the cells revived by the 48 hour time 
point. It was not cytotoxic in FR+ cells. The polymers with 8-carbon and 12-carbon side 
chains were not cytotoxic. This study confirms that the cytotoxic effects observed with 
polymers with ether-linked side chain are due to the bond type and not the number of 
carbons in the side chains. 
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Figure 3.8. Effect of side chain length when attached by ether bond: polymer with 
hydrocarbon side chains attached by ether bonds containing 9 carbons (#34) or 10 
carbons (#26) at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
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Figure 3.9. Effect of side chain length when attached by ester bond: polymer with 
hydrocarbon side chains attached by ester bonds containing 9 carbons (#27) or 10 
carbons (#31) at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
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Figure 3.10. Effect of side chain length when attached by ether-ester bond: polymer 
with hydrocarbon side chains attached by ether-ester bonds containing 6 carbons 
(#58), 8 carbons (#57), or 12 carbons (#62) at 1 g/L in FR- (HT-1080) and FR+ (KB) 
cells (n=3). 
 
3.3.3. Targeting Polymers 
3.3.3.1. EPPT ligand 
The targeting ligand EPPT has been attached to our polymer by two different 
attachment methods and in variable amounts. The cytotoxicity results for all polymers 
containing EPPT attached by triethylene glycol (TEG) are shown in Figure 3.11. Polymer 
with 5% of the linkers having TEG-EPPT attached and the remaining 95% of the linkers 
having either hydrocarbon side chains (#37) or no side chains (#33) were completely 
non-toxic in vitro up to 48 hours. Polymer with 7% of the linkers having TEG-EPPT 
attached and no other side chains (#42) was mildly toxic in uMUC1+ cells at 24 hours, 
but non-toxic in uMUC1- cells. Polymer with 34% of the linkers having TEG-EPPT 
attached and no other side chains (#44) was mildly toxic in uMUC1- cells at 48 hours, 
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but very toxic in uMUC1+ cells. This trend implies increased cytotoxicity with increased 
percent of targeting peptide, possibly due to increased cellular uptake of the polymers 
with increased percent of EPPT. Figure 3.12 shows the cytotoxicity results for polymer 
containing EPPT attached by PEG-3400 (#65). This polymer demonstrated no 
cytotoxicity in vitro over the 48 hour assay time period. Consequently, these results were 
used in planning the uptake experiments described in Chapter 4. 
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Figure 3.11. Cytotoxicity of EPPT-containing polymers: polymer with 5% of the 
linkers having TEG-EPPT attached and the remaining 95% of the linkers having 
hydrocarbon side chains (#37), polymer with 5% of the linkers having TEG-EPPT 
attached and the remaining 95% of the linkers having no side chains (#33), polymer 
with 7% of the linkers having TEG-EPPT attached and no other side chains (#42) 
and polymer with 34% of the linkers having TEG-EPPT attached and no other side 
chains (#44) at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
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Figure 3.12. Cytotoxicity of EPPT-containing polymer: polymer containing EPPT 
attached by PEG-3400 (#65) at 1 g/L in FR- (HT-1080) and FR+ (KB) cells (n=3). 
 
3.3.3.2. Folate ligand 
Varying amounts of the targeting ligand folate has been covalently bound to our 
polymer by three different methods. Figure 3.13 illustrates the cytotoxicity results for two 
polymers that contain folate attached directly to the backbone via the isophthalate linker 
at a concentration of 1 g/L. Polymer with 10% of the linkers having folate attached and 
no other side chains (#50) was not toxic in vitro, but when the remaining 90% of the 
linkers had hydrocarbon side chains attached (#51), the polymer was cytotoxic to both 
FR- and FR+ cells over 48 hours. Folate was also attached to the polymer via a PEG-
3400 spacer at one end of the polymer chain. The cytotoxicity data for two polymers 
containing folate attached in this manner are shown in Figure 3.14. Polymer with PEG-
3400-folate attached at the end of the polymer chain, either with (#59) or without (#56) 
side chains, gave no cytotoxic response with the FR- or FR+ cells.  
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Polymers were also synthesized with folate attached via a PEG-3400 spacer to the 
linker molecule in the backbone and the cytotoxicity results of these polymers are shown 
in Figure 3.15. Polymer with 25% of the linkers having PEG-3400-folate attached and no 
other side chains (#60) was not toxic in either cell line, whereas with the remaining 75% 
of the linkers having hydrocarbon side chains attached (#61), mild toxicity was observed 
only in the FR+ cells. Finally, polymer with 100% of the linkers having PEG-3400-folate 
attached (#64) demonstrated no cytotoxicity. These results indicate that adding 
hydrocarbon side chains to any of the polymers containing folate increases cytotoxicity at 
this higher polymer concentration.  
The cytotoxicity assay was performed at lower concentrations for the two folate-
containing polymers that included hydrocarbon side chains to assess possible dose 
effects. Polymer with 10% of the linkers having folate attached and the remaining 90% 
having hydrocarbon side chains attached (#51) and polymer with  25% of the linkers 
having PEG-3400-folate attached and the remaining 75% having hydrocarbon side chains 
attached (#61) were both not toxic at 0.1 g/L (Figure 3.16). This concentration was used 
in planning the uptake experiments described in Chapter 4. 
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Figure 3.13. Cytotoxicity of folate-containing polymers with folate attached to 
backbone: polymer with 10% of the linkers having folate attached and no other side 
chains (#50) and polymer with 10% of the linkers having folate attached and the 
remaining 90% of the linkers having hydrocarbon side chains attached (#51) at 1 
g/L in FR- (HT-1080) and FR+ (KB) cells (n=3). 
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Figure 3.14. Cytotoxicity of folate-containing polymers with folate attached at end of 
polymer chain: polymer with PEG-3400-folate attached at the end of the polymer 
chain with hydrocarbon side chains (#59) and polymer with PEG-3400-folate 
attached at the end of the polymer chain without side chains (#56) at 1 g/L in FR- 
(HT-1080) and FR+ (KB) cells (n=3). 
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Figure 3.15. Cytotoxicity of folate-containing polymers with folate attached by PEG-
3400: polymer with 25% of the linkers having PEG-3400-folate attached and no 
other side chains (#60) at 1 g/L, polymer with 25% of the linkers having PEG-3400-
folate attached and the remaining 75% of the linkers having hydrocarbon side 
chains attached (#61) at 0.5 g/L, and polymer with 100% of the linkers having PEG-
3400-folate attached (#64) at 1 g/L in FR- (HT-1080) and FR+ (KB) cells (n=3). 
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Figure 3.16. Cytotoxicity of folate-containing polymers at lower concentrations: 
polymer with 10% of the linkers having folate attached and the remaining 90% 
having hydrocarbon side chains attached (#51) at 0.5 g/L and 0.1 g/L and polymer 
with  25% of the linkers having PEG-3400-folate attached and the remaining 75% 
having hydrocarbon side chains attached (#61) at 0.1 g/L in FR- (HT-1080) and FR+ 
(KB) cells (n=3). 
 
3.3.4. Imaging Polymers 
Perfluorocarbon (PFC) was attached to the polymer for the investigation of 19F-
MRI applications by Dr. Jin Zhou Dawson, as mentioned in Chapter 2. The cytotoxicity 
of these polymers was measured in vitro. Polymer with 12-carbon PFC side chains 
attached by ether-ester bonds (#8), polymer with 10-carbon PFC side chains attached by 
ether-ester bonds (#9), and polymer with 7-carbon PFC side chains attached by amide 
bonds (#12) all showed no cytotoxicity in INS-1 cells (Figure 3.17). This implies that 
there is no toxic effect of bond type or number of carbons with PFC side chains. Also, 
PFC-containing polymer with PEG-600 in the backbone (#9) and PFC-containing 
polymer with PEG-900 in the backbone (#10) were both not toxic to INS-1 cells (Figure 
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3.18). The effect on cytotoxicity of PEG length in the backbone of PFC-containing 
polymers was also considered. The PFC-containing polymer with PEG-1500 in the 
backbone (#41) showed no toxic response. However, PFC-containing polymer with PEG-
600 in the backbone (#43) demonstrated toxicity in uMUC1+ cells, but not in uMUC1- 
cells (Figure 3.19). These results imply a correlation between decreased PEG length in 
the backbone and increased cytotoxicity, as also observed with hydrocarbon side chains. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 10 20 30 40 50
Ether Ester, 12 Carbons
Ether Ester, 10 Carbons
Amide, 7 Carbons
Fr
ac
tio
n 
of
 V
ia
bl
e 
C
el
ls
Incubation Time (hr)
INS-1 Cells
Bond Type, # in Side Chain
Fr
ac
tio
n 
of
 V
ia
bl
e 
C
el
ls
 
Figure 3.17. Effect of bond type and number of carbons in side chain on cytotoxicity 
of PFC-containing polymers: polymer with 12-carbon PFC side chains attached by 
ether-ester bonds (#8), polymer with 10-carbon PFC side chains attached by ether-
ester bonds (#9), and polymer with 7-carbon PFC side chains attached by amide 
bonds (#12) at 1 g/L in INS-1 cells (n=3). 
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Figure 3.18. Effect of PEG length in backbone on cytotoxicity of PFC-containing 
polymer: PFC-containing polymer with PEG-600 in the backbone (#9) and PFC-
containing polymer with PEG-900 in the backbone (#10) at 1 g/L in INS-1 cells 
(n=3). 
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Figure 3.19. Effect of PEG length in backbone on cytotoxicity of PFC-containing 
polymers: PFC-containing polymer with PEG-1500 in the backbone (#41) and PFC-
containing polymer with PEG-600 in the backbone (#43) at 1 g/L in uMUC1- (U87) 
and uMUC1+ (BT-20) cells (n=3). 
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Rhodamine B was the first fluorescent dye that was attached to the linker 
molecules in the polymer. As seen in Figure 3.20, polymer with 10% Rhodamine B 
attached and 90% hydrocarbon side chains (#4) was cytotoxic. This cytotoxic effect was 
due to the presence of Rhodamine B, as evidenced by the toxic effect of free Rhodamine 
B. Our collaborators at UML replaced Rhodamine B with FITC as the fluorescent dye in 
the polymer synthesis. Figure 3.21 shows the cytotoxicity data of free FITC, polymer 
with 5% FITC and 95% no side chains (#40), and polymer with 5% FITC and 95% 
hydrocarbon side chains (#28). No cytotoxicity was observed with free FITC or polymer 
with 5% FITC and no other side chains. Some cytotoxicity was seen for polymer with 5% 
FITC and 95% hydrocarbon side chains at the 48 hour time point. Since the hydrocarbon 
side chains were attached by ether bonds, this results was not surprising. The cytotoxicity 
of these hydrocarbon bonds was observed without FITC present, as discussed previously. 
Figure 3.22 shows the cytotoxocity results for polymer containing 5% Cy 5.5 and 95% 
hydrocarbon side chains (#17). Cytotoxicity was observed, however this is probably the 
effect of TEA since this polymer was synthesized before TEA was removed from that 
procedure. 
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Figure 3.20. Cytotoxicity of Rhodamine B: free Rhodamine B and polymer with 
10% Rhodamine B attached and 90% hydrocarbon side chains (#4) at 1 g/L in INS-
1 cells (n=3). 
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Figure 3.21. Cytotoxicity of FITC: free FITC, polymer with 5% FITC and 95% no 
side chains (#40), and polymer with 5% FITC and 95% hydrocarbon side chains 
(#28) at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
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Figure 3.22. Cytotoxicity of Cy 5.5: polymer containing 5% Cy 5.5 and 95% 
hydrocarbon side chains (#17) at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells 
(n=3). 
 
3.3.5. Complex Polymers 
Several complex polymers were synthesized containing FITC, PFC, and EPPT in 
various combinations and amounts. Figure 3.23 shows the cytotoxicity results of these 
complex polymers. Polymer with 5% FITC and 95% PFC (#13) showed no cytotoxicity. 
Polymer with 5% EPPT, 5% FITC, and 90% PFC (#29) was slightly cytotoxic in vitro at 
the 48 hour time point. Polymer with 5% EPPT and 95% PFC (#36) and polymer with 
5% EPPT, 5% FITC, and 90% no side chains (#39) were both cytotoxic. It was 
hypothesized that the harsher conditions of multiple processing steps may have left 
impurities which caused cytotoxicity of these complex polymers. 
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Figure 3.23. Cytotoxicity of complex polymers: polymer with 5% FITC and 95% 
PFC (#13), polymer with 5% EPPT, 5% FITC, and 90% PFC (#29), polymer with 
5% EPPT and 95% PFC (#36) and polymer with 5% EPPT, 5% FITC, and 90% no 
side chains (#39) at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
 
3.3.6. Polymers as Drug Delivery Vehicles 
Initial drug delivery experiments used untargeted polymers with encapsulated 
doxorubicin (DOX). All in vitro drug delivery experiments were performed using 
material encapsulated by our collaborators in Professor Arthur Watterson’s lab at UML, 
as described in Appendix I. In vitro cell death was measured in order to assess the drug 
delivery capability of these polymers. Figure 3.24 shows the drug delivery data for 
polymer containing hydrocarbon side chains with (#14) and without (#26) encapsulated 
DOX. The polymer without encapsulated DOX showed no toxicity, however the polymer 
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with encapsulated DOX showed significant cell death within 24 hours, regardless of 
polymer concentration. The drug delivery data for polymer containing PFC side chains 
with (#15) and without (#43) encapsulated DOX is shown in Figure 3.25. Again, the 
polymer without encapsulated DOX showed no toxicity. However, the polymer with 
encapsulated DOX also did not show toxicity. One possibility is that the PFC side chains 
are more hydrophobic than hydrocarbon side chains, creating a more stable cargo-loaded 
vesicle that does not easily release drug. Another explanation is that the encapsulation 
procedure itself was not successful; the possibility of which is described below. 
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Figure 3.24. Untargeted drug delivery of DOX in polymer containing hydrocarbon 
side chains: polymer containing hydrocarbon side chains with (#14) and without 
(#26) encapsulated DOX in uMUC1- (U87) cells (n=3). 
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Figure 3.25. Untargeted drug delivery of DOX in polymer containing PFC side 
chains: polymer containing PFC side chains with (#15) and without (#43) 
encapsulated DOX in uMUC1- (U87) cells (n=3). 
 
Once the synthetic approach for attaching targeting ligand was developed by our 
collaborators, cytotoxicity experiments were performed to compare cell death in uMUC1- 
and uMUC1+ cells by DOX encapsulated in polymer with and without targeting peptide. 
All experiments used concentrations of 1 g/L polymer and/or 0.02 g/L DOX. Drug 
delivery experiments using DOX encapsulated in polymer with ester-linked hydrocarbon 
side chains with (#38) and without (#35) EPPT peptide were inconclusive due to 
reproducibility issues (Figure 3.26). Two batches of each polymer encapsulating DOX 
were made. Each batch was tested at two days in solution and two weeks in solution. 
Batch 1 of each polymer showed no toxicity in either cell line after two days in solution. 
However, after two weeks in solution, batch 1 of both polymers demonstrated toxicity in 
uMUC1+ cells. Batch 2 of each polymer shows no toxicity in either cell line after two 
days or two weeks in solution, thus exhibiting a lack of reproducibility. In addition, the 
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uMUC1- cell line showed resistance to free DOX, which was later verified in the 
literature [29]. 
Figure 3.27 compares the positive case of cell death due to encapsulated DOX in 
polymer with (#38) and without peptide (#35) from Figure 3.26 with free DOX, the same 
polymers not encapsulating DOX (#37 and #27), and the same polymers in solution with 
free DOX. There was no cell death due to polymer with or without peptide when no DOX 
was encapsulated. In addition, solutions of polymer and free DOX mimic the cell death 
effect of free DOX without polymer. However, loss of viability due to DOX increases 
with encapsulation and increases slightly more with addition of targeting ligand. This 
indicates that the cell death observed in Figure 3.26 can not be explained as DOX having 
been released from the polymer micelles over the two weeks in solution. Encouragingly, 
the greatest loss of viability occurs in uMUC-1+ cells exposed to polymer with peptide 
encapsulating DOX. 
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Figure 3.26 Cell death due to encapsulated DOX: polymer with ester-linked 
hydrocarbon side chains with (#38) and without (#35) EPPT peptide at a polymer 
concentration of 1 g/L and DOX concentration of 0.02 g/L in uMUC1- (U87) and 
uMUC1+ (BT-20) cells (n=3). A and B are for polymer in solution for two days, 
while C and D are for polymer in solution for two weeks. 
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Figure 3.27. Comparison of cell death due to various forms of polymer and DOX: 
polymer with ester-linked hydrocarbon side chains with (#38) and without (#35) 
EPPT peptide at a polymer concentration of 1 g/L and DOX concentration of 0.02 
g/L in uMUC1+ (BT-20) cells (n=3). 
 
Due to the lack of reproducibility in the drug delivery of encapsulated DOX, the 
encapsulation method used by our collaborators at UML was questioned. Experiments 
were initiated to investigate the kinetics of encapsulation and release of DOX from 
micelles of polymer with ester-linked hydrocarbon side chains (#27). All in vitro drug 
delivery data discussed above was performed using material encapsulated by our 
collaborators in Professor Arthur Watterson’s lab at UML, as described in Appendix I. 
For these kinetic experiments, the same method of encapsulation was used, but the DOX 
content of the dialysate was measured by fluorescence plate reader. In the first 
experiment, the dialysate was changed every 24-72 hours and the DOX content of the 
dialysate was measured each time it was changed. The results of this experiment are 
shown in Figure 3.28 as total percent of DOX removed by dialysis as a function of time. 
Throughout the 266 hour time course of this experiment, the percent of DOX removed in 
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the dialysate continued to increase. Since no plateau was reached, it appears that 
equilibrium was not attained. This indicates that the previous encapsulations likely 
resulted in different amounts of encapsulated DOX, as the dialysis was terminated at 
various times, making the results difficult to compare between polymer batches. A 
second experiment was performed at three different temperatures. The dialysate at each 
temperature was not changed at all during the experiment. Figure 3.29 shows the results 
for this experiment, again as total percent of DOX removed by dialysis as a function of 
time. The amount of DOX removed increased with increasing temperature, possibly 
because the higher temperature increases the solubility of DOX in water. A plateau is 
reached at both 25°C and 37°C within 60 hours. However, this merely indicates that the 
solubility limit for DOX in water was reached, since the dialysate was not changed. There 
is no evidence that DOX is actually encapsulated and that no free DOX remains in the 
polymer solution. 
DOX, in the form of its hydrochloride salt, is hydrophilic, leading to the water-
based encapsulation method used here. It was hypothesized that the lack of 
reproducibility in the encapsulation was due to this hydrophilic encapsulation method. 
This DOX encapsulation method used by UML was examined in our lab and found to be 
faulty. Therefore, the project shifted to using the chemotherapeutic drug paclitaxel 
(PAC), a highly hydrophobic drug, such that a well-established hydrophobic 
encapsulation method, described in Appendix I, could be used. 
 
CHAPTER 3. IN VITRO CYTOTOXICITY OF POLYMERS AS DRUG DELIVERY VEHICLES 
 
 
  113  
0
20
40
60
80
100
0 50 100 150 200 250 300
%
 D
ox
or
ub
ic
in
 R
em
ov
ed
 b
y 
D
ia
ly
si
s
Dialysis Time (hr)  
Figure 3.28. Encapsulation of DOX by dialysis, changing dialysate throughout, 
starting with 5 mg DOX and 200 mg polymer in 20 mL water. 
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Figure 3.29. Encapsulation of DOX by dialysis, without changing dialysate, starting 
with 5 mg DOX and 200 mg polymer in 20 mL water. 
 
Drug delivery experiments were performed with encapsulated PAC in polymer 
with ester-linked hydrocarbon side chains. Figure 3.30 shows the cytotoxicity results for 
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encapsulated PAC in polymer with ester-linked hydrocarbon side chains without peptide 
(#49), polymer with ester-linked hydrocarbon side chains without peptide not 
encapsulating PAC (#27), and free PAC. The polymer concentration was 1 g/L. When 
PAC was encapsulated in polymer it resulted in a concentration of 0.02 g/L, however, the 
concentration of free PAC was 0.0003 g/L, the maximum allowed by the solubility limit 
of PAC in water. Merely by encapsulating the drug in polymer, the solubility, and 
thereby the deliverable dose, was increased. Again, the polymer not encapsulating drug is 
not toxic. Encapsulating PAC in polymer increased cell death versus free PAC, however, 
this is likely due to the increased deliverable dose. 
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Figure 3.30. Cell death due to encapsulated PAC: encapsulated PAC in polymer 
with ester-linked hydrocarbon side chains without peptide (#49), polymer with 
ester-linked hydrocarbon side chains without peptide (#27), and free PAC at a 
polymer concentration of 1 g/L, encapsulated PAC concentration of 0.02 g/L, and 
free PAC concentration of 0.0003 g/L in uMUC1+ (BT-20) cells  (n=3). 
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3.4. Discussion 
Overall the polymers used in this study were largely non-toxic when studied in 
vitro. This characteristic enhances the appeal of using these polymers as drug delivery 
vehicles. Given the mild toxicity of the isophthalate linkers, there could be concern if the 
polymers break down in vivo. However, the lack of toxicity of the backbone polymers 
indicates that this will not be a problem. Trace amounts of one reagent, TEA, caused 
toxicity, but changing the reagent resolved the toxicity problem. PEG-600 in the 
backbone caused slight toxicity, but polymers with PEG-900 or PEG-1500 were not 
toxic. Polymers with hydrocarbon side chains attached by ether linkage were toxic and 
polymers with hydrocarbon side chains attached by amide linker were slightly toxic, but 
polymers with ester, ester and amide, and ether-ester linkages were not. In polymers with 
ester-linked hydrocarbon side chains, the length of the side chains did not affect toxicity. 
In polymers with ether-linked and ether-ester-linked hydrocarbon side chains, toxicity 
increased with decreasing side chain length. 
Polymers with EPPT attached by triethylene glycol increased in toxicity with 
increasing percent substitution with EPPT. However, polymers with EPPT attached by 
PEG-3400 were not toxic, even with 100% of the side chains substituted with PEG-3400-
EPPT. Polymer containing folate attached directly to the backbone and no side chains 
was not toxic, but it was toxic with hydrocarbon side chains. Polymers containing folate 
attached at the end of the polymer chain were not toxic. Polymers with folate attached to 
the backbone by PEG-3400 were not toxic except for some mild toxicity when the 
polymer also contained hydrocarbon side chains. All folate-containing polymers were not 
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toxic at lower concentrations, more indicative of the concentrations used in the uptake 
experiments discussed in Chapter 4. 
Polymers containing PFC were not toxic regardless of bond type attaching the 
PFC side chains or the length of those side chains. However, as with polymers with 
hydrocarbon side chains, PEG-600 in the backbone of PFC-containing polymer caused 
toxicity, but polymers with PEG-900 or PEG-1500 were not toxic. Polymer with 
Rhodamine B was very toxic, but it was later determined that free Rhodamine B was 
toxic. Free FITC and polymer with FITC were not cytotoxic, unless the polymer also 
contained hydrocarbon side chains. Polymer with Cy 5.5 was toxic, but the polymer also 
contained hydrocarbon side chains. Polymer containing both FITC and PFC was not toxic 
and polymer containing FITC, PFC and EPPT only showed slight cytotoxicity. However, 
polymer with EPPT and FITC and polymer with EPPT and PFC were both toxic. It 
appears that simple imaging polymers only containing the imaging agent on the backbone 
polymer are not toxic, but further investigation of imaging agents in more complex 
polymers is necessary. 
Drug delivery experiments were performed using polymer encapsulating DOX or 
PAC. DOX encapsulated in polymer containing hydrocarbon side chains demonstrated 
cell death. However, when DOX was encapsulated in polymer containing PFC side 
chains, there was no cell death. It was hypothesized that the higher hydrophobicity of 
PFC side chains may have led to more stable cargo-loaded vesicles that do not easily 
release drug or that drug was not actually encapsulated in this case. Cell death due to 
DOX increased with encapsulation and increased slightly more with the addition of 
targeting ligand to the encapsulating polymer. However, cell death due to DOX 
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encapsulated in polymer with and without polymer was not reproducible. This lack of 
reproducibility was likely due to the poor encapsulation method used by our collaborators 
at UML, leading to variation in the amount of DOX encapsulated. Finally, encapsulating 
PAC in polymer increased cell death as compared to free PAC, probably due to the 
increased deliverable dose allowed by encapsulation in polymer. These results 
demonstrate that these alternating copolymers have had some success as drug delivery 
vehicles in vitro and should be further tested as delivery platforms in vitro and in vivo. 
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Chapter 4. Evaluation of Cellular Uptake of Alternating Copolymers 
In Vitro 
 
4.1. Introduction 
During the past quarter century there has been a steady increase in the number of 
nanoparticles being developed for use as therapeutics, many as anti-cancer therapeutics 
[1-5]. Liposomes, dendrimers, and polymer micelles are all being exploited as platforms 
for nanoparticle drug delivery. Several drug delivery platforms have been approved for 
clinical use [6] and others are showing significant potential in clinical trials [7, 8]. 
Specifically, polymeric micelle-based drug carriers have been developed by many groups 
and are currently under investigation for drug and imaging agent delivery [9-13]. 
Some investigations focus on using polymeric micelles to incorporate various 
drugs into the inner core by chemical conjugation or physical entrapment, using the 
nanoparticles as carriers, or chaperones, for the drug [14-32]. This scheme can increase 
the dose of the drug, by increasing the solubility of very hydrophobic drugs. 
Alternatively, the nanoparticles can protect the drug from destruction under in vivo 
conditions. 
Nanoparticles may be preferentially concentrated at tumor sites through strategic 
targeting. For instance, the phenomenon described as the “enhanced permeability and 
retention (EPR) effect” [33-35], in which nanoparticles accumulate in solid tumors in 
increased amounts as compared to normal tissue has been well documented [36-43] and 
is attributed to pathophysiological characteristics of solid tumors that are not observed in 
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normal tissue. These characteristics include defective tumor blood vessel architecture 
(often termed “leaky vasculature”), defective lymphatic drainage system, and increased 
production of permeability mediators [44, 45]. It has been reported that particles >5 nm in 
diameter get trapped in the tumor tissue [9, 46], but tumors also exhibit a characteristic 
pore cutoff size of 200 nm or greater [47]. Therefore drug delivery particles in the 5-200 
nm size range should passively target tumors due to the EPR effect. It was determined 
that micelles formed from our alternating copolymers are 8-22 nm in diameter [48], 
therefore these particles are in the size range for passive targeting in vivo. 
In addition to passive targeting, nanoparticles can be actively targeted to a tumor 
cell in order to kill the cancerous cells without damaging normal cells. There are many 
technologies which are being used to specifically target molecules or particles to tumor 
cells [49-62]. Often, a monoclonal antibody, a peptide fragment, or a small molecule is 
used as the targeting agent. Typically these targeting agents form a binding pair with the 
target found on the tumor cell surface. Selectivity of the nanoparticles for specific cancer 
cells by targeting allows for reduced incidence of the adverse side effects of the 
chemotherapeutic drugs, however this comes at the expense of adding complexity to the 
nanoparticle preparation, potentially increasing particle size, and the risk of adverse 
biological reactions with the targeting agent. It is desirable for the target biomarker to (1) 
be over-expressed on the tumor cells, (2) be vital to tumor progression so that expression 
is not down-regulated during the life of the tumor, and (3) have limited shedding. The 
targeting ligand should (1) have a high specific affinity for the target antigen, (2) have 
low immunogenicity in vivo, and (3) be efficiently internalized after binding to the 
CHAPTER 4. EVALUATION OF CELLULAR UPTAKE OF ALTERNATING COPOLYMERS IN VITRO 
 
 
  123  
antigen. The targeting pairs chosen for this study, as discussed in Chapter 1, are 
EPPT/underglycosylated mucin-1 (uMUC1) and folate/folate receptor (FR). 
The physical characterization of our alternating copolymers was the focus of the 
doctoral thesis of Jin Zhou Dawson in the Colton group at MIT [48]. The critical micelle 
concentration (CMC) was determined by surface tension measurements to be 12 μM 
(0.07 g/L) for polymer with 100% of the linkers having ester-linked hydrocarbon side 
chains (#27) and 2 μM (0.016 g/L) for polymer with 100% of the linkers having 
perfluorocarbon (PFC) side chains (#10). The sizes of the micelles were determined by 
dynamic light scattering. It was found that micelles formed from the polymer with 100% 
of the linkers having ester-linked hydrocarbon side chains (#27) have a radius of about 4-
5 nm and polymer with 100% of the linkers having PFC side chains (#10) have a radius 
of about 8-9 nm. 
This chapter describes the cellular uptake of our alternating copolymer 
nanoparticles. First, the cellular uptake of the non-targeted polymers is examined 
experimentally in vitro. Next, the rational design of targeted polymers is discussed, with 
respect to polyvalency and ligand tether length. Then, the experimental results of the in 
vitro cellular uptake of targeted alternating copolymers in tumor cells are given for both 
the EPPT/uMUC1 and folate/FR targeting systems. The selectivity of the polymers for 
the targeted cells was evaluated using target-positive and target-negative cell lines as well 
as competition studies. In all experiments, cellular association was determined by 
radioactive labeling of the polymer or free ligand with either 125I or 3H. The chapter 
concludes with discussions of these results and suggestions for future uses of these 
copolymers.  
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4.2. Methods 
4.2.1. Materials and reagents 
A detailed description of the synthesis protocol for each polymer can be found in 
Appendix I. A list of all polymer structures used in this study is given in Appendix II. 
The numbers referred to throughout the remainder of this text correspond to the polymer 
structures as identified in the table presented in Appendix II. 
All polymers were provided by our collaborators in the Arthur Watterson lab at 
the University of Massachusetts, Lowell. All reagents were obtained from commercial 
sources. Phosphate buffered saline (PBS), distilled deionized sterile water, trypsin EDTA 
(1X, 0.25% trypsin/0.53 mM EDTA in HBSS), penicillin-streptomycin solution, RPMI, 
D-glucose, L-glutamine, sodium pyruvate, and fetal bovine serum (FBS) were purchased 
from Mediatech, Inc. Minimum essential media, Eagle, with 2 mM L-glutamine and 
Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino 
acids, and 1.0 mM sodium pyruvate (EMEM) was purchased from ATCC. RPMI 
Medium 1640 (without folic acid) was purchased from GIBCO. Guava Viacount assay 
kit was purchased from Guava Technologies/Millipore. Paraformaldehyde and Triton X-
100 lysis buffer were purchased from EMD Chemicals. Folate was purchased from TCI. 
3H-folate was purchased from American Radiolabeled Chemicals, Inc. Iodine-125 was 
purchased as Na125I from Perkin Elmer. Doxorubicin was purchased from EMD 
Biosciences. Phosphatidylinositol-phospholipase C (PI-PLC) was purchased from Sigma-
Aldrich. 
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4.2.2. Cell lines and culture 
BT-20 cells (human breast carcinoma; uMUC1+), LS174T cells (human colon 
carcinoma; uMUC1+), U87 cells (human brain glioblastoma; uMUC1-), MRC-5 cells 
(human lung fibroblast; uMUC1-), KB cells (human epidermoid carcinoma; FR+), HT-
1080 cells (human fibrosarcoma; FR-) were purchased from the American Type Culture 
Collection and INS-1 cells (rat insulinoma) were a gift from Chris Newgard at Duke 
University. BT-20, LS174T, U87, MRC-5, KB, and HT-1080 cells were all cultured in 
EMEM supplemented with 10% FBS and 1% penicillin–streptomycin solution. INS-1 
cells were cultured in RPMI supplemented with 11.1 mM D-glucose, 1% penicillin–
streptomycin solution, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 μM β-
mercaptoethanol, and 10% FBS. All cells were grown at 37°C in a humidified 
atmosphere containing 5% CO2. 
4.2.3. Confocal microscopy 
Cells were seeded in six-well plates containing 22 mm-diameter glass cover slips 
at a density of 1.5x105 cell/mL and incubated with polymer nanoparticles. The specific 
polymers used are described in section 4.3 (Results) and detailed in Appendices I and II. 
Cells were incubated with 1 g/L polymer or 0.2 g/L free or encapsulated doxorubicin at 
37°C. After incubating for 14 hours in the case of INS-1 cells or 5 hours in the case of 
U87 cells, the cells were washed 3 times with PBS. The cells were then fixed to the slides 
with 4% paraformaldehyde and examined with a Zeiss LSM 510 Meta high resolution 
laser scanning confocal microscope equipped with a 100X oil emersion objective lens at 
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the W.M. Keck Foundation Biological Imaging Facility located at the Whitehead 
Institute. Image analysis was performed using Zeiss LSM software. 
4.2.4. Radioactive uptake assay 
In the experiments using folate to target, cells were grown in RPMI Medium 1640 
(without folic acid) supplemented with 10% FBS and 1% penicillin–streptomycin 
solution for 2 days before the experiment. Otherwise cells were grown continually in 
EMEM supplemented with 10% FBS and 1% penicillin–streptomycin solution. Cells 
growing as a mono-layer were harvested with trypsin and seeded at a concentration of 
1x106 cells/mL 1 day before the start of the experiment. Cells were incubated with 
various amounts of polymer (0.001-1 g/L), EPPT (0.1 g/L) or folate (0.00002-0.002 g/L) 
labeled with a radioactive atom (125I or 3H) at 37°C in a humidified 5% CO2 atmosphere. 
The specific polymers used are described in the Results section and detailed in 
Appendices I and II. At each time point, the cells were washed three times with 100 μL 
PBS. When samples contained 125I, cells were harvested with 100 μL trypsin and the cell 
suspensions were analyzed in a gamma counter (Packard COBRA II Auto-Gamma). 
When samples contained 3H, cells were harvested with 100 μL lysis buffer, 400 μL of 
deionized water and 3.5 mL of scintillation cocktail (Ultima Gold XR) were added, the 
samples were vortexed, and the samples were analyzed in a scintillation counter 
(Beckman Coulter LS6500 Multipurpose Scintillation Counter). The validation of this 
sample preparation procedure for scintillation counting is shown in Appendix IV. All 
experiments were performed in triplicate. The activity of each sample, measured as 
counts per minute (CPM), was compared to the activity measurements of solutions of 
known concentrations to calculate the amount of polymer taken up.  
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More specifically, the polymer solution used in each experiment was diluted to 
various concentrations and the activity, as CPM, was measured for each sample. For 
scintillation counting, polymer solutions were made with cellular debris present in lysis 
buffer. A calibration curve was prepared by plotting each activity (CPM) as a function of 
mass of polymer in grams (g). The slope of the calibration curve has units of g/CPM. 
This slope is used as a calibration factor to convert the activity for each uptake 
experiment sample measured in CPM to mass of polymer in g by the equation 
mass of polymer (g) = measured sample activity (CPM) calibration factor (g/CPM)× (4.1) 
For each sample, the mass of polymer (g) is converted to number of polymer chains (no. 
of polymer chains) using the calculated molecular weight (MW) of the polymer, shown in 
Appendix II, by the equation  
 A
mass of polymer (g) No. of polymer chains = N
MW (g/mol)
×  (4.2) 
where NA is Avogadro’s number (6.022x1023 molecules/mol). The no. of polymer chains 
is converted to number of polymer chains per cell (no. of polymer chains/cell) by 
dividing by the number of cells in each well (no. of cells).   
 no. of polymer chainsno. of polymer chains/cell = 
no. of cells
 (4.3) 
Data is reported as no. of polymer chains/cell. 
For competitive inhibition studies, cells were incubated with labeled folate or 
polymer and an excess (100 μM) of unlabeled folate or polymer at 37°C in a humidified 
CO2 atmosphere. For saturation of the FR, cells were incubated with unlabeled free folate 
for 3 hours at 37°C prior to performing the experiment. For acid wash treatment to 
remove surface bound material and determine the internalized material, at each time point 
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each well was washed twice with PBS followed by one wash with acidified saline (pH 3) 
[58, 63]. To determine the surface bound material, endocytosis was inhibited by 
incubating the cells at 4°C. For treatment of cells with phosphatidylinositol-
phospholipase C (PI-PLC) to cleave the GPI-anchored FR, cells were rinsed twice with 
folate-free media and incubated for 60 min at 37 °C with 1 unit/mL PI-PLC in folate-free 
media. Each well was then rinsed twice with folate-free media [58]. In each of these 
variations, the uptake experiments were otherwise performed as described above. 
4.2.5. Cell counting 
After cells were detached from the plate with trypsin, cell number was evaluated 
by staining cells using a Guava Viacount assay solution and acquiring data with a Guava 
Personal Cell Analysis (PCA) flow cytometer using the Guava Viacount software. 
Dilution factors and original sample volumes were entered as appropriate for each 
sample. Each sample was run in triplicate and 1000 events were acquired per sample. 
4.2.6. Dynamic Light Scattering (DLS) 
Polymer solutions in folate-free media were filtered through 0.45 μm cellulose 
filters. These studies were conducted using a light scattering apparatus from Brookhaven 
Instruments, which consists of a motor driven goniometer (BI-200SM), a digital 
autocorrelator (BI-9000AT), and a photon counter (BI-9025AT). The laser light was 
provided by an Argon ion laser (Spectra-physics 2017-055) operated at a wavelength of 
514 nm, a measurement angle of 90°, and a temperature of 25°C. Results are reported as 
intensity averaged diameters calculated using the CONTIN method. 
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4.2.7. Statistical analysis 
All data were represented as mean ± standard deviation. Statistical significance 
(p<0.05) was determined, where appropriate, by a two-tailed Student t-test. 
4.3. Results 
4.3.1. Cellular uptake of non-targeted polymers 
4.3.1.1. Fluorescence imaging of cellular uptake 
Confocal microscopy studies were carried out to determine if the polymer and 
drug are taken up into cells and the location of the polymer and drug upon uptake into 
cells. Since doxorubicin is a fluorescent molecule, it could be observed by confocal 
microscopy. Polymer with 5% of the linkers having the fluorescent dye FITC and 95% of 
the linkers having perfluorocarbon (PFC) side chains (#13), free doxorubicin, and 
doxorubicin encapsulated in polymer with hydrocarbon side chains (#14) were all studied 
in vitro. Polymer at this concentration (1 g/L) is in the form of micelles. Images of the 
fluorescently labeled polymer alone demonstrated that the polymer is likely confined to 
vesicles within the cytoplasm and it is not found in the nucleus (Figure 4.1). Free and 
encapsulated doxorubicin were largely confined to the nucleus. Since the polymer does 
not enter the nucleus, it is likely that the doxorubicin is released from the polymer. 
However, it was reported in Chapter 3 that cell death due to DOX encapsulated in 
polymer with and without peptide was not reproducible. This lack of reproducibility was 
likely due to a poor encapsulation method, leading to variation in the amount of DOX 
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encapsulated. Therefore, the polymers are taken up by cells, but firm conclusions about 
the delivery of DOX can not be made. 
 
Polymer with FITC 
and Perfluorocarbon
Free Doxorubicin Doxorubicin 
Encapsulated 
in Polymer
50 μm
A B C
D E F
 
Figure 4.1. Confocal microscopy images of cellular uptake of polymer with FITC 
and PFC (#13) at 1 g/L in INS-1 cells, free doxorubicin at 0.02 g/L in U87 cells, and 
doxorubicin encapsulated in polymer (#14) at 1 g/L polymer and 0.02 g/L 
doxorubicin in U87 cell. Note: Top image is fluorescent image, bottom image is 
fluorescent image merged with optical image. 
 
4.3.1.2. Cellular uptake by labeling with 125I 
Initial in vitro experiments focused on the uptake of non-targeted polymers. Each 
polymer was labeled with 125I. The cellular uptake, presented as number of polymer 
chains per cell versus time, for polymer with 100% of the linkers having ester-linked 
hydrocarbon side chains (#27) and polymer with 100% of the linkers having 
perfluorocarbon (PFC) side chains (#10) is shown in Figure 4.2 for uMUC1+ and 
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uMUC1- cell lines. Polymer at this concentration (1 g/L) is in the form of micelles. In 
both uMUC1+ and uMUC1- cells, the uptake is equivalent up to 0.5 hours.  After 0.5 
hours, the hydrocarbon-containing polymer enters the cells faster, roughly linear with 
time, but the uptake of the perfluorocarbon-containing polymer levels off. In addition, the 
results for polymer with 100% of the linkers having ether-ester-linked hydrocarbon side 
chains (#58) are shown in Figure 4.3 for FR+ and FR- cell lines. Polymer at this 
concentration (0.1 g/L) is in the form of micelles. The uptake of this polymer in FR+ and 
FR- cells is much lower than either polymer in uMUC1+ or uMUC1- cells, but the 
concentration was lower by a factor of 10 in the study in FR+ and FR- cells. With all 
three polymers, there was significant cellular uptake into all cell lines, on the order of 
1x107 to 1x109 polymer chains taken up per cell. However, the non-targeted uptake rate 
for each polymer is similar in both positive and negative cells. Since the polymers do 
enter cells, drug or imaging agent that is covalently bound to or encapsulated in the 
polymer will also enter cells. It should be noted that across all uptake data discussed in 
this chapter, the uptake at early time points (0.25 and 0.5 hours) often appear aberrant. 
An explanation for this irregular data is not clear, although it is possibly due to 
inconsistent lengths of time at room temperature during the preparation of the 
experiment.  
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Figure 4.2. Cellular uptake of non-targeted polymer with 100% of the linkers 
having ester-linked hydrocarbon side chains (#27) at 1 g/L in uMUC1- (U87) and 
uMUC1+ (BT-20) cells and non-targeted polymer with 100% of the linkers having 
PFC side chains (#10) at 1 g/L in uMUC1- (MRC-5) and uMUC1+ (BT-20) cells 
(n=3). 
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Figure 4.3. Cellular uptake of non-targeted polymer with 100% of the linkers 
having ether-ester-linked hydrocarbon side chains (#58) at 0.1 g/L in FR- (HT-1080) 
and FR+ (KB) cells (n=3). 
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The polymer solution concentration was examined as a factor affecting the uptake 
of the non-targeted polymers. The cellular uptake of polymer with 100% of the linkers 
having ester-linked hydrocarbon side chains (#27) at three concentrations is shown in 
Figure 4.4 as a function of incubation time. The data plotted for 1 g/L polymer is the 
same as that in Figure 4.2. Data in panels A and B is replotted with an expanded scale in 
panels C and D, respectively. Polymer is in the form of micelles at concentrations of 1 
g/L and 0.1 g/L, but not at 0.01 g/L. The uptake in both cell lines is similar at each 
concentration. In addition, there is a direct correlation between increased polymer 
concentration in solution and increased cellular uptake. The same data plotted as a 
function of polymer concentration is shown in Figure 4.5. Again, data in panels A and B 
is replotted with an expanded scale in panels C and D, respectively. This figure shows 
that the uptake at each time point greater than 0.25 hours is nearly linear in polymer 
concentration, as expected for passive uptake.  
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Figure 4.4. Effect of polymer concentration on the cellular uptake of non-targeted 
polymer with 100% of the linkers having ester-linked hydrocarbon side chains (#27) 
in uMUC1- (U87) and uMUC1+ (BT-20) cells as a function of time (n=3). C and D 
are magnified versions of A and B, respectively. 
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Figure 4.5. Effect of polymer concentration on the cellular uptake of non-targeted 
polymer with 100% of the linkers having ester-linked hydrocarbon side chains (#27) 
in uMUC1- (U87) and uMUC1+ (BT-20) cells as a function of polymer 
concentration (n=3). C and D are magnified versions of A and B, respectively. 
 
4.3.2. Theoretical Design of Targeting Polymers 
After demonstrating that these non-targeted polymers were taken up into cells, it 
was desired to investigate the use of these polymers as targeted delivery vehicles. In 
order to rationally design our alternating copolymers for use as targeted drug delivery 
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vehicles, several theoretical calculations were performed to determine the requisite 
properties and characteristics of the desired copolymers. These properties included the 
minimum number of ligands required per particle to achieve the desired polyvalency and 
the length of the ligand spacer essential for ligand binding. In order to investigate the 
minimum number of ligands required per particle to achieve the desired polyvalency, the 
affinity or avidity of each particle for the targeted receptors needed to be calculated. In 
general, a higher number of ligands on a multivalent particle leads to more ligand-
receptor interactions and a higher avidity of the particle for the receptors. Descriptions of 
the models used along with the interpretation of the results of these calculations are given 
in this section, whereas the detailed calculations are given in Appendix V. The results 
from these calculations guided the synthesis of the targeting polymers used in the uptake 
studies described in sections 4.3.3 and 4.3.4. 
4.3.2.1. Polyvalency estimates 
In biological systems, the weak binding of a ligand to its receptor is often 
enhanced through multivalent interactions. Multivalency, also known as polyvalency, 
occurs when an entity with multiple ligands or binding sites binds to another entity with 
multiple receptors or binding sites, creating numerous ligand-receptor pairs and thus a 
stronger interaction. Two models from the literature were used to analyze the advantage 
of polyvalency for targeted delivery. The avidity of the targeted polymers for the target 
cells was calculated based on the affinity of one ligand for one receptor.  
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Cooperativity Model 
The first model that was considered is based on the cooperativity of multiple 
ligands present on one polymer delivery vehicle [56]. This cooperativity model is derived 
by equating the total Gibbs free energy (ΔGtotal) of binding to the sum of the Gibbs free 
energies for individual binding events (ΔGi).  
 total 1 2 NG G G ... GΔ = Δ + Δ + Δ  (4.4) 
where N is the number of ligands per particle. The association constant, KA, is related to 
the Gibbs free energy of binding by 
 AG RT ln KΔ = −  (4.5) 
where R is the gas constant and T is the temperature. Substituting equation (4.5) into 
equation (4.4) gives 
 A,Apparent A,1 A,2 A,NRT ln K RT ln K RT ln K ... RT ln K⎡ ⎤ ⎡ ⎤ ⎡ ⎤− = − + − + −⎣ ⎦ ⎣ ⎦ ⎣ ⎦  (4.6) 
where KA,Apparent is the apparent association constant for the polyvalent particle and KAi is 
the association constant for the ith binding event. Canceling and rearranging gives 
 A,Apparent A,1 A,2 A,NK K K ...K=  (4.7) 
If it is assumed that each individual binding event is not affected by any other binding 
event (non-cooperativity), the association constants for all binding events are equal. 
Substituting gives 
 ( )NA,Apparent AK K=  (4.8) 
However, since these individual binding events may be positively or negatively affected 
by the previous binding events, a degree of cooperativity between ligands, α, can be 
included in the equation giving 
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 ( ) NA,Apparent AK K α=  (4.9) 
For positive cooperativity, non-cooperativity, and negative cooperativity, α is greater than 
1, equal to 1, and less than 1, respectively. For the calculations shown below, we used α 
values of 2, 1, and 0.5. The dissociation constant, KD, is the reciprocal of the association 
constant and is often used as a metric for the affinity, or avidity, of a binding interaction. 
Therefore, in this model, the apparent dissociation constant of the polymer particle was 
calculated from the equation 
 ( ) ND,Apparent DK K α=  (4.10) 
This model is often used due to its simplicity and is powerful if information can be 
obtained for the degree of cooperativity between ligands. 
 
Structural Model 
The second model uses a structural argument to calculate the binding 
enhancement due to multivalency [64]. Gargano et al. developed the model for a bivalent 
ligand consisting of two ligand binding sites attached by a polymer linker, accounting for 
statistical factors representing the number of permutations that can lead to binding of a 
ligand divided by the number of permutations that can lead to unbinding of a ligand and 
the effective concentration of one polymer end at a given distance from the other bound 
end when the two polymer ends are a set distance apart. This model was then 
extrapolated to a general solution for higher order systems. The apparent dissociation 
constant of the polymer particle was calculated from the equations 
 ( ) 1D,Apparent DK K nBE −=  (4.11) 
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 ( ) n 11 2DBE F sK 10 −− −⎡ ⎤= ⎣ ⎦  (4.12) 
where KD is the dissociation constant for the ligand, BE is defined as the binding 
enhancement per ligand, F is a system-specific statistical factor, s is 30 divided by the 
distance between binding sites on the receptor, in Å, and n is the lesser of the number of 
binding sites on the receptor or the number of ligands or binding sites on the particle. The 
factor 10-2 is due to the inclusion of the maximum effective concentration of a second 
ligand once a first is bound. The statistical factor, F, was assumed to be 1 based on the 
literature [64]. This general solution is applicable assuming that (1) the binding sites are 
equivalent, (2) there is no cooperative binding between ligands, (3) all ligand sites are 
available for binding, and (4) there are no polymer-receptor interactions. These two 
models were used to analyze the polyvalency in both the EPPT/uMUC1 and folate/FR 
systems. 
First, the advantage of polyvalency was examined in the EPPT/uMUC1 system. 
The EPPT synthetic peptide has significant affinity, KD=2.5 x 10-5 M, for the uMUC1-
derived PDTRP epitope, although much lower than the affinity of the parent monoclonal 
antibody, KD=2 x 10-8 M [52]. Assuming 100% underglycosylation of the mucin-1 
protein, the distance between PDTRP binding sequences was calculated as 90 Å, using 
known bond lengths and angles (see Appendix V). Since there are 30-90 repeats of the 
PDTRP sequence on a mucin-1 and this is greater than the number of ligands on the 
polymer, n was always the number of ligands on the polymer carrier. The calculated 
affinity of the targeted alternating copolymer particles with varying numbers of EPPT 
peptides attached is shown for both models in Figure 4.6. The dashed line indicates the 
KD value for the parent monoclonal antibody. If three to four ligands per particle are 
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available for binding, a KD,Apparent equivalent to or lower than the KD for the monoclonal 
antibody is achieved, even for the worst case model. Since three or four ligands need to 
be available for binding, not simply attached to the particle, it was necessary to determine 
how the length of the tether connecting the ligand to the polymer affects the percent of 
ligands on the particle that are available to the surface of the cell. This is discussed in 
section 4.3.2.2. 
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Figure 4.6.  Affinity of polymer drug delivery vehicles targeted with EPPT based on 
number of available ligand sites. 
 
With respect to the folate/FR system, polyvalency may not be a significant issue. 
The FR is a high affinity receptor for the small molecule folate, or folic acid, with a 
dissociation constant, KD, for this binding event of 1x10-10 M [65-67]. This affinity is 
even greater (5X) than the parent monoclonal antibody from which EPPT was derived in 
the uMUC1 targeting system discussed above. Even though polyvalency may not be 
necessary in this system, calculations for the apparent dissociation constant were 
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performed. GPI-anchored FR are clustered in microdomains of around 70 nm in size 
containing approximately 50 FR, therefore they are an average of 100 Å apart [68]. The 
calculated affinity of the targeted alternating copolymer particles with varying numbers 
of folate ligands attached is shown in Figure 4.7. The dashed line indicates the KD value 
for one isolated binding event. The analysis magnifies the point that a polymer with only 
one folate molecule attached will match the affinity of a free folate molecule. However, it 
is clear that increasing the number of folates per particle will only enhance the overall 
affinity of our particles for the target cells. Since the FR is internalized, along with any 
particle bound to the FR, it must be considered that an extremely low KD,Apparent value, 
indicating a very high affinity, may hinder the release of the particle from the FR once 
the complex is internalized into a cell.  However, it has been shown in the literature that 
folate readily dissociates from the FR in the acidic environment of an endosome, 
therefore a multivalent particle will likely dissociate in the endosome as well [58].  
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Figure 4.7. Affinity of polymer drug delivery vehicles targeted with folate based on 
number of available ligand sites. 
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4.3.2.2. Ligand tether length calculations 
Calculations were also made to determine the length of the tether attaching the 
ligand to the polymer particles that is necessary to allow for polyvalency. Several other 
researchers have found that attaching the ligand by a tether greatly increases the cellular 
uptake [67, 69]. A geometric model was used, assuming spherical particles, to calculate 
the fraction of the surface area of the particle able to bind to the surface of the cell for a 
given tether length [70]. The active fractional area of the polymer carrier is described as 
the fraction of carrier surface that is available for binding to the cell. It has been shown to 
be dependent on tether length, ligand size and carrier size. A schematic depicting the 
geometrical arrangement and parameters used in this model is shown in Figure 4.8. 
Assuming that the tether is in a fully extended conformation and using simple geometry, 
the active fractional area of the carrier is given by  
 2
2
4 2
= =RH HA
R R
π
π  (4.13) 
 
where R is the radius of the carrier and H is given by L-dB when L≤R+dB. Here, L is the 
sum of the ligand length and the maximum extended length of the tether and dB is the 
binding distance of the ligand and the receptor. As two entities approach each other, the 
total free energy of the system decreases and at a critical distance the total free energy of 
the system reaches a minimum. It has been shown that for a binding pair having a high 
affinity, the majority of ligand–receptor bond formation will occur at this critical 
distance, also defined as the binding distance. Varying the tether length alters the binding 
distance between the carrier and cell surface receptors since binding distance is a function 
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of tether length. The effect of tether length on binding distance was determined, as 
reported in the literature, by using a combination of Monte Carlo simulations, diffusion 
reaction theory, and surface force measurements [71]. When L>R+dB, H becomes R+x, 
where x is the vertical distance above the horizontal line passing through the center of the 
carrier, indicating the position of the fully extended tether on the carrier surface that is 
tangent to the surface of the carrier and reaching the cell surface. 
 
Binding Distance, dB
x
R
Receptor
H
Fully Extended Tether, 
L, when L > R + dB
Fully Extended Tether, 
L, when L < R + dB
 
Figure 4.8. Schematic of parameters used for ligand tether length calculations 
adapted from [70]. 
 
This study was performed for PEG ranging in molecular weight from 900 to 
10,000 and carrier diameters ranging from 10 nm to 150 nm. The tether length was 
calculated from the PEG molecular weight based on a molecular weight of 44 and a 
length of 350 pm for each PEG repeat unit [70]. The analysis showed that, for our particle 
size of ~10 nm in diameter [48], increasing the tether length by using PEG-3400 as the 
spacer would increase the fraction of the surface area of the particle able to bind to ~75% 
(Figure 4.9). Assuming there is at least one ligand on every other polymer chain and at 
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least eight polymer chains aggregate to form one micelle, this ligand tether length would 
allow for three ligands available for binding to the cell per drug carrier. The availability 
of three ligands for binding satisfies the requirements determined by the polyvalency 
estimates discussed earlier.  
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Figure 4.9. Effect of PEG tether molecular weight on the active fractional area of 
the carrier. 
 
The major assumption of this model is that the tether is in a fully extended 
conformation. It is unlikely that a PEG tether would be fully extended in an aqueous 
environment, therefore this model over-estimates the active fractional area of the carrier. 
Future, more rigorous models could potentially provide more accurate estimates of PEG 
chain length using various available models (ie. random coil, etc.) to estimate the end-to-
end distance of the tether. The purpose of this exercise was to determine the accessibility 
of the ligand attached to the carrier to the receptors on the cell surface. However, another 
assumption of this model is that all ligands are available for binding, ie. not internalized 
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into the particle. Further improvements to this model could account for the availability of 
the ligands based on steric arguments and polymer shielding. 
4.3.2.3. Comparison to experimental data in literature 
The validity of the theoretical calculations discussed earlier, both polyvalency 
estimates and ligand tether length calculations, was tested by using experimental data 
from the literature. Moore et al. investigated the in vitro uptake of cross-linked iron oxide 
nanoparticles modified with Cy5.5 dye and carrying EPPT peptides attached to the 
dextran coat of the nanoparticles [53]. The structural properties of these nanoparticles 
reported in the literature (ie. 35.8 nm in size, 14 EPPT per particle) were used to calculate 
the active fractional area of the particle. It was calculated that the active fractional area of 
the particles was ~10% of the surface, therefore ~1.4 EPPT were accessible per particle. 
See Appendix V for the details of these calculations. Concurrently a Scatchard plot 
analysis was performed on the experimental data from this paper to determine the 
apparent KD of these particles, as shown in Appendix VI. The apparent KD of these iron 
oxide particles was found experimentally to be 8x10-9 M. Figure 4.10 demonstrates that 
the apparent KD for the particles of Moore et al. matches well with the predicted apparent 
KD values from the theoretical neutral cooperativity model. Note that the ligands were not 
attached to the particles by a tether, removing the necessity of the fully extended 
conformation assumption. These results validate the use of these theoretical calculations 
for rationally designing our alternating copolymers for use as targeted drug delivery 
vehicles. 
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Figure 4.10. Theoretical affinity of particles targeted with EPPT ligands as 
compared to experimental data from the literature. 
 
4.3.3. Cellular uptake of targeted polymers with EPPT by labeling with 125I 
In order to gain insight into the uptake of EPPT in uMUC1+ and uMUC1- cell 
lines, experiments were performed with free EPPT labeled with 125I. The uptake of EPPT 
in uMUC1+ cells was twice the uptake in uMUC1- cells (Figure 4.11). Since the uMUC1 
protein is not expressed on the surface of the MRC-5 cells, the uptake in those cells is 
non-specific. However, the uptake in BT-20 cells likely includes both specific and non-
specific uptake since the uMUC1 protein is present in that cell line. In order to increase 
the specific uptake, multivalency is necessary, as described earlier. Appendix VI contains 
an analysis of the kinetic parameters that can be obtained from this data as well as a 
comparison of this data to a theoretical model of EPPT uptake. The experimental data for 
uptake of EPPT was used to estimate the forward reaction rate of the binding event, kf, as 
1.4x10-4 M-1hr-1 and the reverse reaction rate, kr, as 3.4x10-9 hr-1. Using these kinetic 
parameters, the simplest theoretical model, considering one binding event and no 
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internalization, agrees well with the experimental data (~2x108 EPPT per cell) when 7-10 
particles bind per uMUC1 (Figure V.iv in Appendix VI). 
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Figure 4.11. Cellular uptake of EPPT peptide at 0.1 g/L in uMUC1- (MRC-5) and 
uMUC1+ (BT-20) cells (n=3). 
 
Early experiments focused on the uptake of 125I-labeled polymers with and 
without the EPPT peptide. The cellular uptake for polymer with 100% of the linkers 
having ester-linked hydrocarbon side chains (#27) and polymer with 5% of the linkers 
having EPPT attached by a triethylene glycol (TEG) spacer and the remaining 95% of the 
linkers having ester-linked hydrocarbon side chains (#37) is shown in Figure 4.12. 
Polymer at this concentration (1 g/L) is in the form of micelles. The data for polymer 
with 100% of the linkers having ester-linked hydrocarbon side chains is the same as that 
in Figure 4.4 for 1 g/L. In the uMUC1- cell line, there is little overall difference in the 
cellular uptake between the targeted and non-targeted polymers, although the targeted 
polymer is slightly higher at earlier times. However, the cellular uptake of the targeted 
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polymer is twice that of the non-targeted polymer in the uMUC1+ cells. This indicates 
that our polymer nanoparticles may be targeted to cells using the EPPT peptide. 
Interestingly, the total uptake at 3 hours in the uMUC1- cells is similar to the uptake of 
the targeted polymer in the uMUC1+ cells. The non-specific uptake of our nanoparticles 
in uMUC1- cells is higher than the non-specific uptake in uMUC1+ cells. This data can 
also be compared to that for uptake of free EPPT shown in Figure 4.11. At the same 
molar concentration in uMUC1+ cells, ~5x108 EPPT are taken up per cell while ~13x108 
polymer chains are taken up per cell for polymer containing EPPT.  See Appendix VII for 
a kinetic analysis of the internalization and surface bound polymer versus EPPT peptide. 
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Figure 4.12. Cellular uptake of non-targeted polymer with 100% of the linkers 
having ester-linked hydrocarbon side chains (#27) and targeted polymer with 5% of 
the linkers having EPPT attached by a TEG spacer and the remaining 95% of the 
linkers having ester-linked hydrocarbon side chains (#37) at 1 g/L in uMUC1- (U87) 
and uMUC1+ (BT-20) cells (n=3). 
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Next we investigated the effect of increasing the percent of linkers with EPPT 
attached and increasing the spacer length attaching the EPPT to the linker. The cellular 
uptake results for experiments using polymer with 7% of the linkers having TEG-EPPT 
attached and the remaining 93% of the linkers having no side chains (#42), polymer with 
34% of the linkers having TEG-EPPT attached and the remaining 66% of the linkers 
having no side chains (#44), and polymer with 100% of the linkers having EPPT attached 
by a PEG-3400 spacer (#65) are shown in Figure 4.13. These polymers would not be in 
the form of micelles since none have hydrocarbon side chains. Again, all polymers were 
labeled with 125I. In the uMUC1- cell line, the cellular uptake is not greatly affected by 
the increase in the percent of linkers with EPPT at early times, although at 3 hours the 
polymer with the highest amount of peptide has the highest uptake. These results indicate 
that the non-specific uptake of these polymers is quite significant. In the uMUC1+ cells, 
the highest uptake occurred with the polymer with the lowest amount of EPPT. In 
addition, lengthening the spacer attaching the EPPT to the polymer, while eliminating the 
hydrophobic side chains, does not seem to have increased the uptake of the polymer. 
Comparing these results to Figure 4.12, the uptake is higher when hydrocarbon side 
chains are attached to the polymer such that micelles can form (~12x108 polymer chains 
per cell) than when the amount of peptide attached to the polymer is increased (~2-4x108 
polymer chains per cell). The formation of micelles due to the presence of hydrophobic 
side chains and the polyvalent effect of many ligands on each micelle may contribute to 
the increased cellular uptake. 
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Figure 4.13. Effect of amount of EPPT peptide on cellular uptake of targeted 
polymers: polymer with 7% of the linkers having TEG-EPPT attached and the 
remaining 93% of the linkers having no side chains (#42) at 1 g/L in uMUC1- 
(MRC-5) and uMUC1+ (BT-20) cells, polymer with 34% of the linkers having TEG-
EPPT attached and the remaining 66% of the linkers having no side chains (#44) at 
1 g/L in uMUC1- (MRC-5) and uMUC1+ (BT-20) cells, and polymer with 100% of 
the linkers having EPPT attached by a PEG-3400 spacer (#65) at 1 g/L in uMUC1- 
(MRC-5) and uMUC1+ (LS174T) cells (n=3). 
 
The cellular uptake of two imaging polymers was also investigated in the uMUC1 
system. Polymer with 100% of the linkers having PFC chains attached (#10) and polymer 
with 5% of the linkers having EPPT attached by hexaethylene glycol (HEG), 5% of the 
linkers having FITC attached, and 90% of the linkers having no side chain (#39) were 
both labeled with 125I. The polymer with PFC chains is in the form of micelles at this 
concentration (1 g/L), but the polymer with EPPT and FITC is not in the form of micelles 
since it has no hydrocarbon side chains. Curiously, the polymer with EPPT and FITC was 
taken up in higher amounts than the polymer with PFC in uMUC1- cells, as shown in 
Figure 4.14. However, this trend is the same in the uMUC1+ cell lines, possibly 
indicating the selective advantage of attaching the EPPT peptide or demonstrating higher 
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non-specific uptake of the polymer with EPPT. See Appendix VII for a kinetic analysis 
of the internalization and surface bound polymer versus EPPT peptide. 
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Figure 4.14. Cellular uptake of imaging polymer with 100% of the linkers having 
PFC chains attached (#10) at 1 g/L in uMUC1- (MRC-5) and uMUC1+ (BT-20) cells 
and imaging polymer with 5% of the linkers having EPPT attached by HEG, 5% of 
the linkers having FITC attached, and 90% of the linkers having no side chain (#39) 
at 1 g/L in uMUC1- (U87) and uMUC1+ (BT-20) cells (n=3). 
 
As shown with the uptake results for non-targeted polymers, the polymer 
concentration in solution during the incubation can also affect the uptake of polymers. 
The cellular uptake of polymer with 100% of the linkers having ester-linked hydrocarbon 
side chains (#27) and polymer with 5% of the linkers having TEG-EPPT attached and the 
remaining 95% of the linkers having ester-linked hydrocarbon side chains (#37) at three 
concentrations is shown in Figure 4.15 as a function of incubation time. The data for 1 
g/L is the same as that in Figure 4.12. Data in panels A and B is replotted with an 
expanded scale in panels C and D, respectively. Both polymers are in the form of 
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micelles at concentrations of 1 g/L and 0.1 g/L, but not at 0.01 g/L. At each 
concentration, the uptake in the uMUC1- cells is similar to that in the uMUC1+ cells, 
indicating the high level of non-specific uptake of these particles. In addition, there is a 
direct correlation between increased polymer concentration in solution and increased 
cellular uptake. It is clear that, at each concentration, the attachment of the EPPT peptide 
to the polymer increased the cellular uptake in both cell lines. This observation is logical 
for the uMUC1+ cells, however, it is curious for the uMUC1- cells, possibly indicating 
that attaching the EPPT peptide even increases non-specific uptake. The same data 
plotted as a function of polymer concentration is shown in Figure 4.16. Again, data in 
panels A and B is replotted with an expanded scale in panels C and D, respectively. This 
figure shows that the uptake at each time point greater than 0.25 hours is nearly linear in 
polymer concentration. 
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Figure 4.15. Effect of polymer concentration on cellular uptake of polymer with 100% 
of the linkers having ester-linked hydrocarbon side chains (#27) and polymer with 
5% of the linkers having TEG-EPPT attached and the remaining 95% of the linkers 
having ester-linked hydrocarbon side chains (#37) in uMUC1- (U87) and uMUC1+ 
(BT-20) cells as a function of time (n=3). C and D are magnified versions of A and B, 
respectively. 
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Figure 4.16. Effect of polymer concentration on cellular uptake of polymer with 100% 
of the linkers having ester-linked hydrocarbon side chains (#27) and polymer with 
5% of the linkers having TEG-EPPT attached and the remaining 95% of the linkers 
having ester-linked hydrocarbon side chains (#37) in uMUC1- (U87) and uMUC1+ 
(BT-20) cells as a function of concentration (n=3). C and D are magnified versions of 
A and B, respectively. 
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Overall, the uptake results in uMUC1- and uMUC1+ cells for polymers 
containing EPPT did not effectively demonstrate the selectivity of our polymers for the 
targeted cells. The cellular uptake of polymer with 5% of the linkers having TEG-EPPT 
attached and the remaining 95% of the linkers having ester-linked hydrocarbon side 
chains was twice that of polymer with 100% of the linkers having ester-linked 
hydrocarbon side chains, although the difference was not statistically significant. In 
addition, increasing the percent of linkers containing the targeting ligand EPPT did not 
increase the uptake. Therefore, the targeting pair was changed to folate/FR, a model 
system used often in the literature.  
4.3.4. Cellular uptake of targeted polymers with folate by labeling with 125I and 3H 
In order to confirm that our FR+ cells did in fact express the FR, uptake 
experiments were first performed with 3H-folate. Studies in the literature reported 
culturing cells in folate-free media, performing uptake experiments in 24-well plates and 
collecting cells using lysis buffer. Our previous experiments had used 96-well plates and 
the cells were removed using trypsin. Therefore, for comparison purposes, these 
experiments additionally explored the effect of growth media (folate-free versus regular 
folate-containing media), well size (24-well plates versus 96-well plates), and cellular 
material removal method (trypsin versus lysis buffer). In each case, the uptake of the 
labeled 3H-folate was measured in the absence and presence of an excess of unlabeled 
folate. If uptake is due to receptor-mediated endocytosis via the FR, an excess of 
unlabeled folate will compete with the labeled 3H-folate for the FR, thereby decreasing 
the measured uptake. The uptake of 3H-folate dropped significantly in the presence of an 
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excess of unlabeled folate, regardless of the type of plate, growth media, or cell removal 
method, as shown Figure 4.17. This confirms that the FR+ cells do express the FR. It was 
determined that there was no difference in uptake between 24-well plates and 96-well 
plates, indicating that well size does not affect uptake. The uptake in cells grown in 
folate-free media for two days before the experiment was ~2.5X higher than that in cells 
continually grown in regular folate-containing media. This is because depriving the cells 
of folate causes the up-regulation of the FR. Finally, there was a small difference between 
collecting the cellular material by trypsin or lysis buffer. In each case, using lysis buffer 
showed higher uptake. In all subsequent experiments, cells were grown in folate-free 
media for two days before the experiment and cellular matter was collected using lysis 
buffer. Additionally, it was confirmed that the FR- cells do not express the FR, since little 
3H-folate was taken up in these cells (Figure 4.18). Our results, when cells were grown in 
folate-free media, are equivalent to those reported in the literature, ~107 3H-folate per cell 
taken up over a 3 hour incubation period [63, 72]. Appendix VI contains a comparison of 
this data to a theoretical model of folate uptake. The simplest theoretical model, 
considering one binding event and no internalization, agrees well with the experimental 
data at times greater than 1 hour (Figure V.vi in Appendix VI). The uptake results for free 
folate can also be compared with the uptake results for free EPPT from Figure 4.11. As 
mentioned, the number of free folate molecules taken up per cell is on the order of 107, 
however, the number of free EPPT molecules taken up per cell is on the order of 108. 
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Figure 4.17. Cellular uptake of 3H-folate at 50 nM in FR+ (KB) cells under various 
conditions (excess unlabeled folate concentration = 100 μM) (n=3). 
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Figure 4.18. Cellular uptake of 3H-folate at 50 nM in FR- (HT-1080) and FR+ (KB) 
cells (n=3). 
 
Additionally, the amount of cell-associated 3H-folate was assessed under various 
conditions affecting the expression of the FR, as shown in Figure 4.19. As mentioned, the 
uptake of 3H-folate in cells that had been grown for two days before the experiment in 
folate-free media (up-regulation) was higher than the uptake in cells that were 
continuously grown in regular media and demonstrated the highest uptake of 3H-folate of 
all conditions investigated here. This is due to the up-regulation of the FR in the cells 
grown in folate-free media. Furthermore, the uptake of 3H-folate was investigated in cells 
that had been grown for two days in folate-free media and then incubated with 100 μM 
unlabeled free folate for 3 hours immediately before the start of the experiment (down-
regulation). The unlabeled free folate acted to saturate and down-regulate the FR. As 
shown in Figure 4.19, the uptake of 3H-folate was lower when the cells were saturated 
with unlabeled free folate before the experiment, as compared to the uptake in cells 
grown in folate-free media or regular media. These results confirm the effect of the up-
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regulation and down-regulation of the FR on the cellular uptake of 3H-folate by receptor-
mediated endocytosis. 
Also, as previously discussed, the presence of an excess (100 μM) of unlabeled 
folate did inhibit uptake of labeled folate. In addition, the cell-associated 3H-folate after 
acidic saline wash (internalized) was found to be ~3X lower than the total uptake in 
folate-free media (up-regulation) and the cell-associated 3H-folate when the experiment 
was performed at 4°C (surface bound) was ~2X lower than the total cell-associated 3H-
folate. However, the sum of the surface bound and internalized 3H-folate is slightly less 
than the total uptake, which may be explained by the slower binding kinetics at 4°C [73]. 
Uptake of 3H-folate, in cells that were pre-treated with PI-PLC to cleave the GPI-anchor 
attaching the FR to the cell surface (non-specific), is lower than total uptake and slightly 
lower than internalized folate. This indicates that most of the internalized 3H-folate is due 
to non-specific uptake, confirmed in the literature [63, 65]. Finally, when the cells were 
pre-treated with PI-PLC to cleave the GPI-anchor attaching the FR to the cell surface and 
then incubated at 4°C (non-specific surface bound), the surface bound folate decreased, 
confirming the removal of the FR from the surface of the cell. 
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Figure 4.19. Cellular uptake of 3H-folate at 50 nM in FR+ (KB) cells under 
conditions affecting the regulation of the FR (n=3). 
 
The effect of varying the concentration on the cellular uptake of 3H-folate was 
also explored. The cellular uptake results for 3H-folate at three concentrations (50 nM, 
500 nM, and 5 μM) are shown in Figure 4.20. Increasing the concentration of 3H-folate 
did increase the uptake of 3H-folate at the 3 hour time point, however, when the number 
of folate molecules per cell was normalized by concentration the uptake was not 
equivalent for all three concentrations, demonstrating that the uptake of 3H-folate is not 
linear with concentration and is likely saturating the FR. It is evident from Figure 4.20 
that the uptake of folate is relatively insensitive to concentration in FR+ cells. 
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Figure 4.20. Cellular uptake of 3H-folate in FR+ (KB) cells at various concentrations 
(n=3). 
 
The uptake of several different polymers containing folate was investigated by 
labeling the polymers with 125I. Polymers were synthesized with three different 
attachment methods for folate. The first series of polymers were produced with folate 
attached directly to the polymer backbone at the hydroxyl linker. The cellular uptake of 
polymer with 10% of the linkers having folate attached without a spacer and the 
remaining 90% of the linkers having no side chains (#50) and polymer with 10% of the 
linkers having folate attached without a spacer and the remaining 90% of the linkers 
having ether-linked hydrocarbon side chains (#51) is shown in Figure 4.21. Polymer with 
hydrocarbon side chains is in the form of micelles at a concentration of 0.1 g/L, but 
polymer without hydrocarbon side chains is not. For both cell lines the number of 
polymer chains per cell was higher for polymer without side chains than for that with side 
chains, however, the concentration used was higher (1 g/L versus 0.1 g/L) for polymer 
without side chains. In addition, for both polymers, the uptake was the same in both FR- 
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and FR+ cells and in the absence and presence of an excess of folate, indicating non-
specific uptake only. 
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Figure 4.21. Cellular uptake of polymers with folate attached directly to the linkers: 
polymer with 10% of the linkers having folate attached without a spacer and the 
remaining 90% of the linkers having no side chains (#50) at 1 g/L and polymer with 
10% of the linkers having folate attached without a spacer and the remaining 90% 
of the linkers having ether-linked hydrocarbon side chains (#51) at 0.1 g/L in FR- 
(HT-1080) and FR+ (KB) cells (n=3). 
 
The second series of polymers were produced with folate attached to the end of 
the polymer chain with a PEG-3400 spacer. The spacer was introduced based on the 
ligand tether length calculations described in Section 4.3.2.2. The cellular uptake of 
polymer with PEG-3400-folate attached at the end of the polymer chain and no side 
chains (#56), polymer with PEG-3400-folate attached at the end of the polymer chain and 
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ether-ester-linked hydrocarbon side chains (#59), and polymer without folate and with 
ether-ester-linked hydrocarbon side chains (#58) is shown in Figure 4.22. Polymers with 
hydrocarbon side chains are in the form of micelles at a concentration of 0.1 g/L, but 
polymer without hydrocarbon side chains is not. As with the previous series of polymers, 
the number of polymer chains per cell was higher for folate-containing polymer without 
side chains than for that with side chains in both cell lines, but, again, the concentration 
used was higher (1 g/L versus 0.1 g/L) for polymer without side chains. In addition, 
polymer with side chains and no folate was taken up in higher amounts in both cell lines 
than polymer with side chains and folate, demonstrating no advantage due to the 
attachment of the targeting ligand. Finally, for all three polymers, the uptake was similar 
in both FR- and FR+ cells and the uptake was either the same in the absence and presence 
of an excess of folate or slightly higher in the presence of folate, likely indicative of non-
specific uptake only. 
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Figure 4.22. Cellular uptake of polymer with PEG-3400-folate at the end of the 
polymer chain: polymer with PEG-3400-folate attached at the end of the polymer 
chain and no side chains (#56) at 1 g/L, polymer with PEG-3400-folate attached at 
the end of the polymer chain and ether-ester-linked hydrocarbon side chains (#59) 
at 0.1 g/L, and polymer without folate and with ether-ester-linked hydrocarbon side 
chains (#58) at 0.1 g/L in FR- (HT-1080) and FR+ (KB) cells (n=3). 
 
Finally, the third series contained polymers with PEG-3400-folate attached to the 
polymer backbone at the hydroxyl linker. Results for polymer with 25% of the linkers 
having PEG-3400-folate attached and the remaining 75% of the linkers having no side 
chains (#60), polymer with 25% of the linkers having PEG-3400-folate attached and the 
remaining 75% of the linkers having ether-ester-linked hydrocarbon side chains (#61), 
and polymer with 100% of the linkers having PEG-3400-folate attached (#64) is shown 
in Figure 4.23. Polymer with hydrocarbon side chains is in the form of micelles at a 
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concentration of 0.1 g/L, but the polymers without hydrocarbon side chains are not. For 
polymers with 25% of the linkers having PEG-3400-folate, the uptake was higher for 
polymer with side chains than for that without side chains in both cell lines. The highest 
number of polymer chains per cell was with polymer with 100% of the linkers having 
PEG-3400-folate attached, potentially signifying a correlation between increased number 
of folate per particle and increased uptake. However, the polymer concentration used was 
higher (1 g/L versus 0.1 g/L) for this polymer. For all three polymers, the uptake was 
similar in both FR- and FR+ cells and the uptake was the same in the absence and 
presence of folate, likely indicating non-specific uptake only. Interestingly, if we 
compare these results to the uptake results for the polymer without folate and with ether-
ester-linked hydrocarbon side chains (#58) in Figure 4.22, we see that the uptake was 
again higher for the polymer with side chains and no folate than for polymer with 25% of 
the linkers having PEG-3400-folate attached and the remaining 75% of the linkers having 
the same ether-ester-linked hydrocarbon side chains (#61), confirming the lack of an 
advantage due to the attachment of the targeting ligand. 
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Figure 4.23. Cellular uptake of polymers with PEG-3400-folate attached: polymer 
with 25% of the linkers having PEG-3400-folate attached and the remaining 75% of 
the linkers having no side chains (#60) at 0.1 g/L, polymer with 25% of the linkers 
having PEG-3400-folate attached and the remaining 75% of the linkers having 
ether-ester-linked hydrocarbon side chains (#61) at 0.1 g/L, and polymer with 100% 
of the linkers having PEG-3400-folate attached (#64) at 1 g/L in FR- (HT-1080) and 
FR+ (KB) cells (n=3). 
 
An indirect study of polymer binding was also pursued by analyzing the uptake of 
3H-folate in the presence of an excess of polymer. These competition studies have been 
used by others in the literature to demonstrate particle binding [58, 72, 74]. If the polymer 
decreases the uptake of the 3H-folate, the polymer may be binding to the FR, blocking the 
3H-folate binding. The folate-containing polymers used in the direct studies above were 
used in this indirect study: polymer with 10% of the linkers having folate attached 
without a spacer and the remaining 90% of the linkers having no side chains (#50), 
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polymer with 10% of the linkers having folate attached without a spacer and the 
remaining 90% of the linkers having ether-linked hydrocarbon side chains (#51), polymer 
with PEG-3400-folate attached at the end of the polymer chain and no side chains (#56), 
polymer with PEG-3400-folate attached at the end of the polymer chain and ether-ester-
linked hydrocarbon side chains (#59), polymer with 25% of the linkers having PEG-
3400-folate attached and the remaining 75% of the linkers having no side chains (#60), 
polymer with 25% of the linkers having PEG-3400-folate attached and the remaining 
75% of the linkers having ether-ester-linked hydrocarbon side chains (#61), and polymer 
with 100% of the linkers having PEG-3400-folate attached (#64). All polymers with 
hydrocarbon side chains are in the form of micelles at a concentration of 100 μM, but 
those polymers without hydrocarbon side chains are not. The results are depicted in 
Figure 4.24 as number of 3H-folate per cell versus incubation time on a linear plot (left) 
and a semi-log plot (right). The two polymers with PEG-3400-folate attached at the end 
of the polymer chain only inhibited the uptake of 3H-folate slightly, while all other folate-
containing polymers tested inhibited the uptake by 1 or 2 orders of magnitude. Polymer 
with 100% of the linkers having PEG-3400-folate attached decreased the uptake by 
380X. Intriguingly, the polymers with side chains inhibited the uptake less than those 
with no side chains. It is possible that the formation of micelles decreases the ability to 
block the binding of the 3H-folate to the FR. These results suggest that binding of the 
targeted polymers to the FR may be occurring, thereby blocking the 3H-folate from 
binding. 
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Figure 4.24. Competitive inhibition of the uptake of 3H-folate at 50 nM by an excess 
of folate-containing polymers at 100 μM in FR+ (KB) cells: polymer with 10% of the 
linkers having folate attached without a spacer and the remaining 90% of the 
linkers having no side chains (#50), polymer with 10% of the linkers having folate 
attached without a spacer and the remaining 90% of the linkers having ether-linked 
hydrocarbon side chains (#51), polymer with PEG-3400-folate attached at the end of 
the polymer chain and no side chains (#56), polymer with PEG-3400-folate attached 
at the end of the polymer chain and ether-ester-linked hydrocarbon side chains 
(#59), polymer with 25% of the linkers having PEG-3400-folate attached and the 
remaining 75% of the linkers having no side chains (#60), polymer with 25% of the 
linkers having PEG-3400-folate attached and the remaining 75% of the linkers 
having ether-ester-linked hydrocarbon side chains (#61), and polymer with 100% of 
the linkers having PEG-3400-folate attached (#64) (n=3). 
 
Several non-targeted polymers were used in the same indirect study to compare 
the inhibition of 3H-folate to that of targeted polymers: polymer with no folate and no 
side chains (#24), polymer with methyl groups attached to the linkers (#66), polymer 
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with PEG-3400-COOH attached to the linkers (#67), and PEG-900. None of these 
polymers have hydrocarbon side chains, so none would be in the form of micelles. 
Polymer with methyl groups attached and polymer with PEG-3400-COOH attached did 
not significantly inhibit the uptake of 3H-folate as shown in Figure 4.25. PEG-900 
decreased the uptake by 2X and backbone polymer with no folate and no side chains 
decreased the uptake by 15X. This inhibition may be due to possible hydrogen bonding 
of the polymer and folate or the polymer and FR. However, it seems that the same effect 
would be observed for all polymers, but it was not.   
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Figure 4.25. Competitive inhibition of the uptake of 3H-folate at 50 nM by an excess 
of polymers without folate at 100 μM in FR+ (KB) cells: polymer with no folate and 
no side chains (#24), polymer with methyl groups attached to the linkers (#66), 
polymer with PEG-3400-COOH attached to the linkers (#67), and PEG-900 (n=3). 
 
Given that the iodinated polymers did not demonstrate selectivity, but the 3H-
folate uptake studies indicated inhibition of 3H-folate uptake by the folate-targeted 
polymers, it was hypothesized that the iodination procedure was negatively impacting the 
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ability of the targeting polymer to target the appropriate cells. In order to investigate this, 
polymer was labeled with 3H. The uptake results for polymer with 98% of the linkers 
having PEG-3400-folate attached and the remaining 2% of the linkers having methyl 
groups containing 3H attached (#71) at three polymer concentrations (50 nM, 500 nM and 
5 μM) in the presence and absence of an excess (100 μM) of unlabeled folate are shown 
in Figure 4.26 plotted on linear plots (top) as well as semi-log plots (bottom). This 
polymer does not contain hydrocarbon side chains, therefore it is not in the form of 
micelles. In the FR+ cell line, at each concentration, the uptake is the same in the 
presence and absence of an excess of unlabeled folate. This indicates that either there is 
only non-specific uptake since the uptake can not be decreased by competing with 
unlabeled folate or the specific uptake is insignificant compared to the non-specific 
uptake. In addition, there is a linear increase in uptake over time at each polymer 
concentration in both cell lines, and uptake increases with increasing polymer 
concentration. Finally, the uptake in the FR- cell line is lower than that in the FR+ cell 
line, which could potentially be construed as demonstrating specificity, but since the 
presence of an excess of ligand does not alter the amount of uptake, we must conclude 
that the non-specific uptake is different between these two cell lines. The uptake of 3H-
folate observed in Figure 4.24 and Figure 4.25 (~107 molecules per cell at 3 hours) was 
achieved when the cells were incubated in a 50 nM solution of 3H-folate. From Figure 
4.26 we see that the uptake of tritiated polymer at a concentration of 50 nM solution is 
~106 polymer chains per cell. Therefore, the 3H-folate uptake is an order of magnitude 
higher than that of tritiated polymer at the same concentration.  It is likely that this higher 
uptake of 3H-folate is due to receptor-mediated endocytosis. 
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Figure 4.26. Cellular uptake of tritiated folate-containing polymer with 98% of the 
linkers having PEG-3400-folate attached and the remaining 2% of the linkers 
having methyl groups containing 3H attached (#71) at various concentrations in FR- 
(HT-1080) and FR+ (KB) cells as a function of time (n=3). 
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4.3.5. In-depth analysis of polymer cell-association 
In order to determine why our folate-targeted polymers were not behaving as 
other polymer systems reported in the literature, the amount of cell-associated folate-
containing polymer was assessed under various conditions affecting the expression of the 
FR, as shown in Figure 4.27 for three concentrations of polymer (50 nM, 500 nM, and 5 
μM). First, the uptake of the tritiated folate-containing polymer was observed in cells that 
had been grown under three conditions which varied the regulation of the FR. The 
cellular uptake of polymer was examined in cells that had been grown for two days 
before the experiment in folate-free media to up-regulate the FR, cells that were 
continuously grown in regular folate-containing media, and cells that had been grown for 
two days in folate-free media and then incubated with 100 μM unlabeled free folate for 3 
hours immediately before the start of the experiment to saturate and down-regulate the 
FR. As shown in Figure 4.27, the uptake of tritiated folate-containing polymer was 
equivalent in all three cases at each polymer concentration and therefore independent of 
the up-regulation or down-regulation of the FR. 
In addition, polymer uptake in the presence of an excess (100 μM) of unlabeled 
folate, polymer that was internalized, and non-specific polymer uptake after cells were 
treated with PI-PLC were all approximately the same as the uptake when the FR was up-
regulated or down-regulated. For experiments run at polymer concentrations of 500 nM 
and 5 μM, this is easily concluded from Figure 4.27. When the polymer concentration 
was 50 nM, the trends were the same, but there was more divergence of the data. Small 
errors in solution makeup could impact this lowest concentration more than the higher 
concentrations, which may explain this divergence. At all polymer concentrations, the 
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surface bound polymer, that which was cell-associated when incubated at 4°C, was much 
lower than the cell-associated polymer under all other conditions. It is likely that the 
surface bound polymer is the polymer that is bound to the FR. For a polymer 
concentration of 5 μM, surface bound polymer was ~20X lower than the total uptake in 
folate-free media. For 500 nM, the surface bound polymer was ~10X lower than the total 
uptake and for 50 nM, the surface bound polymer was ~4X lower. When the cells were 
pre-treated with PI-PLC to cleave the GPI-anchor attaching the FR to the cell surface and 
then incubated at 4°C, the surface bound polymer decreased for all polymer 
concentrations, confirming that a low level of polymer binds to the FR and that the 
amount of polymer bound to the FR is masked because it is overwhelmed by the much 
larger non-specific uptake of the polymer. It is important to note that the non-specific 
uptake of this polymer in these cells is not unusually high, but rather high when 
compared to the specific uptake. When compared to non-specific uptake of polymers 
containing EPPT in uMUC1- and uMUC1+ cells at comparable concentrations, as 
described in Section 4.3.3, the non-specific uptake of polymer is similar. 
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Figure 4.27. Cellular uptake of tritiated folate-containing polymer with 98% of the 
linkers having PEG-3400-folate attached and the remaining 2% of the linkers 
having methyl groups containing 3H attached (#71) at various concentrations (50 
nM, 500 nM, and 5 μM) in FR+ (KB) cells under conditions affecting the regulation 
of the FR (n=3).  
 
To facilitate a deeper understanding of the cellular association of the polymer as 
compared to free folate, it is worthwhile to graph the data in Figure 4.19 and Figure 4.27 
by experimental condition. All data for cells grown in folate-free media and incubated 
with 3H-folate or folate-containing polymer are shown as a function of incubation time in 
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Figure 4.28. The graph on the right is an expanded version of the graph on the left. In 
folate-free media, the uptake of polymer at a concentration of 50 nM was ~4X lower than 
the uptake of folate at the same concentration, the uptake of polymer at a concentration of 
500 nM was about the same as that for folate at the same concentration, and the uptake of 
polymer at a concentration of 5 μM was ~10X higher than the uptake of folate at the 
same concentration. All data for cells grown in folate-free media and incubated at 4°C 
with 3H-folate or folate-containing polymer, which limits uptake to surface bound 
material, are shown as a function of incubation time in Figure 4.29. For a polymer 
concentration of 50 nM, the surface bound polymer was ~4X lower than that for folate at 
the same concentration, similar to the results for total uptake in folate-free media. The 
shape of the curves for 50 nM, 500 nM, and 5 μM folate-containing polymer indicates 
saturation of the FR, again indicating that the polymer is bound to the FR at these low 
levels. 
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Figure 4.28. Comparison of cellular uptake of 3H-folate or polymer with 98% of 
the linkers having PEG-3400-folate attached and the remaining 2% of the linkers 
having methyl groups containing 3H attached (#71) in folate-free media in FR+ (KB) 
cells as a function of time (Left axis = 108, Right axis = 107) (n=3). 
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Figure 4.29. Comparison of surface bound 3H-folate or polymer with 98% of the 
linkers having PEG-3400-folate attached and the remaining 2% of the linkers 
having methyl groups containing 3H attached (#71) in FR+ (KB) cells as a function 
of time (n=3). 
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 The data in Figure 4.28 and Figure 4.29 can also be graphed as a function of 
concentration. All data for cells grown in folate-free media and incubated with 3H-folate 
or folate-containing polymer are shown as a function of concentration in Figure 4.30. 
Again, the graph on the right is an expanded version of the graph on the left. The uptake 
of 3H-folate in folate-free media saturates the FR at all time points, as observed by the 
curve of the lines with increased concentration. The uptake of folate-containing polymer 
in folate-free media is linear with concentration, implying non-specific behavior. All data 
for cells grown in folate-free media and incubated at 4°C with folate-containing polymer, 
giving the surface bound material, are shown as a function of concentration in Figure 
4.31. The surface bound folate-containing polymer is not quite linear with concentration. 
Perhaps the surface bound polymer starts to saturate the FR at these concentrations, but 
polymer does not saturate the FR to the extent of free folate.  
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Figure 4.30. Comparison of uptake of 3H-folate or polymer with 98% of the 
linkers having PEG-3400-folate attached and the remaining 2% of the linkers 
having methyl groups containing 3H attached (#71) in folate-free media in FR+ (KB) 
cells as a function of concentration (Left axis = 108, Right axis = 107) (n=3). 
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Figure 4.31. Comparison of surface bound 3H-folate or polymer with 98% of the 
linkers having PEG-3400-folate attached and the remaining 2% of the linkers 
having methyl groups containing 3H attached (#71) in FR+ (KB) cells as a function 
of concentration (n=3). 
  
This cell-association data can also be normalized by the bulk concentration of 3H-
folate or folate-containing polymer (Cbulk). The normalized cellular uptake of 3H-folate 
and folate-containing polymer is shown in Figure 4.32, again with the graph on the right 
being an expanded version of the graph on the left. When normalized, the highest uptake 
of 3H-folate occurs with the lowest folate concentration. This trend agrees with the point 
discussed above that the FR is likely saturating with increased concentration. When the 
uptake of folate-containing polymer is normalized by bulk solution concentration, the 
results for all three concentrations align, indicative of non-specific behavior. The 
normalized surface bound 3H-folate and folate-containing polymer is shown in Figure 
4.33, with the expanded graph on the right. The highest normalized surface bound folate-
containing polymer occurs with the lowest bulk solution concentration. This behavior is 
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similar to the behavior of normalized 3H-folate uptake in folate-free media, again 
indicating the surface bound polymer is likely bound to the FR. The normalized non-
specific uptake of 3H-folate and folate-containing polymer is shown in Figure 4.34. All 
non-specific uptake for folate and folate-containing polymer become similar when 
normalized. This level of uptake is indicative of the non-specific uptake for this cell line. 
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Figure 4.32. Comparison of normalized cellular uptake of 3H-folate or polymer with 
98% of the linkers having PEG-3400-folate attached and the remaining 2% of the 
linkers having methyl groups containing 3H attached (#71) in folate-free media in 
FR+ (KB) cells as a function of time (Left axis = 105, Right axis = 104) (n=3). 
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Figure 4.33. Comparison of normalized surface bound 3H-folate or polymer with 
98% of the linkers having PEG-3400-folate attached and the remaining 2% of the 
linkers having methyl groups containing 3H attached (#71) in FR+ (KB) cells as a 
function of time (Left axis = 105, Right axis = 104) (n=3). 
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Figure 4.34.  Comparison of normalized non-specific cellular uptake of 3H-folate or 
polymer with 98% of the linkers having PEG-3400-folate attached and the 
remaining 2% of the linkers having methyl groups containing 3H attached (#71) in 
FR+ (KB) cells as a function of time (n=3). 
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Figure 4.35 shows the normalized cell-associated 3H-folate and folate containing 
polymer as a function of concentration. The results for uptake in folate free media are 
shown in A and the results for surface bound polymer are shown in B. Again, it appears 
that the FR is saturated with 3H-folate as the bulk solution concentration is increased, 
since the uptake in folate-free media drops sharply and then levels out when normalized. 
In contrast, the normalized uptake of folate-containing polymer in folate-free media is 
nearly independent of concentration at all three time points. However, the normalized 
surface bound polymer shows similar behavior to normalized folate uptake in folate-free 
media with apparent saturation of the FR with increased concentration. This alternative 
analysis of the cell-association data affirms the inference that the polymer does bind to 
the FR at levels much lower than the non-specific uptake. 
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Figure 4.35. Comparison of normalized cellular uptake in folate-free media and 
surface bound 3H-folate or polymer with 98% of the linkers having PEG-3400-folate 
attached and the remaining 2% of the linkers having methyl groups containing 3H 
attached (#71) in FR+ (KB) cells as a function of concentration (n=3). 
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In summary, it is clear that polymer is taken up non-specifically in high amounts, 
as compared to specific uptake. An excess of unlabeled folate did not measureably 
decreased the uptake of polymer in folate-free media, even though it was able to decrease 
the uptake of labeled folate by competitive inhibition. Up- or down-regulation of the FR 
had no measureable effect on polymer uptake, but did affect folate uptake. Also, cleaving 
the FR with PI-PLC did not measureably affect polymer uptake, but did decrease folate 
uptake. When normalized, all non-specific uptake for folate and folate-containing 
polymer align, indicating the level of non-specific uptake for this cell line. It is also 
apparent that a low level of polymer does bind to the FR. For each polymer 
concentration, the amount of surface bound polymer is much lower than the total uptake 
of polymer in folate-free media. The curves for this surface bound polymer indicate 
saturation and binding to the FR. Finally, the amount of surface bound folate and polymer 
is decreased when treated with PI-PLC to remove FR, confirming the attachment to the 
FR. 
4.3.6. Size measurement of polymer and free folate in folate-free media by DLS 
A possible explanation for the inability to demonstrate selectivity with the folate 
targeted polymers could be that some of the attached folate molecules may not be 
available for binding, a phenomenon previously discussed in the literature [75]. Baker et. 
al. used molecular dynamics simulations of folate-targeted dendrimers to show that local 
branch aggregation was observed, depending on capping of the surface amines, and 
folates were internalized, suggesting a decreased potential for receptor interaction. Since 
several of our polymers used in the uptake studies can not form micelles of the type 
envisioned in Figure 2.4 due to a lack of hydrophobic side chains, it may be likely that 
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the polymers are forming aggregates resulting from folate-folate and/or PEG-PEG 
interactions, possibly in the form of structured micelles, leaving most of the attached 
folate unavailable to bind to the FR. The self assembly of free folate in water has been 
investigated in the literature [76-79]. It was reported that folate forms tetrameric columns 
held together by hydrogen bonds in water. These results may be extended to the case of 
polymer bound folate. 
To investigate the formation of polymer aggregates in solution, light scattering 
measurements were made to determine the size of particles in folate-free media for 
polymer with 100% of the linkers having PEG-3400-folate attached (#64), polymer with 
PEG-3400-COOH attached to the linkers (#67), polymer with 25% of the linkers having 
PEG-3400-folate attached and the remaining 75% of the linkers having ether-ester-linked 
hydrocarbon side chains (#61), and polymer with no folate and no side chains (#24). 
Polymer or free folate was dissolved in folate free media without serum. The results for 
the intensity averaged diameters are reported in Table 4.1. Included with the results are 
the date on which the solution was made and the date on which the measurement was 
made in order to assess any time-dependent behavior.  
When measured the same day the 100 μM solution was made, polymer with 100% 
of the linkers having PEG-3400-folate attached (#64) formed aggregates that were 183 
nm in size. However, 2 days after solution makeup the aggregates measured 69.5 nm and 
14 days after solution makeup the aggregates measured 142 nm. Single polymer chains in 
solution would be on the order of 10 nm in diameter. Therefore it seems that aggregates 
of multiple polymers chains are forming and the formation of these aggregates is a 
dynamic process in which the aggregates increase and decrease over time.  The 100 μM 
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solution of polymer with 100% of the linkers having PEG-3400-folate attached (#64) was 
diluted to 5 μM, 500 nM, and 50 nM 2 days after the original solution was made up. 
These solutions were then measured by DLS the same day they were diluted in order to 
determine if aggregate size decreased with concentration. The 5 μM solution measured 
aggregates of 73.4 nm, similar in size to the 69.5 nm aggregates in the 100 μM solution. 
However, the 500 nM and 50 nM solutions did not scatter enough light to obtain a 
measurement. After 14 days in solution, the 5 μM, 500 nM, and 50 nM solutions all did 
not scatter enough light to obtain a measurement. It is clear that when polymer with 
100% of the linkers having PEG-3400-folate attached was at a high enough concentration 
to scatter light, aggregates were observed.  
Polymer with PEG-3400-COOH attached to the linkers (#67) measured 57.2 nm 
in size after 2 days in solution, which was surprising since this polymer did not contain 
folate. Polymer with 25% of the linkers having PEG-3400-folate attached and the 
remaining 75% of the linkers having ether-ester-linked hydrocarbon side chains (#61) 
measured 120 nm the same day the solution was made. But neither scattered light after 2 
weeks in solution. And polymer with no folate and no side chains (#24) did not scatter 
light in solution the day the solution was made or 2 weeks later. 
It was thought that perhaps free folate in solution could also form aggregates and 
may influence the formation of aggregates of folate-containing polymer or increase the 
size of aggregates folate-containing polymer. Polymer with 100% of the linkers having 
PEG-3400-folate attached (#64) in solution at a concentration of 100 μM with 50 nM free 
folate, representative of the concentrations in the competitive inhibition studies, formed 
aggregates 185 nm in size the same day the solution was made and 89.6 nm in size after 2 
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days in solution. These sizes are similar to those for polymer at the same concentration 
without free folate in solution, therefore it does not appear that the free folate greatly 
influences the formation or size of these aggregates. Finally, free folate in solution at 50 
nM or 100 μM did not scatter enough light to measure the size by DLS. 
 
Table 4.1. Measurement of intensity averaged diameter of polymer with 100% of the 
linkers having PEG-3400-folate attached (#64), polymer with PEG-3400-COOH 
attached to the linkers (#67), polymer with 25% of the linkers having PEG-3400-
folate attached and the remaining 75% of the linkers having ether-ester-linked 
hydrocarbon side chains (#61), polymer with no folate and no side chains (#24), and 
free folate in folate-free media with no serum by DLS (n=3). 
  Diameter (nm) 
Solution 
Solution 
Makeup Date 
25-March-2009 27-March-2009 08-April-2009 
100 μM #64 25-March-2009 183 ± 25 69.5 ± 1.0 142 ± 17 
5 μM #64 
Diluted on 
27-March-2009 
- 73.4 ± 23.0 
Not Enough 
Scatter 
500 nM #64 
Diluted on 
27-March-2009 
- Not Enough Scatter 
Not Enough 
Scatter 
50 nM #64 
Diluted on 
27-March-2009 
- Not Enough Scatter 
Not Enough 
Scatter 
100 μM #67 25-March-2009 - 57.2 ± 0.5 
Not Enough 
Scatter 
100 μM #61 27-March-2009 - 120 ± 2 
Not Enough 
Scatter 
100 μM #24 27-March-2009 - Not Enough Scatter 
Not Enough 
Scatter 
100 μM #64 + 
50 nM free folate 
25-March-2009 185 ± 11 89.6 ± 10.3 - 
50 nM free folate 25-March-2009 
Not Enough 
Scatter 
Not Enough Scatter 
Not Enough 
Scatter 
100 μM free 
folate 
25-March-2009 
Not Enough 
Scatter 
Not Enough Scatter 
Not Enough 
Scatter 
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4.3.7. Comparison of theoretical calculations to experimental uptake results 
It is clear from all of the experimental uptake data presented here, for polymer 
containing EPPT or folate, that we were not able to demonstrate the overwhelming 
selectivity that the polymers were designed to possess. As mentioned in Section 4.3.2 on 
the theoretical design of targeting polymers, certain assumptions were made when 
performing the design calculations. Likely these assumptions were not met; therefore the 
targeting was not demonstrated successfully. First, the assumption was made that 
neighboring ligands were not negatively cooperative, at least not to a large extent.  
However, it is possible that the ligands do negatively impact the binding of neighboring 
ligands, abrogating the polyvalent effect that we designed the polymers to contain. 
Second, it was assumed that all ligands were available for binding. This assumption 
likely fails, particularly for the folate system, given the DLS results showing aggregates 
in solution and the reports in the literature of aggregate formation of folate molecules. 
The failure of these assumptions likely resulted in the inability to demonstrate targeting. 
4.3.8. Cellular uptake of free 125I 
As mentioned above, it was hypothesized that the iodination procedure was 
negatively impacting the ability of the targeting polymer to target the appropriate cells. 
One possibility was that free iodine remaining in the polymer solution, despite the 
separation procedure after the iodination reaction, was interfering with the uptake results. 
With the purpose of determining the impact of the free 125I on the uptake experiments, in 
vitro experiments were performed to examine the cellular uptake of free 125I. To simulate 
the separation process, a representative sample of free 125I was passed through a 
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Sephadex column. The amount of free 125I that passed through the column was measured 
by Kevin Brower. It was found that, in the worst separation case, there was ~2,000,000 
CPM collected in the fractions in which polymer is typically collected. Therefore, uptake 
experiments were performed starting with solutions with activity levels in this range. The 
results of these experiments are shown in Figure 4.36. The uptake was observed to be 
0.002-0.006 CPM per cell for all activities tested. In addition, in the presence of 100 μM 
of backbone polymer with no ligand and no side chains (#24) the uptake of free iodine 
was equivalent to that in the absence of polymer, verifying that there is no carrier effect 
due to the polymer in solution. The results for the highest activity were also graphed as 
CPM per cell with the results for polymer with 100% of the linkers having ester-linked 
hydrocarbon side chains (#27) and polymer with 5% of the linkers having TEG-EPPT 
and the remaining 95% of the linkers having ester-linked hydrocarbon side chains (#37), 
shown in Figure 4.37. This comparison shows that the activity in each cellular sample 
due to any free iodine remaining the polymer solution is low, at most, 10% of the 
measured activity. Based on these results it is not likely that residual free iodine 
remaining in the polymer solution after the iodination and separation greatly impacts the 
results presented in this chapter. 
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Figure 4.36. Cellular uptake of free iodine at levels mimicking residual free iodine 
remaining after polymer labeling in uMUC1+ (BT-20) cells (n=3). 
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Figure 4.37. Cellular uptake of free iodine as compared to polymer with 100% of the 
linkers having ester-linked hydrocarbon side chains (#27) and polymer with 5% of 
the linkers having TEG-EPPT and the remaining 95% of the linkers having ester-
linked hydrocarbon side chains (#37) in uMUC1+ (BT-20) cells (n=3). 
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4.4. Discussion 
The alternating copolymers used in this study were taken up by cells in vitro. 
Microscopy images of the fluorescently labeled polymer alone demonstrated that the 
polymer was likely confined to vesicles within the cytoplasm and it was not found in the 
nucleus, but encapsulated doxorubicin was shown to be largely confined to the nucleus. 
These results verify the in vitro uptake of the polymers. However, the targeting abilities 
of these polymers were less clear. 
Upon initial testing, the polymers used in this study appeared largely non-specific 
for the targeted cells when studied in vitro. The cellular uptake of polymer with 5% of the 
linkers having TEG-EPPT attached and the remaining 95% of the linkers having ester-
linked hydrocarbon side chains was twice that of polymer with 100% of the linkers 
having ester-linked hydrocarbon side chains, although the difference was not statistically 
significant. In addition, increasing the percent of linkers containing the targeting ligand 
EPPT did not increase the uptake, especially without hydrocarbon side chains also on the 
polymer. 
For polymers containing folate, regardless of the amount of folate attached, the 
length of the spacer used, or the type of radioactive label used, the uptake did not 
decrease in the presence of an excess of folate, indicating a high amount of non-specific 
uptake for all folate-containing polymers. However, when all of these folate-containing 
polymers were used to competitively inhibit 3H-folate, the two polymers with PEG-3400-
folate attached at the end of the polymer chain only inhibited the uptake of 3H-folate 
slightly, but all other folate-containing polymers tested inhibited the uptake by 1 or 2 
orders of magnitude, suggesting that the targeted polymers bind to the FR. Only one 
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polymer not containing folate was able to inhibit the uptake of 3H-folate slightly, 
indicating that polymers with folate attached had an advantage to inhibiting free folate 
uptake. 
The uptake results for polymer with 98% of the linkers having PEG-3400-folate 
attached and the remaining 2% of the linkers having methyl groups containing 3H 
attached have shown that, at all three concentrations tested, the uptake was the same in 
the presence and absence of an excess of unlabeled folate. This agreed with the results for 
all other folate-containing polymers and indicated that either there was only non-specific 
uptake, since the uptake can not be decreased by competing with unlabeled folate, or the 
specific uptake was insignificant compared to the non-specific uptake. 
Some papers in the literature state that coating particles in PEG can increase the 
cellular uptake of the particles without any targeting [80-82], however there are also 
several papers that say that attaching PEG inhibits cellular uptake [83-86]. Given the lack 
of agreement in the literature, it is unclear what effect PEG is having on the uptake of our 
polymer. The particles in the literature were all 40 nm to 700 nm in size. Additionally, 
there is an indication in the literature, in general, that non-specific uptake increases with 
decreased particle size for the range from 40-350 nm [87]. The largely non-specific 
uptake demonstrated with our polymers may be supported by the literature.  
A more in-depth study of the cell-association of these polymers clarified that 
polymer was taken up non-specifically in high amounts. An excess of unlabeled folate, 
up- or down-regulation of the FR, and cleaving the FR did not measureably affect 
polymer uptake, but did alter folate uptake. All non-specific uptake for folate and folate-
containing polymer align when normalized, indicating the level of non-specific uptake for 
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this cell line. Furthermore, it was also determined that a low level of polymer does bind 
to the FR. The amount of surface bound polymer was much lower than the total uptake of 
polymer in folate-free media for each polymer concentration investigated. In addition, the 
amount of surface bound folate and polymer decreased when the FR was cleaved, 
confirming the attachment of polymer to the FR. 
Light scattering measurements showed that polymers that contain folate form 
aggregates of multiple polymers chains and the formation of these aggregates is a 
dynamic process in which the aggregates increase and decrease over time. Surprisingly, 
one polymer that did not contain folate did form aggregates. When polymer with folate 
attached was in solution with free folate, aggregates formed and were of similar size to 
polymer without free folate in solution, indicating that the free folate does not greatly 
influence the formation or size of these aggregates. Also, at concentrations representative 
of the uptake experiments, free folate in solution did not scatter enough light to measure 
the size by DLS. These results confirmed that polymer aggregation was occurring and 
this aggregation was likely causing at least a portion of the folate ligands to be hidden in 
the aggregate and unavailable for binding to the FR. 
The aggregation of polymers is the most likely mechanistic cause of the failure of 
the folate-containing polymers to demonstrate targeting. Since many of the attached 
folate molecules were potentially inside of the aggregates, they were not available for 
binding thereby decreasing the effective concentration of folate. This would result in 
lower specific binding of polymer to the FR, as evidenced by the fact that the amount of 
surface bound polymer was lower than expected based on surface bound folate amounts. 
Future designs for targeting polymers should account for the lessons learned in the 
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studies discussed here. Namely, ligands should be chosen that have no likelihood of 
aggregating in solution such that all ligands are available for binding. In addition, 
aggregation concerns should be decreased by incorporating fewer ligands into the 
structure. In order to decrease the necessary number of ligands in the polymer, targeting 
ligands should be chosen that have extremely high affinity for their targets such that 
polyvalency is not required. The versatility of these polymer constructs allows for 
continued optimization of a targeting delivery system for drugs and imaging agents as 
lessons discovered from passed studies are incorporated into the design. 
While these polymers did not have the selective advantage that was anticipated 
due to the high level of non-specific uptake and the low level of specific binding, it is 
clear that the polymers are taken up by cancerous cells in vitro. The alternating 
copolymers used in this study could be redesigned to contain an external charge in the 
corona to attempt to decrease the non-specific uptake such that the selective advantage 
could be discerned or new targeting ligands can be chosen to minimize the issues 
observed in this study. It was reported in Chapter 3 that the alternating copolymers 
studied here have had some success as drug delivery vehicles in vitro. Therefore, these 
polymers should be further tested as delivery platforms in vitro and in mouse models of 
human cancer to determine the in vivo delivery capabilities. The initial pharmacokinetic 
studies of these polymers in vivo are discussed in Chapter 5, although the work is 
ongoing by others (ie. Kevin Brower in the Colton group). 
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Chapter 5. Initial Biodistribution Studies of Alternating Copolymers In 
Vivo 
 
5.1. Introduction 
Nanoparticles may be preferentially concentrated in vivo at tumor sites through 
strategic passive or active targeting. The phenomenon described as the “enhanced 
permeability and retention (EPR) effect” [1-10], in which nanoparticles accumulate in 
solid tumors in increased amounts as compared to normal tissue has been well 
documented [11-18] and is attributed to pathophysiological characteristics of solid tumors 
that are not observed in normal tissue. These characteristics include defective tumor 
blood vessel architecture (often termed “leaky vasculature”), defective lymphatic 
drainage system, and increased production of permeability mediators [5, 7]. It has been 
reported that particles >5 nm in diameter get trapped in the tumor tissue [8, 19], but 
tumors also exhibit a characteristic pore cutoff size of 200 nm or greater [4]. Therefore 
drug delivery particles in the 5-200 nm size range should passively target tumors due to 
the EPR effect. It was determined that micelles formed from our alternating copolymers 
are 8-22 nm in diameter [20], therefore these particles are optimal for passive targeting in 
vivo. 
In addition to passive targeting, nanoparticles can be actively targeted to a tumor 
cell in order to kill the cancerous cells without damaging normal cells. There are many 
technologies which are being used to specifically target molecules or particles to tumor 
cells [21-34]. Often, a monoclonal antibody, a peptide fragment, or a small molecule is 
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used as the targeting agent. Typically these targeting agents form a binding pair with the 
target found on the tumor cell surface. Selectivity of the nanoparticles for specific cancer 
cells by targeting allows for reduced incidence of the adverse side effects of the 
chemotherapeutic drugs, however this comes at the expense of adding complexity to the 
nanoparticle preparation, potentially increasing particle size, and the risk of adverse 
biological reactions with the targeting agent.  
Many studies in the literature have targeted tumors in vivo by passive targeting 
using the EPR effect [11-18]. Others have additionally used active targeting to tumor 
cells to increase accumulation of nanoparticles in the tumor [35-38]. The alternating 
copolymers used in this study, described in detail in Chapter 2, were designed to 
passively and actively target tumors. It was reported in Chapter 3 that these alternating 
copolymers are largely non-toxic and have had some success as drug delivery vehicles in 
vitro. The cellular uptake of these polymers was investigated in Chapter 4. While these 
polymers did not have the overwhelming selectivity that was anticipated and the specific 
uptake of these polymers through the targeted receptor-mediated endocytosis pathway 
can not be substantiated, it is clear that they are taken up by cancerous cells in vitro. 
These in vitro studies warranted initial investigation of these polymers in mouse models 
of human cancer to determine the in vivo delivery capabilities.  
This chapter describes the in vivo experimental work that was done in 
collaboration with Kevin Brower from the Colton Lab in the Department of Chemical 
Engineering at the Massachusetts Institute of Technology. Preliminary pharmacokinetic 
studies were performed to examine the biodistribution and blood circulation of the 
alternating copolymers in xenograft models of human tumors in nude (nu/nu) mice using 
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radioactively labeled polymers.  Results were obtained by collecting blood samples and 
harvesting organs at specified time points and measuring the radioactivity of these 
samples. A detailed description of the synthesis protocol for each polymer can be found 
in Appendix I. A list of all polymer structures used in this study is given in Appendix II. 
The numbers referred to throughout the remainder of this text correspond to the polymer 
structures as identified in the table presented in Appendix II. 
5.2. Methods 
5.2.1. Materials and reagents 
All polymers were provided by our collaborators in the Arthur Watterson lab at 
the University of Massachusetts, Lowell. All reagents were obtained from commercial 
sources. Phosphate buffered saline (PBS), trypsin EDTA (1X, 0.25% trypsin/0.53 mM 
EDTA in HBSS), penicillin-streptomycin solution, and fetal bovine serum (FBS) were 
purchased from Mediatech, Inc. Minimum essential media, Eagle, with 2 mM L-
glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-
essential amino acids, and 1.0 mM sodium pyruvate (EMEM) was purchased from 
ATCC. Hank’s buffered salt solution (HBSS) was purchased from Lonza. Guava 
Viacount assay kit was purchased from Guava Technologies/Millipore.  
5.2.2. Cell lines and culture 
BT-20 cells (human breast carcinoma; underglycosylated mucin-1 positive 
(uMUC1+)) and KB cells (human epidermoid carcinoma; folate receptor positive (FR+)) 
were purchased from the American Type Culture Collection. BT-20 and KB cells were 
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cultured in EMEM supplemented with 10% FBS and 1% penicillin–streptomycin 
solution. All cells were grown at 37°C in a humidified atmosphere containing 5% CO2 in 
preparation for tumor induction in mice. 
5.2.3. Cell counting 
After cells were detached from the flask with trypsin, cell number was evaluated 
by staining cells using a Guava Viacount assay solution and acquiring data with a Guava 
Personal Cell Analysis (PCA) flow cytometer using the Guava Viacount software. 
Dilution factors and original sample volumes were entered as appropriate for each 
sample. Each sample was run in triplicate and 1000 events were acquired per sample. 
5.2.4. Tumor induction by subcutaneous injection in nu/nu mice 
Once cells were counted, cells were centrifuged at 300 RCF for 5 minutes, 
washed with one volume of HBSS, centrifuged again, and finally suspended in the 
appropriate volume of HBSS to result in 2-5x106 cells per 50 uL. Each nu/nu mouse was 
injected with 50 uL of HBSS containing 2-5x106 cells subcutaneously in the flank. Mice 
that were injected with FR+ (KB) cells were fed a low-folate diet purchased from 
Research Diets to ensure up-regulation of the FR in the FR+ cells.  Mice were cared for 
under compliance with the guidelines of the Committee on Animal Care in the Division 
of Comparative Medicine at the Massachusetts Institute of Technology.   
5.2.5. Biodistribution 
After tumors reached ~0.5 cm in diameter, as measured by micrometer (typically 
~3 weeks), mice were injected intraveneously with the 125I-labeled polymer (0.86 mg). 
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Five or twenty-four hours later, animals were sacrificed. Tumors, fluids, and organs were 
removed and weighed. The collected tissue or fluid was analyzed in a gamma counter 
(Packard COBRA II Auto-Gamma). The activity of each sample was compared to the 
activity measurements of polymer solutions of known concentrations to calculate the 
amount of polymer taken up. Biodistribution results were expressed as the percentage of 
the injected dose per gram of tissue (% ID/g tissue) or percentage of injected dose (% 
ID). Experiments were performed using a protocol approved by the Committee on 
Animal Care in the Division of Comparative Medicine at the Massachusetts Institute of 
Technology. 
5.2.6. Statistical analysis 
All data were represented as mean ± standard deviation. Statistical significance 
(p<0.05) was determined, where appropriate, by a two-tailed Student t-test. 
5.3. Results 
5.3.1. Biodistribution of non-targeted polymers in mice with no tumors 
In the first in vivo biodistribution study, twelve nu/nu mice were injected 
subcutaneously with uMUC1+ (BT-20) cells. After 2 months, no tumors had developed. 
With the help of Professor Anna Moore at the Martinos Center for Biomedical Imaging at 
Massachusetts General Hospital, it was determined that these cells were no longer 
tumorigenic. The cells were reordered twice from ATCC and none of the lots induced 
tumors in nu/nu mice. We proceeded with the study to investigate the biodistribution of 
the non-targeted polymer in vivo in the absence of a tumor. 
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Each mouse was injected retro-orbitally with 300 μL PBS containing 0.86 mg (10 
μCi) of non-targeted polymer with 100% of the linkers having ester-linked hydrocarbon 
side chains (#27) labeled with 125I. One hour after injection, each mouse was bled via the 
tail vein to collect a blood sample. After 24 hours, each mouse was euthanized and the 
blood, tumor, liver, spleen, kidney, heart, and lung were collected. The results of the 
biodistribution and blood circulation are shown in Figure 5.1. The biodistribution data 
(left) are shown as percent of injected dose per gram of tissue (% ID/g tissue). For all 
harvested organs, the % ID/g tissue was less than 0.5%. The blood circulation data (right) 
are presented as percent of injected dose (% ID). One hour after injection, the % ID in the 
blood was approximately 5% and 24 hours after injection, the % ID was less than 1%. 
These low values imply that a majority of the injected polymer is excreted within 24 
hours.  Approximately 10 μCi per mouse was crudely measured, using a sodium iodide 
detector, in the urine and the excretions in the cage, which was consistent with the low 
levels in the organs.  
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Figure 5.1.  Biodistribution and blood circulation of non-targeted polymer with 
100% of the linkers having ester-linked hydrocarbon side chains (#27) labeled with 
125I injected retro-orbitally in nu/nu mice. 
 
5.3.2. Biodistribution of targeted polymers in mice with tumors 
In the second biodistribution study, twelve nu/nu mice were injected 
subcutaneously with FR+ (KB) cells and six control mice received subcutaneous 
injections of HBSS. The tumor take rate was at 100% within three weeks in the mice 
injected with cells. Mice were divided into two groups. One group was injected retro-
orbitally with 200 uL PBS containing 0.86 mg (10 μCi) of targeted polymer with 100% 
of the linkers having PEG-3400-folate attached (#64) labeled with 125I. The second group 
was injected via the tail vein with 250 uL PBS containing 0.86 mg (10 μCi) or targeted 
polymer with 100% of the linkers having PEG-3400-folate attached (#64) labeled with 
125I.  Mice were bled via the tail vein to collect blood at 1, 2, 5, and 24 hours.  Mice were 
sacrificed at either 5 or 24 hours and samples were taken of tail, tumor, liver, spleen, 
kidney, heart, lung, and brain. The results of the biodistribution (left) and blood 
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circulation (right) for the mice injected retro-orbitally are shown in Figure 5.2. At the 5 
hour and 24 hour time points, the highest % ID/g tissue was in the kidneys. It appears that 
the polymer did not cross the blood-brain barrier, due to the low levels in the brain. In 
addition, there was accumulation in the tumor, as desired, likely due to the passive 
targeting mentioned earlier. The values for each organ were lower at the 24 hour time 
point than the 5 hour time point. The % ID in the blood decreased over time and the 
blood half-life was calculated to be ~30 minutes. 
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Figure 5.2. Biodistribution and blood circulation of targeted polymer with 100% of 
the linkers having PEG-3400-folate attached (#64) labeled with 125I injected retro-
orbitally in nu/nu mice. 
 
The results of the biodistribution (left) and blood circulation (right) for the mice 
injected via the tail vein are shown in Figure 5.3. In the case of the tail vein injection, the 
tail was collected and the activity was measured.  The activity in the tail was subtracted 
from the injected dose as it is assumed that this material was injected into the tail tissue 
rather than into the bloodstream. At the 5 hour and 24 hour time points, the highest % 
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ID/g tissue was in the kidneys, as with the retro-orbital injection. It appears the polymer 
did cross the blood-brain barrier in very low amounts, although it was not statistically 
different from the retro-orbital injection and these low amounts may have been due to 
cross-contamination during organ harvesting. Again, there was significant accumulation 
in the tumor, as desired. The values for each organ were lower at the 24 hour time point 
than the 5 hour time point, as expected. The % ID in the blood decreased over time and 
the blood half-life was again calculated to be ~35 minutes. There was no statistical 
difference in biodistribution between the two injection types. However, at 1 hour after 
injection, there were statistically higher levels of polymer in the blood of mice receiving 
the injection by the tail vein than by retro-orbital injection, although at all other time 
points there was no statistical difference in % ID in the blood. As with the first study with 
non-targeted polymer, nearly all the dose was excreted by 24 hours. 
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Figure 5.3. Biodistribution and blood circulation of targeted polymer with 100% of 
the linkers having PEG-3400-folate attached (#64) labeled with 125I injected via the 
tail vein in nu/nu mice. 
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5.4. Discussion 
The alternating copolymers used in this study do accumulate in tumors in vivo. 
Similar studies in the literature report levels of 0.04-2.7 % ID/g tissue [35-38], 
comparable to the levels of accumulation (0.08-1.0 % ID/g tissue) observed in these 
studies. These same studies from the literature report levels of 20-60 % ID/g tissue in the 
liver, while our polymers only accumulate 0.3-1.5 % ID/g tissue in the liver. It is 
desirable to minimize the accumulation in other organs, while maximizing the 
accumulation in the tumor tissue. Therefore, this preliminary study warrants continued 
investigation of our polymer platform as a delivery vehicle in vivo.   
During the analysis of the results of these studies, it was determined that the most 
appropriate injection method is via the tail vein rather than by retro-orbital injection in 
order to more precisely ascertain the total injected dose. It was recommended that the tail 
and the injection syringe be measured for activity and that activity be subtracted from the 
theoretical injected dose in order to give the actual injected dose to be used in the 
calculations.  Future experiments investigating the behavior of these alternating 
copolymers in vivo will be performed using the tail vein injection method by Kevin 
Brower from the Colton Lab in the Department of Chemical Engineering at the 
Massachusetts Institute of Technology. 
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Appendix I. Description of Methods for Polymer Synthesis 
 
I.i. Synthesis of backbone polymer 
Backbone polymer was synthesized by the enzymatic reaction of dimethyl 5-
amino-isophthalate (0.05mmol), dimethyl 5-hydroxy-isophthalate (0.95 mmol) and PEG-
900 (1.0 mmol). This mixture was placed in a round-bottom flask, enzyme (10 wt % wrt 
monomers) was added, and the reaction vial was then placed in a constant temperature oil 
bath maintained at 90°C under vacuum. The reaction was allowed to proceed for 48 h, 
after which it was quenched by adding water and filtering off the enzyme and any 
unreacted monomer under vacuum. The filtrate was dialyzed using a membrane (MWCO 
6000). After the completion of dialysis, the product was obtained as a semisolid by 
freeze-drying. Obtained product was fully characterized on the basis of its detailed 
spectral studies including 1H-NMR, 13C-NMR, IR and GPC [1-3]. Alternatively, the 
procedure was performed without dimethyl 5-hydroxy-isophthalate but with 1.0 mmol 
dimethyl 5-amino-isophthalate to produce backbone polymer with 100% amino linkers or 
without dimethyl 5-amino-isophthalate but with 1.0 mmol dimethyl 5-hydroxy-
isophthalate to produce backbone polymer with 100% hydroxy linkers. The synthesis was 
also carried out with PEG-600, PEG-1500, and PEG-10000 to produce backbone polymer 
with higher PEG ratios. The procedure was also performed with 4Å molecular sieves (20 
wt% wrt monomers) to decrease the water content in the reaction mixture [4]. 
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I.ii. Attachment of hydrocarbon side chains 
I.ii.a. Ether bond 
Equimolar quantities of polymer with free hydroxyl groups on 100% of the 
linkers and bromodecane were dissolved in dry acetone, and to the resultant solution was 
added an equimolar amount of anhydrous potassium carbonate. The reaction mixture was 
refluxed, and progress of the reaction was monitored by TLC using ethyl acetate in 
petroleum ether (30%). After completion, the potassium carbonate was removed by 
filtration, and the solvent was removed under vacuum to give the product [1]. This 
procedure was also performed with bromononane or 11-bromoundecanoic acid in place 
of bromodecane. Other alternatives that were synthesized used polymers with free 
hydroxyl groups on 90% of the linkers or 95% of the linkers. 
I.ii.b. Ester bond 
Polymer with free hydroxyl groups on the linkers (1.0 mmol) was dissolved in 
anhydrous acetonitrile followed by the addition of anhydrous potassium carbonate (3.0 
mmol) and nonanoyl chloride (1.2 mmol) under nitrogen. The reaction mixture was 
stirred at room temperature for 6 h under reflux and progress of the reaction was 
monitored by TLC using ethyl acetate in petroleum ether (30%). After completion of the 
reaction, salt was removed by filtration and the solvent removed under vacuum to give 
the product [4]. This procedure was also performed with decanoyl chloride or 
tetradecanoyl chloride in place of nonanoyl chloride. Other alternatives that were 
synthesized used polymers with free hydroxyl groups on 90% of the linkers or 95% of the 
linkers. 
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I.ii.c. Ether ester bond 
To a solution of polymer with free hydroxyl groups on 90% of the linkers (1.0 
mmol) in 25 ml of dry acetonitrile, anhydrous potassium carbonate (0.85 mmol) was 
added followed by decyl bromo acetate (0.81 mmol) and the resulting solution was 
refluxed in an oil bath maintained at 60°C. Progress of the reaction was monitored by 
TLC. After completion of the reaction, salts were filtered off and acetonitrile was 
removed to give the amphiphilic polymer as solid [3-5]. 
I.ii.d. Amide bond 
Polymer with free amino groups on the linkers (1.0 mmol) was dissolved in 
anhydrous dichloromethane followed by the addition of anhydrous potassium carbonate 
(3.0 mmol) and nonanoyl chloride (1.2 mmol) under nitrogen. The reaction mixture was 
stirred at room temperature for 6 h under reflux and progress of the reaction was 
monitored by TLC using ethyl acetate in petroleum ether (30%). After completion of the 
reaction, salt was removed by filtration and the solvent removed under vacuum to give 
the product [4]. Other alternatives that were synthesized used polymers with free amino 
groups on 5% of the linkers. 
I.iii. Attachment of perfluorocarbon side chains 
I.iii.a. Ether ester bond 
To a solution of polymer with free hydroxyl groups on 90% of the linkers (1.0 
mmol) in 25 ml of dry acetonitrile, anhydrous potassium carbonate (0.85 mmol) was 
added followed by 1H,1H,2H,2H-perfluorodecyl bromo acetate (0.81 mmol) and the 
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resulting solution was refluxed in an oil bath maintained at 60°C. Progress of the reaction 
was monitored by TLC. After completion of the reaction, salts were filtered off and 
acetonitrile was removed to give the amphiphilic polymer as solid [3-5]. This procedure 
was also performed with 1H,1H,2H,2H-perfluorododecyl bromo acetate in place of 
1H,1H,2H,2H-perfluorodecyl bromo acetate. Other alternatives that were synthesized 
used polymers with free hydroxyl groups on 95% of the linkers or 100% of the linkers. 
I.iii.b. Amide bond 
To a solution of polymer with free amino groups on the linkers (1.0 mmol) in 25 
ml of dry acetonitrile, anhydrous potassium carbonate (0.85 mmol) was added followed 
by perfluorooctanoyl chloride (0.81 mmol) and the resulting solution was stirred at room 
temperature. Progress of the reaction was monitored by TLC. After completion of the 
reaction, salts were filtered off and acetonitrile was removed to give the amphiphilic 
polymer as solid [4]. This procedure was also performed with perfluorononanoyl chloride 
in place of perfluorooctanoyl chloride. 
I.iv. Attachment of fluorescent labels 
I.iv.a. Rhodamine B 
Rhodamine B was converted to its acid chloride using oxalyl chloride. Treatment 
of the polymer (substituted with a decane chain as the hydrophobic group on the linkers) 
with the Rhodamine B acid chloride and base gave a reaction to form an ester linkage 
with the CH2OH groups at the ends of the polymer chains, binding it covalently to the 
polymer. 
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I.iv.b. FITC 
FITC (fluorescein-5-isothiocyanate) dye (0.067 mmol) was added to a three-neck 
round bottom flask containing backbone polymer with free amino groups on 5% of the 
linkers (1.0 mmol) dissolved in anhydrous DMF (10 ml) under a nitrogen environment. 
The resulting mixture was stirred at room temperature for four hours. Upon completion of 
the reaction, DMF was removed by washing several times with excess hexane. Obtained 
residue was further dried under vacuum and then subjected to dialysis using a membrane 
(MWCO 6000-8000) to get rid of unreacted FITC in the obtained product [3, 4]. 
I.iv.c. Cy 5.5 
Backbone polymer with free amino groups on 5% of the linkers (100 mg) in 0.5 
M sodium bicarbonate with the pH adjusted to 9.6 was added to 1 mg of Cy5.5 dye 
(Amersham-Pharmacia, Cat.#Q15408). The mixture was incubated on a rotator overnight 
at room temperature. After incubation, the mixture was purified from non-reacted dye on 
G-25 Sephadex column equilibrated with 20 mM sodium citrate buffer with 0.15 M 
NaCl, pH 8.0 [6]. 
I.v. Attachment of targeting ligands 
I.v.a. EPPT with triethylene glycol spacer 
Attachment of triethylene glycol as spacer 
Polymer containing free hydroxyl groups on 5% of the linkers (1.0 mmol) was 
dissolved in anhydrous acetonitrile and added to a three-neck round bottom flask 
containing freshly fused K2CO3 (0.044mmol) under a nitrogen environment with constant 
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stirring. In a drop-wise manner, triethylene glycol bromo acetate (0.043mmol), dissolved 
in anhydrous acetonitrile, was added. The resulting reaction mixture was refluxed for 6-8 
hours and the progress of the reaction was monitored by TLC. After completion of the 
reaction, salts were filtered off and the filtrate was concentrated at reduced pressure to get 
the desired product. Obtained product was characterized by its 1H-NMR and 13C-NMR 
spectrum [3, 4]. 
 
Activation of hydroxyl group on spacer 
The activation was carried out under nitrogen by stirring disuccinimidyl carbonate 
(0.13 mmol) and polymer from the previous step (1.0 mmol) dissolved in anhydrous 
acetonitrile (20 ml) in a three-neck round bottom flask in the presence of a catalytic 
amount of DMAP (3 mg). The resulting mixture was stirred for 12 hours. After 
completion of the reaction, solvent was removed under vacuum at room temperature. 
Salts were removed by repeated precipitation with diethyl ether in acetonitrile. The 
obtained pure compound was dried, characterized, and used in the next step [3, 4]. 
 
Attachment of peptide (EPPT) 
Activated polymer (1.0 mmol) was stirred with peptide (EPPT, 0.045 mmol) in 
phosphate buffer (pH 7.2) for 12 hours. Obtained product was dialyzed using a 
membrane (MWCO 6000). After the completion of dialysis, peptide attached polymer 
was obtained as a semisolid by freeze-drying [3, 4]. This entire scheme for attachment of 
the EPPT peptide with the triethylene glycol linker was also performed with polymer 
containing free hydroxyl groups on 7% of the linkers and 34% of the linkers. 
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I.vi. Radiolabeling of polymers 
I.vi.a. Iodination with 125I 
Immediately before use, wash Pierce iodination beads with 500 μl of phosphate 
buffered saline (PBS) per bead. Dry the beads on filter paper. Add beads to a solution of 
carrier-free Na125I (approximately 1 mCi per 100 μg of protein) diluted with PBS and 
incubate for 5 minutes. A small reaction vial is optimal for this step. Dissolve or dilute 
protein in PBS and add to the reaction vessel. Incubate reaction mixture for 15 minutes. 
Stop the reaction by removing the solution from the reaction vessel. Once beads are 
separated from the solution, the reaction will stop [7]. Wash with sodium metabisulfite 
(12 mg/mL in PBS) and BSA solution (2 mg/mL in PBS). Separate the product by size-
exclusion chromatography using Sephadex G-15. Weigh out the appropriate amount of 
dry Sephadex for the required bed volume of your column. To prepare the column, add 
enough buffer to the Sephadex to equal the total volume of the column plus 30%. Swell 
for 3 hours. After swelling is complete, decant the supernatant. Add buffer to make a 
75% suspension. Degas the suspension before packing. Pour the entire slurry into the 
column in one portion, taking care not to trap air bubbles. Start the gravity flow to initiate 
packing [7]. Once the column is prepared, pour reaction solution into column and collect 
samples at bottom of column.   
I.vi.b. Methylation with 3H 
Polymer is treated with anhydrous potassium in acetonitrile, followed by addition 
of radioactive methyl iodide (C3H3I). Stir for 6 hours. After completion of the reaction, 
K2CO3 is filtered and filtrate is concentrated to get the desired product. 
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I.vii. Encapsulation of chemotherapeutic drugs in polymer micelles 
I.vii.a. Doxorubicin 
Make separate solutions of 200 mg polymer (any polymer containing hydrophobic 
side chains which can form a micelle) in 5 mL water and 5 mg doxorubicin in 5 mL 
water. Mix the two solutions together and further dilute it to make a resultant solution of 
20 mL. Dialyze against water (100 mL) using a membrane (MWCO 1000). Frequently 
change the water (approximately every 6 hours), continuing the dialysis until the water in 
the flask is colorless (~1 week). Freeze-dry the sample to remove water and obtain the 
encapsulated product. Estimate the percent of encapsulated material by UV spectrum [8].  
I.vii.b. Paclitaxel 
The amphiphilic polymer and the hydrophobic drug paclitaxel were dissolved in 
methanol to obtain 1:5 drug/polymer w/w ratios, and they were mixed for 15 min. 
Organic solvent was removed under vacuum, and the highly viscous mixture of drug and 
polymer obtained was dissolved with an extensive vortexing in water to form 
nanomicelles. The mixture was dialyzed using a membrane (MWCO 1000). The product 
was freeze-dried to obtain the paclitaxel-loaded nanoparticles [1, 4, 9]. 
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Appendix II. Table of Polymers 
 
# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
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C
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C CF3
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# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
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O
O
O
O OR
NH
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O F2C C
F2
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C
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C
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Y
CF3
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O
O
O
O OR
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OO
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C
F2
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F2
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OCH2OCO(CH2)2(CF
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5% FITC 
14 
O
O
O
O ORY
O
n m
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100% O(CH2)9CH3 
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Encapsulated 
15 
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Doxorubicin 
Encapsulated 
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O
O
O
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OO
Y
NH
O
O
n n yz
O
OFITC
900 - 95% OCO(CH2)7CH3 5% FITC 
17 
O
O
O
O OR
OO
Y
NH
O
O
n n yz
O
OCy5.5
900 - 95% OCO(CH2)7CH3 5% Cy5.5 
 
APPENDIX II. TABLE OF POLYMERS 
 
 
   
227 
 
# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
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O
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O
O
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O
O
O
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O
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O
TEG
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O
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O
O
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O
O
O
O OR
OO
Y
NH2
O
OH
n n yz
O 900 - 95% OH 5% NH2 
24 
O
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5% 
NHCO(CH2)7CH3 
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# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
 
26 
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O ORY
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27 
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O ORY
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# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
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O
O
O
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34 
O
O
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O
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Doxorubicin 
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O
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O
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O
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OH
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# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
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O
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O
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n w
O
O
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OH
n y
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900 - 95% OH 5% FITC 
41 
O
O
O
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O
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O
O
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900 8091 66% OH 34% TEG-EPPT 
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O
O
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O
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900 - 
100% 
OCO(CH2)7CH3 
 
Paclitaxel 
Encapsulated 
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# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
 
50 
O
O
O
OY
O
n w
O
O
O
O OR
OH
n y
Folate
O
900 5221 90% OH 10% Folate 
51 
O
O
O
OY
O
n w
O
O
O
O OR
n y
Folate
O
O
900 6006 90% O(CH2)9CH3 10% Folate 
52 
O
O
O
O ORY
NH
n m
O  
600 - 100% NHCO(CH2)7CH3 
53 
O
O
O
O ORY
NH
n m
O  
900 - 100% NHCO(CH2)7CH3 
54 
O
O
O
O ORY
NH
n m
O  
1500 - 100% NHCO(CH2)7CH3 
56 
O
O
O
O ORFolate-PEG3400
OH
n' m
900 8841 
100% OH 
 
PEG3400-Folate at 
end of chain 
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# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
 
57 
O
O
O
O OR
O
n m
O
O
Y
900 - 
100% 
OCH2OCO(CH2)7CH
3 
58 
O
O
O
O OR
O
n m
O
O
Y
 
900 5795 
100% 
OCH2OCO(CH2)5CH
3 
59 
O
O
O
O OR
O
n m
O
O
Folate-PEG3400
900 9636 
100% 
OCH2OCO(CH2)5CH
3 
 
PEG3400-Folate at 
end of chain 
60 
O
O
O
OY
O
n w
O
O
O
O OR
OH
n y
PEG3400-Folate
900 11501 75% OH 25% PEG3400-Folate 
61 
O
O
O
OY
O
n w
O
O
O
O OR
O
n y
PEG3400-Folate
O
O
w=25%, y=75%
900 12296 
75% 
OCH2OCO(CH2)5CH
3 
25% PEG3400-Folate 
62 
O
O
O
O OR
O
n m
O
O
Y
900 - 
100% 
OCH2OCO(CH2)11C
H3 
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# Structure PEG MW 
Polymer 
MW 
Side Chains and 
Encapsulant 
 
64 
O
O
O
OY
O
n
OR
PEG3400-Folate  
900 31005 100% PEG3400-Folate 
65 
O
O
O
OY
O
n
OR
PEG3400-EPPT  
900 37890 100% PEG3400-EPPT 
66 
O
O
O
OY
O
n
OR
CH3  
900 5075 100% OCH3 
67 
O
O
O
OY
O
n
OR
PEG3400-COOH  
900 28800 100% PEG3400-COOH 
71 900 30485 98% PEG3400-Folate 2% CH3 
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Note: Polymers numbered 23 and higher were synthesized in the absence of triethlyamine 
(TEA). 
 
Y=PEG, CH3, or H 
R=H, linker, or sidechain 
 
z,w = 5%, v = 7% or 34%, u = 10%, x = 90%, y = 95%, except where noted 
 
PEG = polyethylene glycol 
TEG = triethylene glycol 
 
Calculation of MW:  
For each polymer, the backbone was assumed to have a MW of 5000 g/mol. Typical MW 
of backbone was typically in the range of 3000-7000 g/mol. It was also assumed that each 
polymer backbone has 5 linker molecules. The MW of one polymer chain was calculated 
based on the known MW of each side chain and the percent of substitution of the side 
chains. 
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Appendix III. Cell Counting by Flow Cytometry 
 
III.i. Methods 
III.i.a. Materials and reagents 
All polymers were provided by our collaborators in the Arthur Watterson lab at 
the University of Massachusetts, Lowell. All reagents were obtained from commercial 
sources. Trypsin EDTA (1X, 0.25% trypsin/0.53 mM EDTA in HBSS), penicillin-
streptomycin solution, and fetal bovine serum (FBS) were purchased from Mediatech, 
Inc. Minimum essential media, Eagle, with 2 mM L-glutamine and Earle's BSS adjusted 
to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM 
sodium pyruvate (EMEM) was purchased from ATCC. Guava Viacount assay kit was 
purchased from Guava Technologies/Millipore.  
III.i.b. Cell lines and culture 
KB cells (human epidermoid carcinoma; FR+) and HT-1080 cells (human 
fibrosarcoma; FR-) were purchased from the American Type Culture Collection. KB and 
HT-1080 cells were cultured in EMEM supplemented with 10% FBS and 1% penicillin–
streptomycin solution. All cells were grown at 37°C in a humidified atmosphere 
containing 5% CO2. 
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III.i.c. Seeding of cells and solution make up 
The cells growing as a mono-layer were harvested with trypsin EDTA (1X, 0.25% 
trypsin/0.53 mM EDTA in HBSS). Each cell line was seeded on a 96-well plate at a cell 
density of 2x105 cells/mL 1 day before the start of the experiment. Cells were incubated 
under sterile conditions at 37°C in a humidified atmosphere containing 5% CO2. The 
polymer solution was made by dissolving polymer (1 g/L) in cell media and sterile 
filtered through a 0.2 μm filter. 
III.i.d. Cell counting 
At each time point (0, 2, 6, 24, and 48 hours), cells were detached from the well 
with trypsin and cell number was evaluated by staining cells using a Guava Viacount 
assay solution and acquiring data with a Guava Personal Cell Analysis (PCA) flow 
cytometer using the Guava Viacount software. Dilution factors and original sample 
volumes were entered as appropriate for each sample. Typically, 360 μL of Guava 
Viacount assay solution were added to 40 μL of cell suspension. Each sample was run in 
triplicate and 1000 events were acquired per sample. 
III.ii. Results and Discussion 
Cells were counted during incubation in cell media (control) or a 1 g/L solution of 
polymer with 100% of the linkers having ether-ester linked hydrocarbon side chains 
(#57). As mentioned, cells were plated at a cell density of 2x105 cells/mL 1 day before 
the start of the experiment. Cells were counted at time points corresponding to those in 
the cytotoxicity assay described in Chapter 3. The results are shown in Figure III.1. In the 
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FR- (HT-1080) cells, the cells grew at the same rate, ~3000 cells/mL/hr, when incubated 
in cell media or polymer solution. The cell growth in FR+ (KB) cells is less clear. It 
appears that the cells began the experiment in a lag phase of growth, however, the cells 
seem to have replicated between seeding the previous day and the start of the experiment, 
since at t=0 cells were at a density of ~3.5x105 cells/mL. After the 24 hour time point, the 
cells proliferate, however the growth rates are different in cell media and polymer 
solution. Cells incubated in cell media grew at a rate of ~20,000 cells/mL/hr and cells 
incubated in polymer solution grew at a rate of ~8,000 cells/mL/hr. Overall, the cell 
density was not affected by incubation in polymer solution in either cell line, with the 
exception of the 48 hour time point in FR+ (KB) cells.  
 
0 10 20 30 40 50
Incubation Time (hr)
FR+ Cells (KB)
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50
Control
Polymer
C
el
l D
en
si
ty
 (c
el
ls
/m
L 
x 
10
-6
)
Incubation Time (hr)
FR- Cells (HT-1080)A B
C
el
l D
en
si
ty
 (c
el
ls
/m
L 
x 
10
-6
)
 
Figure III.1. Cell counting during incubation with cell media (control) or a 1 g/L 
solution of polymer with 100% of the linkers having ether-ester linked hydrocarbon 
side chains (#57) in FR- (HT-1080) and FR+ (KB) cells (n=3). 
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Appendix IV. Validation of Scintillation Counting Sample 
Preparation 
 
IV.i. Methods 
IV.i.a. Materials and reagents 
All polymers were provided by our collaborators in the Arthur Watterson lab at 
the University of Massachusetts, Lowell. All reagents were obtained from commercial 
sources. Phosphate buffered saline (PBS), distilled deionized sterile water, trypsin EDTA 
(1X, 0.25% trypsin/0.53 mM EDTA in HBSS), penicillin-streptomycin solution, and fetal 
bovine serum (FBS) were purchased from Mediatech, Inc. Minimum essential media, 
Eagle, with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium 
bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate (EMEM) 
was purchased from ATCC. RPMI Medium 1640 (without folic acid) was purchased 
from GIBCO. 3H-folate was purchased from American Radiolabeled Chemicals, Inc. 
Guava Viacount assay kit was purchased from Guava Technologies/Millipore. Triton X-
100 lysis buffer were purchased from EMD Chemicals. SOLVABLE™ was purchased 
from Perkin Elmer. 
IV.i.b. Cell lines and culture 
KB cells (human epidermoid carcinoma; FR+) were purchased from the American 
Type Culture Collection. KB cells were cultured in EMEM supplemented with 10% FBS 
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and 1% penicillin–streptomycin solution. All cells were grown at 37°C in a humidified 
atmosphere containing 5% CO2. 
IV.i.c. Validation of scintillation counting sample preparation 
Cells were grown in RPMI Medium 1640 (without folic acid) supplemented with 
10% FBS and 1% penicillin–streptomycin solution for 2 days before the experiment. 
Cells growing as a mono-layer were harvested with trypsin and seeded at a concentration 
of 1x106 cells/mL 1 day before the start of the experiment. Cells were incubated with 3H-
folate (50 nM) or polymer with 98% of the linkers having PEG-3400-folate attached and 
the remaining 2% of the linkers having methyl groups containing 3H attached (#71) (50 
nM, 500 nM, or 5 μM) at 37°C in a humidified 5% CO2 atmosphere for 3 hours. At each 
time point, the cells were washed three times with 100 μL PBS. Cells were lysed by 
adding 100 μL lysis buffer. To half of the samples, 400 μL of deionized water and 3.5 
mL of scintillation cocktail (Ultima Gold XR) were added. To the other half of the 
samples, 100 μL of SOLVABLE™, 300 μL of deionized water, and 3.5 mL of 
scintillation cocktail (Ultima Gold XR) were added. The samples were vortexed and then 
analyzed in a scintillation counter (Beckman Coulter LS6500 Multipurpose 
Scintillation Counter). All experiments were performed in triplicate. The activity of 
each sample was reported as counts per minute (CPM). 
IV.i.d. Statistical analysis 
All data are represented as mean ± standard deviation. Statistical insignificance 
(p>0.05) was determined, where appropriate, by an unpaired, two-tailed Student t-test. 
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IV.ii. Results and Discussion 
The purpose of this validation was to show that it was not necessary to use 
SOLVABLE to solubilize all of the cellular debris and that the scintillation counter 
results were the same in the presence or absence of SOLVABLE. The results for the case 
of the uptake of 3H-folate in FR+ cells are shown in Figure IV.i. No statistically 
significant difference in activity was observed between cells treated with lysis buffer and 
cells treated with lysis buffer and SOLVABLE. The p-value calculated by the Student’s t 
test was greater than 0.6, verifying that there was no statistical difference between the 
two sample preparation methods. The results for the case of the uptake of 3H-polymer in 
FR+ cells are shown in Figure IV.ii. Notably, no statistically significant difference in 
activity between cells treated with lysis buffer and cells treated with lysis buffer and 
SOLVABLE was observed at any of the three concentrations. The p-value calculated by 
the Student’s t test was greater than 0.3, additionally verifying that there was no statistical 
difference between the two sample preparation methods. 
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Figure IV.i. Validation of scintillation counting preparation method using 50 nM 
3H-folate. 
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Figure IV.ii. Validation of scintillation counting preparation method using 50 
nM, 500 nM, and 5 μM 3H-polymer. 
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Appendix V. Detailed Calculations for Theoretical Design of 
Targeting Polymers 
 
V.i. Calculations for EPPT 
V.i.a. Cooperativity polyvalency calculations 
A cooperativity model from the literature [1], the derivation of which is shown in 
Chapter 4, can be used to calculate the apparent dissociation constant of a polyvalent 
particle containing EPPT from the equation 
 ( ) ND,Apparent DK K α=  (1) 
where KD,Apparent is the apparent dissociation constant of a polyvalent particle, KD is the 
dissociation constant for one ligand, α is the degree of cooperativity between ligands, and 
N is the number of ligands per particle. The binding of EPPT with the underglycosylated 
mucin-1 (uMUC1)-derived PDTRP epitope has a dissociation constant of 2.5x10-5 M [2]. 
For positive cooperativity, noncooperativity, and negative cooperativity, α is greater than 
1, equals 1, and is less than 1, respectively, therefore for these calculations we chose 
values of 2, 1, and 0.5 for α. The results of these calculations are shown in Table V.i. 
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Table V.i. Calculated apparent dissociation constant, KD,Apparent, for EPPT-
containing particles from the cooperativity model. 
N α=2 α=1 α=0.5
1 6.25 x 10-10 2.50 x 10-5 5.00 x 10-3
2 3.91 x 10-19 6.25 x 10-10 2.50 x 10-5
3 2.44 x 10-28 1.56 x 10-14 1.25 x 10-7
4 1.53 x 10-37 3.91 x 10-19 6.25 x 10-10
5 9.54 x 10-47 9.77 x 10-24 3.13 x 10-12  
 
V.i.b. Structural polyvalency calculations 
A structural model from the literature [3], the description of which is given in 
Chapter 4, can be used to calculate the apparent dissociation constant of a polyvalent 
particle containing EPPT from the equations 
 ( ) 1D,Apparent DK K nBE −=  (2) 
 ( ) n 11 2DBE F sK 10 −− −⎡ ⎤= ⎣ ⎦  (3) 
where KD,Apparent is the apparent dissociation constant of a polyvalent particle, KD is the 
dissociation constant for the ligand, BE is the binding enhancement per ligand, F is a 
system-specific statistical factor, s is 30 divided by the distance between binding sites on 
the receptor, in Å, and n is the lesser of the number of binding sites on the receptor or the 
number of ligands or binding sites on the particle. Again, the binding of EPPT with the 
uMUC1-derived PDTRP epitope has a dissociation constant of 2.5x10-5 M [2]. The 
statistical factor, F, was assumed to be 1 based on the literature [3]. There are 60 carbon-
carbon and carbon-nitrogen bonds in one 20 amino acid PDTRP repeat unit and the bond 
length of a carbon-carbon or carbon-nitrogen bond is ~150 pm. Therefore, the distance 
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between PDTRP sequences on uMUC1, assuming 100% underglycosylation, was 
calculated to be 90 Å. Therefore, s is equal to 0.33. The results of the calculations of 
apparent dissociation constants are shown in Table V.ii. 
 
Table V.ii. Calculated apparent dissociation constant, KD,Apparent, for EPPT-
containing particles from the structural model. 
n BE KD,Apparent
1 1.0 x 100 2.5 x 10-5
2 1.3 x 102 9.4 x 10-8
3 1.8 x 104 4.7 x 10-10
4 2.4 x 106 2.6 x 10-12
5 3.2 x 108 1.6 x 10-14  
 
V.ii. Calculations for Folate 
V.ii.a. Cooperativity polyvalency estimates 
As with EPPT, the cooperativity model from the literature [1] can be used to 
calculate the apparent dissociation constant of a polyvalent particle containing folate 
from the equation 
 ( ) ND,Apparent DK K α=  (4) 
where KD,Apparent is the apparent dissociation constant of a polyvalent particle, KD is the 
dissociation constant for one ligand, α is the degree of cooperativity between ligands, and 
N is the number of ligands per particle. The folate receptor (FR) is a high affinity 
receptor for the small molecule folate, or folic acid, with a dissociation constant, KD, for 
this binding event of 1x10-10 M [4-6]. For positive cooperativity, noncooperativity, and 
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negative cooperativity, α is greater than 1, equals 1, and is less than 1, respectively, 
therefore for these calculations we chose values of 2, 1, and 0.5 for α. The results of these 
calculations are shown in Table V.iii. 
 
Table V.iii. Calculated apparent dissociation constant, KD,Apparent, for folate-
containing particles from the cooperativity model. 
N α=2 α=1 α=0.5
1 1.00 x 10-20 1.00 x 10-10 1.00 x 10-5
2 1.00 x 10-40 1.00 x 10-20 1.00 x 10-10
3 1.00 x 10-60 1.00 x 10-30 1.00 x 10-15
4 1.00 x 10-80 1.00 x 10-40 1.00 x 10-20
5 1.00 x 10-100 1.00 x 10-50 1.00 x 10-25  
 
V.ii.b. Structural polyvalency estimates 
Also as with EPPT, the structural model from the literature [3] can be used to 
calculate the apparent dissociation constant of a polyvalent particle containing folate 
from the equations 
 ( ) 1D,Apparent DK K nBE −=  (5) 
 ( ) n 11 2DBE F sK 10 −− −⎡ ⎤= ⎣ ⎦  (6) 
where KD,Apparent is the apparent dissociation constant of a polyvalent particle, KD is the 
dissociation constant for the ligand, BE is the binding enhancement per ligand, F is a 
system-specific statistical factor, s is 30 divided by the distance between binding sites on 
the receptor, in Å, and n is the lesser of the number of binding sites on the receptor or the 
number of ligands or binding sites on the particle. Again, the FR is a high affinity 
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receptor for folate with a dissociation constant, KD, for this binding event of 1x10-10 M 
[4-6]. The statistical factor, F, was assumed to be 1 based on the literature [3]. GPI-
anchored FRs are clustered in microdomains of around 70 nm in size containing 
approximately 50 FRs, therefore they are an average of 100 Å apart [7]. Therefore, s is 
equal to 0.30. The results of the calculations of apparent dissociation constants are shown 
in Table V.iv. 
 
Table V.iv. Calculated apparent dissociation constant, KD,Apparent, for folate-
containing particles from the structural model. 
n BE KD,Apparent
1 1.0 x 100 1.0 x 10-10
2 3.0 x 107 1.7 x 10-18
3 9.2 x 1014 3.6 x 10-26
4 2.8 x 1022 9.0 x 10-34
5 8.4 x 1029 2.4 x 10-41  
 
V.ii.c. Ligand tether length calculations 
A geometric model was used, assuming spherical particles, to calculate the 
fraction of the surface area of the particle able to bind to the surface of the cell for a given 
tether length [8] in order to determine the length of the tether attaching the ligand to the 
polymer particles that is necessary to allow for polyvalency. This model was described in 
Chapter 4. Assuming that the tether is in a fully extended conformation and using simple 
geometry, the active fractional area of the carrier is given by  
 2
2
4 2
= =RH HA
R R
π
π  (7) 
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where R is the radius of the carrier and H is given by L-dB when L≤R+dB. Here, L is the 
sum of ligand length and the maximum extended length of the tether and dB is the binding 
distance of the ligand and the receptor. The effect of tether length on binding distance 
was determined, as reported in the literature, by using a combination of Monte Carlo 
simulations, diffusion reaction theory, and surface force measurements [9]. When 
L>R+dB, H becomes R+x, where x is the vertical distance above the horizontal line 
passing through the center of the carrier, indicating the position of the fully extended 
tether on the carrier surface that is tangent to the surface of the carrier and reaching the 
cell surface. These parameters are more clearly depicted in the schematic in Figure V.i. 
The MATLAB code used to calculate the active fractional area of the carrier as a function 
of tether length is shown. This analysis was performed at particle diameters of 10, 25, 50, 
100, and 150 nm and for tethers from PEG 900 to PEG 10,000.  
 
Binding Distance, dB
x
R
Receptor
H
Fully Extended Tether, 
L, when L > R + dB
Fully Extended Tether, 
L, when L < R + dB
 
Figure V.i. Schematic of parameters used for ligand tether length calculations 
adapted from [8]. 
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V.ii.c.1. MATLAB code for ligand tether length calculations 
%Calculating Active Fractional Area of Carrier (AFAC) 
%Reference: Ghaghada, Journal of Controlled Release, 104 (2005) 113-128 
 
function AFAC = calc_AFAC_for_graph() 
  
%Make a vector of carrier diameters and calculate the radius, R, in nm. 
Carrier_diameter=[10, 25, 50, 100, 150]; 
R=Carrier_diameter/2; 
  
%Make a vector of PEG molecular weights to base the calculation on and 
calculate the tether length, L, in nm. 
%Length of one PEG repeat is 350 pm. 
%Length of folate calculated from Ghaghada (2005) to be 2.107 nm. 
%Molecular weight of one PEG repeat is 44. 
PEG_MW=900:100:10000; 
L=(PEG_MW/44*350)/1000+2.107; 
  
%Calculate binding distance, db, in nm. 
%Reference: Jeppeson, Science, 293 (2001) 465-468 
db=0.0036*PEG_MW+5.9968; 
  
%Iterate through each carrier diameter and each PEG molecular weight. 
for i=1:length(R); 
    for j=1:length(L); 
        if L(j) <= R(i) + db(j); 
            H=L(j)-db(j); 
        else L(j) > R(i) + db(j); 
            x=calc_x(R(i),db(j),L(j)); 
            H=R(i)+x; 
        end; 
        AFAC(i,j)=H/(2*R(i)); 
    end; 
end; 
  
%Make a figure of the results. 
figure; 
plot(PEG_MW, AFAC); 
axis square; 
legend('10 nm', '15 nm', '20 nm', '25 nm', '50 nm', '75 nm', '100 nm', 
'120 nm', '150 nm'); 
xlabel('PEG Molecular Weight'); 
ylabel('AFAC'); 
  
%Save the results in a text file. 
save AFAC.txt AFAC -ASCII; 
  
end 
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V.iii. Comparison to experimental data in literature 
As mentioned in Chapter 4, the validity of the theoretical calculations, both 
polyvalency estimates and ligand tether length calculations, was tested by using 
experimental data from the literature. Moore et al. investigated the in vitro uptake of 
cross-linked iron oxide nanoparticles modified with Cy5.5 dye and carrying EPPT 
peptides attached to the dextran coat of the nanoparticles [10]. The structural properties 
of these nanoparticles reported in the literature (ie. 35.8 nm in size, 14 EPPT per particle) 
were used to calculate the active fractional area of the particle. Assuming the bond length 
of a carbon-carbon or carbon-nitrogen bond is ~150 pm, the length of a fully extended 
EPPT-FITC was calculated to be 9.6 nm. Since there was no tether used in these iron 
oxide particles, L, the sum of ligand length and the maximum extended length of the 
tether, used in the calculation of the active fractional area of the particle was 9.6 nm and 
dB, the binding distance, was 6 nm. Since the diameter of the particle was 35.8 nm, the 
radius, R, was 17.9 nm, therefore H, given by L-dB since L≤R+dB, is 3.6 nm. The active 
fractional area of the particles was calculated to be ~10% of the surface, therefore ~1.4 
EPPT were accessible per particle since there were 14 EPPT per particle.  For the 
calculation of the apparent dissociation constant, KD,Apparent, from the experimental data in 
Moore et al., see Appendix V.  
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Appendix VI. Theoretical Modeling of Cellular Uptake 
 
VI.i. Analysis of EPPT cellular uptake 
VI.i.a. Calculation of experimental specific uptake 
Experimental specific uptake was calculated by subtracting non-specific uptake in 
the uMUC1- cell line from total uptake in uMUC1+ cell line. Figure VI.i shows the 
results of this calculation. The graph of the specific uptake can be used to estimate the 
kinetic parameters, such as the forward rate constant, kf, and the reverse rate constant, kr. 
The theoretical model discussed later is compared to this specific uptake data. Note that 
this calculation assumes that the non-specific uptake is equivalent in both cell lines.  
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Figure VI.i. Calculation of specific uptake from total uptake in uMUC1+ cells and 
non-specific uptake in uMUC1- cells. 
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VI.i.b. Kinetic parameters for uptake model 
VI.i.b.1. Scatchard analysis from literature 
The number of underglycosylated mucin-1 (uMUC1) proteins per cell was not 
found in the literature.  In order to estimate this value, a Scatchard plot analysis was 
performed on data of uptake of polyvalent particles containing EPPT from Moore et al. 
[1] to determine the number of uMUC1 proteins per cell for uMUC1+ (BT-20) cells. In 
the simplest case of binding 
 
f
r
k
k
P L C+ R  (8) 
where P is the surface protein, here the uMUC1 protein, L is the ligand, here EPPT, and 
C is the complex of EPPT with the PDTRP sequence. It is assumed here that only one 
polyvalent nanoparticle can bind per uMUC1. At equilibrium, 
 [ ][ ][ ]rD f
P LkK
k C
= =  (9) 
where KD is the dissociation constant for the binding interaction, kf is the forward 
reaction rate, kr is the reverse reaction rate, [P] is the concentration of protein, [L] is the 
concentration of ligand, and [C] is the concentration of complex. By material balance, 
 [ ] [ ] [ ]oP P C= −  (10) 
where [P]o is the initial concentration of protein. This value represents the number of 
uMUC1 per cell. Inserting equation (3) into equation (2) gives 
 
[ ] [ ]( )[ ]
[ ]oD
P C L
K
C
−=  (11) 
which leads to 
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 [ ] [ ] [ ][ ]oD
P L
C
K L
= +  (12) 
Rearranging equation (5) gives 
 [ ][ ] [ ]
[ ]o
D D
PC 1 C
L K K
= − +  (13) 
From this equation it is clear that plotting [C] versus [C]/[L] leads to a straight line with a 
slope of -1/KD and a y-intercept of [P]o/KD. Data was estimated for BT-20 cells from 
Figure 2 in Moore et al. [1] and plotted as [C] versus [C]/[L], as shown in Figure VI.ii. 
The slope of a linear fit to this line was -2x10-7 and the y-intercept was 9, therefore KD 
was calculated to be 8x10-9 M and [P]o, the number of uMUC1 per cell, was found to be 
3x107. 
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Figure VI.ii. Scatchard plot analysis using data from Moore et al. [1]. 
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VI.i.b.2. Graphic analysis from experimental specific uptake 
In order to pursue a theoretical model to describe the uptake of EPPT, kinetic 
parameters for the binding interaction were needed. The dissociation constant, KD, for the 
interaction of EPPT with the PDTRP sequence has been reported in the literature as 
2.5x10-5 M [2], however the forward and reverse reaction rates, kf and kr respectively, 
were not reported. The rate law describing the interaction of EPPT with PDTRP is given 
by 
 [ ] [ ][ ] [ ]f rd C k P L k Cdt = −  (14) 
The experimental specific uptake calculated earlier can be used to estimate kf and kr using 
this equation. The specific uptake data is shown again in Figure VI.iii divided into two 
regions, I and II. During region I, the initial uptake period, the reverse reaction can be 
assumed to be zero, therefore the slope, d[C]/dt, can be used to calculate kf given [P] and 
[L]. From the slope of the dashed line for region I in Figure VI.iii, kf was calculated to be 
1.4x10-4 M-1hr-1. Given the calculated kf, the full form of equation (7) was applied, using 
the slope of region II for d[C]/dt, to calculate kr as 3.4x10-9 hr-1. 
 
APPENDIX VI. THEORETICAL MODELING OF CELLULAR UPTAKE 
 
 
   
257 
0
0.5
1
1.5
2
2.5
3
0 0.5 1 1.5 2 2.5 3
Sp
ec
ifi
c 
U
pt
ak
e 
as
 #
 E
PP
T 
/ C
el
l (
x 
10
-8
)
Incubation Time (hr)
I
II
Sp
ec
ifi
c 
U
pt
ak
e 
as
 #
 E
PP
T 
/ C
el
l (
x 
10
-8
)
 
Figure VI.iii. Estimation of kinetic parameters from experimental uptake data. 
 
VI.i.c. Theoretical model of EPPT cellular uptake 
The parameters which have been described here, namely number of uMUC1 per 
cell, kf, kr, and KD, can be used in a simple theoretical model of cellular uptake for the 
purpose of comparing to experimental data. The simplest model considers one EPPT 
binding per PDTRP sequence and no internalization into the cell. Attempts were made to 
include internalization in the model, but convergence of the ODE solver was never 
achieved. Since each uMUC1 protein contains 30-90 repeat units of the PDTRP sequence 
[3], the concentration of binding sites is p times [P], where p, the number of PDTRP 
sequences per uMUC1, is conservatively assumed to be 30 for the following calculations. 
Including this in the rate law governing the interaction of EPPT and uMUC1 gives 
 [ ] [ ][ ] [ ]f rd C k p P L k Cdt = −  (15) 
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where kf is the forward reaction rate, kr is the reverse reaction rate, p is the number of 
PDTRP sequences per uMUC1, [P] is the concentration of uMUC1, [L] is the 
concentration of EPPT, and [C] is the concentration of complexes of EPPT with PDTRP. 
The material balances are 
 [ ] [ ] [ ]op P p P C= −  (16) 
 [ ] [ ] [ ]oL L C= −  (17) 
where [P]o is the initial concentration of uMUC1 and [L]o is the initial concentration of 
EPPT. The ordinary differential equation in (8) was solved using an ODE solver in 
MATLAB. The MATLAB code is shown below. The results of this calculation are 
shown in Figure VI.iv as compared to the experimental data. The theoretical model 
agrees well with the experimental data when 7-10 EPPT are bound per uMUC1. 
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Figure VI.iv. Theoretical model of EPPT uptake compared to experimental data. 
 
%EPPT Uptake Kinetic Model with Material Balance in BT20 cells. 
%Notes: ONE Bond, no internalization, no clusters. 
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function uptake = EPPT_uptake_BT20_Cells() 
  
clear; 
  
%Definitions: 
%N_T = Total number of surface receptors per cell for BT20 cells. 
%kf = 2-D binding rate constant, nm^2/mol/hr. 
%kr = 2-D dissociation rate constant, 1/hr. 
%Kd = 2-D equilibrium constant, mol/nm^2. 
%C_carrier_initial = Initial concentration of free carrier in solution,  
%mol/nm^3. 
%C_carrier_total = Total concentration of free carrier per area, 
mol/nm^2. 
%C_carriers_free = Concentration of free receptors, mol/nm^2. 
%C_receptors_free = Concentration of free receptors, mol/nm^2. 
%C_bound = Concentration of bound carriers, mol/nm^2. 
%N = number of cells per well. 
%a = total number of ligands per carrier available for binding. 
%b = total number of binding sites per receptor available for binding. 
  
%Parameters: 
C_carrier_initial=5.5e-5; %M 
N_T=3e7; %Receptors/cell 
Cells_per_well=50000; %Cells per well 
Volume_per_well=100e-6; %Volume of solution in L 
Volume_per_well=Volume_per_well*1e24; %Volume of solution in nm^3 
Cells_per_volume=Cells_per_well/Volume_per_well; %Cells/nm^3 
Cell_surface_area=5e8; %nm^2 
Z=Cells_per_volume*Cell_surface_area; %nm^2/nm^3 
C_carrier_total=C_carrier_initial/1e24/Z; %mol/nm^2 
max_binding_per_receptor=10; %Assumed 10 carrier max bind per receptor. 
C_receptors_initial=N_T*max_binding_per_receptor/Cell_surface_area/6e23
; %mol/nm^2 
C_receptors_total=C_receptors_initial; %mol/nm^2 
p=30; 
  
%Rate Constants: 
Kd=2e-5; %M (Moore, 2004. Sivolapenko, 1995 gives 2.5e-5 M.) 
Kd=Kd/1e24; %mol/nm^3 
Kd=Kd/Z; %mol/nm^2 
kf=1.35e4; %1/M/hr 
kf=kf*1e24; %nm^3/mol/hr 
kf=kf*Z; %nm^2/mol/hr 
kr=kf*Kd; %1/hr 
  
a=1; 
b=p; 
Inputs = [kf, kr, C_carrier_total, C_receptors_total, a, b]; 
tspan=[0 3]; 
[T,uptake]=ode15s(@EPPT_uptake_ODEs,tspan,0,[],Inputs); 
  
%Make figures of the results. 
uptake=uptake*Cell_surface_area*6e23; 
uptake(:,2)=C_carrier_total*Cell_surface_area*6e23-uptake(:,1); 
uptake(:,3)=C_receptors_total*Cell_surface_area*6e23-uptake(:,1); 
t_expt=[0 0.5 1 3]; 
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uptake_expt=[0 1.22e8 1.67e8 2e8]; 
std_dev=[0 0.751000477e8 0.588744352e8 0.931897145e8]; 
figure; 
subplot(4,1,1); 
errorbar(t_expt, uptake_expt,std_dev,'ro'); 
axis([0 3 0 3e8]); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
legend ('Bound Ligand - Experiment'); 
subplot(4,1,2); 
plot(T, uptake(:,1)); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
legend ('Bound Ligand - Theory'); 
subplot(4,1,3); 
plot(T, uptake(:,2)); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
legend ('Free Ligand'); 
subplot(4,1,4); 
plot(T, uptake(:,3)); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
legend ('Free Receptors'); 
  
%Save the results in a text file. 
save ('EPPT_Uptake_BT20_Cells.txt','uptake','-ASCII'); 
save ('EPPT_Uptake_BT20_Cells_Time.txt','T','-ASCII'); 
save 
('EPPT_Uptake_BT20_Cells_Variables.txt','a','b','max_binding_per_recept
or','N_T','-ASCII'); 
  
end 
 
%EPPT Uptake Kinetic Model with Material Balance - Differential 
Equations 
 
function dC_dt = EPPT_uptake_ODEs(t,C,Inputs) 
  
%C = [C_bound] 
%Inputs = [kf, kr, C_carrier_total, C_receptors_total, a, b] 
kf=Inputs(1); 
kr=Inputs(2); 
C_carrier_total=Inputs(3); 
C_receptors_total=Inputs(4); 
a=Inputs(5); 
b=Inputs(6); 
  
dC_dt(1)=kf*a*(C_carrier_total-C(1))*b*(C_receptors_total-C(1))-
kr*C(1); 
  
return; 
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VI.ii. Analysis of folate cellular uptake 
VI.ii.a. Scatchard analysis from experimental data 
The number of folate receptors (FRs) per cell was calculated from experimental 
data as described in section VI.i.b.1. Again using the equation, 
 [ ][ ] [ ]
[ ]o
D D
PC 1 C
L K K
= − +  (18) 
experimental data of folate uptake, from Figure 4.19 in Chapter 4, was plotted as [C] 
versus [C]/[L]. The plotted data is shown in Figure VI.v and the resulting [P]o, the 
number of FRs per cell, was found to be 3x107. This value was used in the theoretical 
model of folate uptake discussed in the next section. 
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Figure VI.v. Scatchard plot analysis using experimental data of folate uptake. 
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VI.ii.b. Theoretical model of folate cellular uptake 
The same simple theoretical model of cellular uptake that was used for EPPT was 
used to predict the uptake of folate. The number of FRs per cell was as calculated earlier 
and KD, kf, and kr were from the literature [4, 5]. In the case of folate, only one folate 
could bind per FR, therefore the parameter p used for EPPT is not necessary here. Again 
the model considers one binding event and no internalization into the cell. Once more, 
attempts were made to include internalization in the model, but convergence of the ODE 
solver was never achieved. The rate law governing the interaction is 
 [ ] [ ][ ] [ ]f rd C k P L k Cdt = −  (19) 
where kf is the forward reaction rate, kr is the reverse reaction rate, [P] is the 
concentration of FRs, [L] is the concentration of folate, and [C] is the concentration of 
complexes of folate with FR. The material balances are 
 [ ] [ ] [ ]oP P C= −  (20) 
 [ ] [ ] [ ]oL L C= −  (21) 
where [P]o is the initial concentration of FR and [L]o is the initial concentration of folate. 
The ordinary differential equation in (12) was solved using an ODE solver in MATLAB. 
The MATLAB code is shown below. The results of this calculation are shown in Figure 
VI.vi as compared to the experimental data from Figure 4.19 in Chapter 4. The 
theoretical model agrees well with the experimental data at long times, although at early 
times there is some disagreement. 
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Figure VI.vi. Theoretical model of folate uptake compared to experimental data. 
 
%Folate Uptake Kinetic Model with Material Balance in KB cells. 
%Reference: Ghaghada, Journal of Controlled Release, 104 (2005) 113-128 
%Note: This analysis does NOT include downregulation of the folate 
receptor 
%when the threshold concentration is reached. 
%Note: ONE Bond, no internalization, no clusters. 
 
function uptake = folate_uptake_KB_Cells() 
  
clear; 
  
%Definitions: 
%N_T = Total number of surface receptors per cell for KB cells. 
%kf = 2-D binding rate constant, nm^2/mol/hr. 
%kr = 2-D dissociation rate constant, 1/hr. 
%Kd = 2-D equilibrium constant, mol/nm^2. 
%C_carrier_initial = Initial concentration of free carrier in solution,  
%mol/nm^3. 
%C_carrier_total = Total concentration of free carrier per area, 
mol/nm^2. 
%C_carriers_free = Concentration of free receptors, mol/nm^2. 
%C_receptors_free = Concentration of free receptors, mol/nm^2. 
%C_bound = Concentration of bound carriers, mol/nm^2. 
%N = number of cells per well. 
%a = total number of ligands per carrier available for binding. 
%b = total number of binding sites per receptor available for binding. 
  
%Parameters: 
C_carrier_initial=5e-6; %M 
N_T=3e7; %From Scatchard plot analysis of experimental data. 
Cells_per_well=100000; %Cells per well 
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Volume_per_well=100e-6; %Volume of solution in L 
Volume_per_well=Volume_per_well*1e24; %Volume of solution in nm^3 
Cells_per_volume=Cells_per_well/Volume_per_well; %Cells/nm^3 
Cell_surface_area=5e8; %nm^2 
Z=Cells_per_volume*Cell_surface_area; %nm^2/nm^3 
C_carrier_total=C_carrier_initial/1e24/Z; %mol/nm^2 
max_binding_per_receptor=1; %Assumed 10 carrier max bind per receptor. 
C_receptors_initial=N_T*max_binding_per_receptor/Cell_surface_area/6e23
; %mol/nm^2 
C_receptors_total=C_receptors_initial; %mol/nm^2 
a=1; 
b=1; 
  
%Rate Constants: 
Kd=1e-10; %M (Low, P., et al., Acc Chem Res, 2007. 41(1): p. 120-9.) 
Kd=Kd/1e24; %mol/nm^3 
Kd=Kd/Z; %mol/nm^2 
kf=1.5524e4; %1/M/min %Reference: Ghaghada, Journal of Controlled 
Release, 104 (2005) 113-128 
kf=kf*60; %1/M/hr 
kf=kf*1e24; %nm^3/mol/hr 
kf=kf*Z; %nm^2/mol/hr 
kr=kf*Kd; %1/hr 
  
Inputs = [kf, kr, C_carrier_total, C_receptors_total, a, b]; 
tspan=[0 3]; 
[T,uptake]=ode15s(@folate_uptake_ODEs,tspan,0,[],Inputs); 
  
%Make figures of the results. 
uptake=uptake*Cell_surface_area*6e23; 
uptake(:,2)=C_carrier_total*Cell_surface_area*6e23-uptake(:,1); 
uptake(:,3)=C_receptors_total*Cell_surface_area*6e23-uptake(:,1); 
t_expt=[0 0.5 1 3]; 
uptake_expt=[0 8.71e6 1.06e7 1.27e7]; 
std_dev=[0 4.66e5 4.83e5 5.20e5]; 
figure; 
subplot(4,1,1); 
errorbar(t_expt, uptake_expt,std_dev,'ro'); 
axis([0 3 0 2e7]); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
legend ('Bound Ligand - Experiment'); 
subplot(4,1,2); 
plot(T, uptake(:,1)); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
legend ('Bound Ligand - Theory'); 
subplot(4,1,3); 
plot(T, uptake(:,2)); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
legend ('Free Ligand'); 
subplot(4,1,4); 
plot(T, uptake(:,3)); 
xlabel('Time (hr)'); 
ylabel('Number per cell'); 
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legend ('Free Receptors'); 
  
%Save the results in a text file. 
save ('Folate_Uptake_KB_Cells.txt','uptake','-ASCII'); 
save ('Folate_Uptake_KB_Cells_Time.txt','T','-ASCII'); 
save 
('Folate_Uptake_KB_Cells_Variables.txt','a','b','max_binding_per_recept
or','N_T','-ASCII'); 
  
end 
 
%Folate Uptake Kinetic Model with Material Balance - Differential 
Equations 
 
function dC_dt = folate_uptake_ODEs(t,C,Inputs) 
  
%C = [C_bound] 
%Inputs = [kf, kr, C_carrier_total, C_receptors_total, a, b] 
kf=Inputs(1); 
kr=Inputs(2); 
C_carrier_total=Inputs(3); 
C_receptors_total=Inputs(4); 
a=Inputs(5); 
b=Inputs(6); 
  
dC_dt(1)=kf*a*(C_carrier_total-C(1))*b*(C_receptors_total-C(1))-
kr*C(1); 
  
return; 
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Appendix VII. Kinetic Analysis of Experimental Uptake of EPPT 
and EPPT-Containing Polymer 
 
VII.i. Analysis of kinetics of cellular uptake 
VII.i.a. Separation of internalized and surface bound material 
An analysis of the kinetics of the binding and internalization of EPPT and EPPT-
containing polymer can be performed from the experimental uptake data. It was assumed 
that a line can be fit to the data for the long times and extrapolated back to the y-axis. A 
horizontal line from this point on the y-axis, parallel to the x-axis, indicates the level of 
surface bound peptide or polymer. The value between this horizontal line and the linear 
fit to the long time data points gives the internalized peptide or polymer. These analyses 
are shown in Figure VII.i for EPPT peptide, Figure VII.ii for polymer with 5% EPPT and 
95% hydrocarbon side chains (#37), and Figure VII.iii for polymer with 5% EPPT and 
5% FITC with no other side chains (#39). 
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Figure VII.i. Separation of surface bound and internalized EPPT peptide. 
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Figure VII.ii. Separation of surface bound and internalized polymer with 5% EPPT 
(#37). 
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Figure VII.iii. Separation of surface bound and internalized polymer with 5% EPPT 
and 5% FITC (#39). 
 
VII.i.b. Comparison of internalized and surface bound material for EPPT 
peptide and EPPT-containing polymer 
The surface bound and internalized amounts can be compared between EPPT 
peptide, polymer with 5% EPPT (#37) and polymer with 5% EPPT and 5% FITC (#39), 
as shown in Figure VII.iv. The amount of surface bound polymer is ~2X that of EPPT. 
This is likely due to the formation of polymer micelles such that several polymer chains 
were bound for each EPPT bound on the micelle. In addition, the rate of internalization of 
polymer with 5% EPPT is ~3X that of EPPT and polymer with 5% EPPT and 5% FITC. 
Again this can be explained by several polymer chains being internalized per EPPT due 
to the formation of micelles. 
 
APPENDIX VII. KINETIC ANALYSIS OF EXPERIMENTAL UPTAKE OF EPPT AND EPPT-
CONTAINING POLYMER 
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Figure VII.iv. Comparison of surface bound and internalized EPPT peptide, 
polymer with 5% EPPT (#37), and polymer with 5% EPPT and 5% FITC (#39). 
 
 
